HISTORICAL SALES CHART





June 2013

SUMMARY OF YEAR TO DATE SALES BY COUNTRY

		2013 Actual US$'000	% of Total %	2012 Actual US$'000	2013 vs 2012 %	2013 MYE US$'000	2013 vs MYE %	2013 Budget US$'000	2013 vs Bud %
Germany	(Mundipharma GmbH)	174,111	9.7	174,566	99.7	174,151	100.0	186,764	93.2
UK	(Napp Pharmaceuticals Ltd)	123,213	6.8	127,415	96.7	123,453	99.8	120,858	101.9
Nordic	(Norpharma / Mundipharma)	49,109	2.7	53,874	91.2	48,694	100.9	46,872	104.8
France	(Mundipharma SAS)	43,198	2.4	37,538	115.1	42,288	102.2	38,472	112.3
Italy	(Mundipharma Srl)	35,159	2.0	28,338	124.1	35,625	98.7	32,296	108.9
Switzerland	(Mundipharma Medical Co)	26,043	1.4	24,638	105.7	26,164	99.5	24,872	104.7
Austria	(Mundipharma GesmbH)	22,268	1.2	21,916	101.6	22,208	100.3	20,329	109.5
Spain	(Mundipharma SL)	21,171	1.2	18,860	112.3	21,225	99.7	19,779	107.0
Netherlands	(Mundipharma Pharmaceuticals BV)	15,576	0.9	19,314	80.6	15,685	99.3	16,815	92.6
Eastern Europe	(Mundipharma Medical GmbH)	9,213	0.5	8,832	104.3	9,148	100.7	10,169	90.6
Ireland	(Mundipharma Pharmaceuticals Ltd)	7,764	0.4	7,921	98.0	7,817	99.3	8,098	95.9
Belgium	(Mundipharma CVA)	5,228	0.3	4,996	104.6	5,114	102.2	6,247	83.7
Poland	(Norpharma)	4,561	0.3	4,072	112.0	4,586	99.5	4,180	109.1
South Africa	(Mundipharma Pty Ltd)	1,442	0.1	517	278.6	1,483	97.2	1,595	90.4
Portugal	(Mundipharma Farmaceutica Lda)	234	0.0	211	111.3	217	107.9	217	107.9
Total Europe		**538,290**	**29.9**	**533,007**	**101.0**	**537,858**	**100.1**	**537,562**	**100.1**
China	(MCPC)	32,554	1.8	21,843	149.0	31,397	103.7	25,210	129.1
Korea	(Mundipharma Korea Ltd)	14,809	0.8	11,241	131.7	14,776	100.2	12,856	115.2
Philippines	(Mundipharma Dist GmbH)	7,683	0.4	7,122	107.9	8,131	94.5	8,654	88.8
Thailand	(Mundipharma (Thailand) Ltd)	3,020	0.2	0	0.0	2,534	119.2	1,616	186.9
Malaysia	(Mundipharma Pharm. Sdn Bhd)	2,045	0.1	1,126	181.5	2,005	102.0	1,902	107.5
Hong Kong	(Mundipharma (Hong Kong) Ltd)	889	0.0	205	434.4	896	99.2	928	95.7
Singapore	(Mundipharma Pharmaceutical Pte Ltd)	577	0.0	522	110.6	620	93.1	781	73.9
Vietnam	(R.O. of Mundipharma Pharm. Pte. Ltd.)	486	0.0	0	0.0	486	100.0	480	101.3
Myanmar	(R.O. of Mundipharma Pharm. Pte. Ltd.)	335	0.0	0	0.0	0	n/a	217	154.1
Total Asia		**62,398**	**3.5**	**42,059**	**148.4**	**60,845**	**102.6**	**52,644**	**118.5**
Australia	(Mundipharma Pty Ltd)	75,421	4.2	70,719	106.6	76,058	99.2	75,115	100.4
New Zealand	(Mundipharma NZ Ltd)	3,271	0.2	3,836	85.3	3,160	103.5	2,483	131.7
Total ANZ		**78,692**	**4.4**	**74,556**	**105.5**	**79,219**	**99.3**	**77,599**	**101.4**
Canada	(Purdue Pharma)	141,387	7.8	173,014	81.7	156,921	90.1	156,921	90.1
Total excluding USA		**820,767**	**45.5**	**822,635**	**99.8**	**834,843**	**98.3**	**824,725**	**99.5**
U.S.A.	(Purdue Pharma LP)	981,222	54.5	1,064,796	92.2	1,033,236	95.0	1,193,444	82.2
Total Sales		**1,801,989**	**100.0**	**1,887,431**	**95.5**	**1,868,079**	**96.5**	**2,018,169**	**89.3**

SUMMARY OF THIS MONTH'S SALES BY COUNTRY

		2013 Actual US$'000	% of Total %	2012 Actual US$'000	2013 vs 2012 %	2013 MYE US$'000	2013 vs MYE %	2013 Budget US$'000	2013 vs Bud %
Germany	(Mundipharma GmbH)	29,952	10.1	30,138	99.4	30,372	98.6	31,325	95.6
UK	(Napp Pharmaceuticals Ltd)	18,608	6.3	21,798	85.4	18,834	98.8	18,861	98.7
Nordic	(Norpharma / Mundipharma)	8,040	2.7	8,177	98.3	8,045	99.9	8,388	95.9
France	(Mundipharma SAS)	7,065	2.4	6,599	107.1	6,880	102.7	6,484	109.0
Italy	(Mundipharma Srl)	6,301	2.1	4,729	133.2	6,766	93.1	6,183	101.9
Switzerland	(Mundipharma Medical Co)	4,281	1.4	4,134	103.5	4,281	100.0	4,180	102.4
Spain	(Mundipharma SL)	3,730	1.3	3,958	94.2	3,783	98.6	3,929	94.9
Austria	(Mundipharma GesmbH)	3,666	1.2	3,800	96.5	3,607	101.7	3,461	106.0
Netherlands	(Mundipharma Pharmaceuticals BV)	2,376	0.8	3,532	67.3	2,485	95.6	2,984	79.6
Eastern Europe	(Mundipharma Medical GmbH)	1,630	0.6	2,061	79.1	1,653	98.6	2,157	75.6
Ireland	(Mundipharma Pharmaceuticals Ltd)	1,058	0.4	1,332	79.4	1,111	95.3	1,423	74.3
Belgium	(Mundipharma CVA)	864	0.3	774	111.7	891	97.0	1,028	84.1
Poland	(Norpharma)	624	0.2	678	92.0	744	83.9	748	83.4
South Africa	(Mundipharma Pty Ltd)	264	0.1	110	240.5	315	84.0	331	79.8
Portugal	(Mundipharma Farmaceutica Lda)	0	0.0	38	0.0	39	0.0	39	0.0
Total Europe		**88,460**	**29.9**	**91,858**	**96.3**	**89,806**	**98.5**	**91,521**	**96.7**
China	(MCPC)	5,884	2.0	3,999	147.1	5,281	111.4	4,468	131.7
Korea	(Mundipharma Korea Ltd)	2,460	0.8	2,168	113.5	2,588	95.1	2,408	102.2
Philippines	(Mundipharma Dist GmbH)	1,197	0.4	1,053	113.6	1,760	68.0	1,491	80.2
Thailand	(Mundipharma (Thailand) Ltd)	395	0.1	0	0.0	144	274.5	297	133.0
Vietnam	(R.O. of Mundipharma Pharm. Pte. Ltd.)	359	0.1	0	0.0	359	100.0	88	407.5
Malaysia	(Mundipharma Pharm. Sdn Bhd)	311	0.1	204	152.8	303	102.6	303	102.7
Hong Kong	(Mundipharma (Hong Kong) Ltd)	149	0.1	76	197.3	172	86.8	186	80.1
Singapore	(Mundipharma Pharmaceutical Pte Ltd)	76	0.0	83	92.2	119	64.1	209	36.5
Myanmar	(R.O. of Mundipharma Pharm. Pte. Ltd.)	0	0.0	0	0.0	0	0.0	36	0.0
Total Asia		**10,831**	**3.7**	**7,582**	**142.9**	**10,727**	**101.0**	**9,486**	**114.2**
Australia	(Mundipharma Pty Ltd)	12,223	4.1	13,609	89.8	12,928	94.5	13,080	93.4
New Zealand	(Mundipharma NZ Ltd)	557	0.2	586	95.0	467	119.3	188	297.0
Total ANZ		**12,780**	**4.3**	**14,195**	**90.0**	**13,395**	**95.4**	**13,267**	**96.3**
Canada	(Purdue Pharma)	22,863	7.7	24,210	94.4	27,552	83.0	27,552	83.0
Total excluding USA		**134,934**	**45.6**	**137,845**	**97.9**	**141,480**	**95.4**	**141,826**	**95.1**
U.S.A.	(Purdue Pharma LP)	161,244	54.4	162,352	99.3	181,224	89.0	198,949	81.0
Total Sales		**296,178**	**100.0**	**300,197**	**98.7**	**322,704**	**91.8**	**340,775**	**86.9**

June 2013


YTD SALES COMPARISON - TOP 15 COUNTRIES BY VALUE (EXCL USA)
2013 ACTUAL vs 2012 ACTUAL (%)
2013 ACTUAL vs 2013 BUDGET (%)
50%
30%
10%
(10)%
(30)%
(12)%
(10)%
(8)%
(6)%
(4)%
(2)%
1%
3%
5%
China
Korea
Italy
France
Spain
Australia
Switzerland
Austria
Germany
Ireland
Eastern Europe
UK
Nordic
Canada
Netherlands


2013 YTD SALES vs 2012 YTD SALES BY COUNTRY (EXCL USA & CANADA)
YTD Growth ($000s)
$11,000
$10,000
$9,000
$8,000
$7,000
$6,000
$5,000
$4,000
$3,000
$2,000
$1,000
$0
($1,000)
($2,000)
($3,000)
($4,000)
($5,000)
China
Italy
France
Other Asia
Australia
Korea
Spain
Other Europe
Switzerland
Philippines
Poland
Eastern Europe
Austria
Belgium
Ireland
Germany
New Zealand
Netherlands
UK
Nordic

June 2013

YEAR TO DATE SALES

	USA	Europe	Canada	ANZ	Asia	**2013**		2012	*2013*	2013	*2013 vs*	2013	*2013 vs*
	(Purdue Pharma LP)		(Purdue Pharma)			**Total**	*% of*	Actual	*vs 2012*	MYE	*MYE*	Budget	*Bud*
	US$'000	US$'000	US$'000	US$'000	US$'000	**US$'000**	*Total*	US$'000	*%*	US$'000	*%*	US$'000	*%*
OxyContin	871,998	95,401	54,748	32,574	21,788	**1,076,510**	*59.7*	1,230,943	*87.5*	1,131,299	*95.2*	1,263,716	*85.2*
Targin / Targinact		119,490	1,160	9,858	5,127	**135,635**	*7.5*	107,725	*125.9*	136,139	*99.6*	138,891	*97.7*
Other Oxycodone		45,350	1,205	3,213	2,514	**52,282**	*2.9*	50,613	*103.3*	51,928	*100.7*	49,012	*106.7*
MST	5,163	30,894	2,452	5,811	10,527	**54,847**	*3.0*	56,946	*96.3*	55,663	*98.5*	54,725	*100.2*
DHC		6,398		842		**7,240**	*0.4*	7,335	*98.7*	7,298	*99.2*	7,280	*99.5*
Tramadol / Ryzolt	(165)	2,339	2,743		6,108	**11,025**	*0.6*	10,327	*106.8*	10,124	*108.9*	9,533	*115.7*
Palladone / Dilaudid	6,448	38,238	50,478	1,597		**96,762**	*5.4*	94,562	*102.3*	93,109	*103.9*	93,358	*103.6*
Norspan / BuTrans	60,016	67,457	3,794	24,224	2,300	**157,792**	*8.8*	135,128	*116.8*	166,640	*94.7*	167,744	*94.1*
Transtec		3,854				**3,854**	*0.2*	4,900	*78.7*	3,936	*97.9*	4,505	*85.6*
Other		3,919	3,566	561	287	**8,333**	*0.5*	10,315	*80.8*	8,710	*95.7*	8,164	*102.1*
ANALGESIC - Total	**943,460**	**413,342**	**120,146**	**78,681**	**48,651**	**1,604,280**	***89.0***	**1,708,793**	***93.9***	**1,664,846**	***96.4***	**1,796,928**	***89.3***
	58.8%	*25.8%*	*7.5%*	*4.9%*	*3.0%*	***100.0%***							
ANTISEPTIC - Total	**5,777**	**9,692**	**703**		**12,248**	**28,420**	***1.6***	**21,536**	***132.0***	**27,590**	***103.0***	**26,106**	***108.9***
	20.3%	*34.1%*	*2.5%*	*0.0%*	*43.1%*	***100.0%***							
Flutiform		7,314				**7,314**	*0.4*			7,676	*95.3*	10,391	*70.4*
Uniphyl / Uniphyllin		1,936	830		154	**2,920**	*0.2*	3,094	*94.4*	2,885	*101.2*	2,928	*99.7*
Other Respiratory		812	202		22	**1,036**	*0.1*	1,150	*90.0*	1,074	*96.4*	1,120	*92.5*
RESPIRATORY - Total		**10,062**	**1,032**		**176**	**11,270**	***0.6***	**4,245**	***265.5***	**11,636**	***96.9***	**14,439**	***78.1***
	0.0%	*89.3%*	*9.2%*	*0.0%*	*1.6%*	***100.0%***							
Adizem		7,833				**7,833**	*0.4*	8,758	*89.4*	8,154	*96.1*	8,987	*87.2*
Other					140	**140**	*0.0*	129	*108.0*	133	*105.3*	120	*116.7*
CARDIOVASCULAR - Total		**7,833**			**140**	**7,973**	***0.4***	**8,887**	***89.7***	**8,286**	***96.2***	**9,107**	***87.5***
	0.0%	*98.2%*	*0.0%*	*0.0%*	*1.8%*	***100.0%***							
Senokot	10,822	28	8,820		605	**20,275**	*1.1*	19,509	*103.9*	18,951	*107.0*	18,956	*107.0*
Colace	13,727					**13,727**	*0.8*	14,429	*95.1*	14,912	*92.1*	14,863	*92.4*
Other		3,510				**3,510**	*0.2*	3,697	*94.9*	3,555	*98.7*	3,555	*98.7*
LAXATIVE - Total	**24,550**	**3,538**	**8,820**		**605**	**37,512**	***2.1***	**37,636**	***99.7***	**37,417**	***100.3***	**37,374**	***100.4***
	65.4%	*9.4%*	*23.5%*	*0.0%*	*1.6%*	***100.0%***							
Levact		70,473				**70,473**	*3.9*	63,384	*111.2*	72,124	*97.7*	75,554	*93.3*
DepoCyte		3,786			38	**3,824**	*0.2*	7,722	*49.5*	3,715	*102.9*	3,267	*117.0*
Folotyn					227	**227**	*0.0*			229	*99.0*	171	*133.0*
ONCOLOGY - Total		**74,259**			**265**	**74,524**	***4.1***	**71,143**	***104.8***	**76,068**	***98.0***	**78,992**	***94.3***
	0.0%	*99.6%*	*0.0%*	*0.0%*	*0.4%*	***100.0%***							
Intermezzo	4,726					**4,726**	*0.3*	4,282	*110.4*	7,388	*64.0*	19,141	*24.7*
Other	2,709	19,564	10,686	11	313	**33,283**	*1.8*	30,909	*107.7*	42,236	*78.8*	36,082	*92.2*
ALL OTHER - Total	**7,436**	**19,564**	**10,686**	**11**	**313**	**38,009**	***2.1***	**35,191**	***108.0***	**42,236**	***90.0***	**55,223**	***68.8***
	19.6%	*51.5%*	*28.1%*	*0.0%*	*0.8%*	***100.0%***							
TOTAL SALES	**981,222**	**538,290**	**141,387**	**78,692**	**62,398**	**1,801,989**	**100.0**	**1,887,431**	***95.5***	**1,868,079**	***96.5***	**2,018,169**	***89.3***
	54.5%	*29.9%*	*7.8%*	*4.4%*	*3.5%*	***100.0%***							

June 2013

MONTH SALES

	USA (Purdue Pharma LP) US$'000	Europe US$'000	Canada (Purdue Pharma) US$'000	ANZ US$'000	Asia US$'000	**2013 Total US$'000**	*% of Total*	2012 Actual US$'000	*2013 vs 2012 %*	2013 MYE US$'000	*2013 vs MYE %*	2013 Budget US$'000	*2013 vs Bud %*
OxyContin	143,922	14,368	8,295	5,308	3,794	**175,687**	*59.3*	193,995	*90.6*	195,952	*89.7*	207,029	*84.9*
Targin / Targinact		21,353	160	1,721	930	**24,164**	*8.2*	20,375	*118.6*	23,886	*101.2*	24,729	*97.7*
Other Oxycodone		7,249	199	580	380	**8,408**	*2.8*	8,477	*99.2*	8,063	*104.3*	8,048	*104.5*
MST	956	4,892	390	914	1,698	**8,849**	*3.0*	9,533	*92.8*	9,231	*95.9*	9,310	*95.0*
DHC		980		74		**1,054**	*0.4*	1,213	*86.9*	1,144	*92.2*	1,255	*84.0*
Tramadol / Ryzolt	(193)	420	464		1,258	**1,949**	*0.7*	2,409	*80.9*	1,783	*109.3*	1,779	*109.5*
Palladone / Dilaudid	479	6,564	8,662	271		**15,977**	*5.4*	16,218	*98.5*	15,875	*100.6*	15,835	*100.9*
Norspan / BuTrans	10,298	10,971	726	3,824	408	**26,227**	*8.9*	24,016	*109.2*	28,768	*91.2*	29,213	*89.8*
Transtec		550				**550**	*0.2*	638	*86.3*	641	*85.9*	701	*78.5*
Other		331	586	87	38	**1,043**	*0.4*	1,632	*63.9*	1,094	*95.4*	1,348	*77.4*
ANALGESIC - Total	**155,462**	**67,679**	**19,483**	**12,779**	**8,507**	**263,908**	***89.1***	**278,506**	***94.8***	**286,436**	***92.1***	**299,248**	***88.2***
	58.9%	*25.6%*	*7.4%*	*4.8%*	*3.2%*	***100.0%***							
ANTISEPTIC - Total	**983**	**1,883**	**96**		**2,108**	**5,070**	***1.7***	**3,665**	***138.4***	**5,185**	***97.8***	**4,510**	***112.4***
	19.4%	*37.1%*	*1.9%*	*0.0%*	*41.6%*	***100.0%***							
Flutiform		1,951				**1,951**	*0.7*			2,321	*84.1*	2,919	*66.8*
Uniphyl / Uniphyllin		306	142		25	**473**	*0.2*	509	*92.9*	465	*101.7*	474	*99.9*
Other Respiratory		120	21		2	**143**	*0.0*	162	*88.3*	167	*85.4*	169	*84.5*
RESPIRATORY - Total		**2,377**	**163**		**27**	**2,567**	***0.9***	**671**	***382.5***	**2,953**	***86.9***	**3,562**	***72.1***
	0.0%	*92.6%*	*6.3%*	*0.0%*	*1.1%*	***100.0%***							
Adizem		1,050				**1,050**	*0.4*	1,529	*68.7*	1,370	*76.6*	1,386	*75.7*
Other					21	**21**	*0.0*	21	*101.2*	18	*119.8*	20	*106.8*
CARDIOVASCULAR - Total		**1,050**			**21**	**1,071**	***0.4***	**1,550**	***69.1***	**1,388**	***77.2***	**1,406**	***76.2***
	0.0%	*98.0%*	*0.0%*	*0.0%*	*2.0%*	***100.0%***							
Senokot	1,964	8	1,622		82	**3,677**	*1.2*	2,912	*126.2*	3,137	*117.2*	3,134	*117.3*
Colace	1,773					**1,773**	*0.6*	2,230	*79.5*	2,478	*71.6*	2,481	*71.5*
Other		525				**525**	*0.2*	571	*91.9*	576	*91.2*	591	*88.9*
LAXATIVE - Total	**3,738**	**533**	**1,622**		**82**	**5,975**	***2.0***	**5,713**	***104.6***	**6,190**	***96.5***	**6,205**	***96.3***
	62.6%	*8.9%*	*27.1%*	*0.0%*	*1.4%*	***100.0%***							
Levact		10,988				**10,988**	*3.7*	11,195	*98.2*	12,596	*87.2*	13,484	*81.5*
DepoCyte		673			10	**683**	*0.2*	1,274	*53.6*	565	*120.8*	811	*84.2*
Folotyn					25	**25**	*0.0*			31	*79.3*	65	*38.0*
ONCOLOGY - Total		**11,661**			**35**	**11,696**	***3.9***	**12,507**	***93.5***	**13,192**	***88.7***	**14,360**	***81.4***
	0.0%	*99.7%*	*0.0%*	*0.0%*	*0.3%*	***100.0%***							
Intermezzo	618					**618**	*0.2*	(7,369)	*(8.4)*	1,136	*54.4*	5,084	*12.2*
Other	443	3,277	1,500	1	51	**5,272**	*1.8*	4,954	*106.4*	7,359	*71.6*	6,400	*82.4*
ALL OTHER - Total	**1,061**	**3,277**	**1,500**	**1**	**51**	**5,890**	***2.0***	**(2,415)**	***(243.9)***	**7,359**	***80.0***	**11,484**	***51.3***
	18.0%	*55.6%*	*25.5%*	*0.0%*	*0.9%*	***100.0%***							
TOTAL SALES	**161,244**	**88,460**	**22,863**	**12,780**	**10,831**	**296,178**	**100.0**	**300,197**	***98.7***	**322,704**	***91.8***	**340,775**	***86.9***
	54.4%	*29.9%*	*7.7%*	*4.3%*	*3.7%*	***100.0%***							

June 2013

SALES BY PRODUCT - YEAR TO DATE

	2013 Actual		2012 Actual		2013 vs 2012		2013 MYE		2013 vs MYE	
	Total US$'000	*% of Total*	Total US$'000	*% of Total*	US$'000	*%*	Total US$'000	*% of Total*	US$'000	*%*
Excluding OxyContin										
Norspan / BuTrans	157,792	*21.8*	135,128	*20.6*	22,664	*116.8*	166,640	*22.6*	(8,848)	*94.7*
Targin / Targinact	135,635	*18.7*	107,725	*16.4*	27,911	*125.9*	136,139	*18.5*	(504)	*99.6*
Palladone / Dilaudid	96,762	*13.3*	94,562	*14.4*	2,200	*102.3*	93,109	*12.6*	3,653	*103.9*
All Other Analgesic	71,709	*9.9*	73,162	*11.1*	(1,453)	*98.0*	71,872	*9.8*	(163)	*99.8*
Levact	70,473	*9.7*	63,384	*9.7*	7,089	*111.2*	72,124	*9.8*	(1,651)	*97.7*
MST	54,847	*7.6*	56,946	*8.7*	(2,099)	*96.3*	55,663	*7.6*	(817)	*98.5*
All Other	29,239	*4.0*	27,742	*4.2*	1,497	*105.4*	30,826	*4.2*	(1,587)	*94.9*
Antiseptic	28,420	*3.9*	21,536	*3.3*	6,884	*132.0*	27,590	*3.7*	830	*103.0*
Senokot	20,275	*2.8*	19,509	*3.0*	765	*103.9*	18,951	*2.6*	1,324	*107.0*
Colace	13,727	*1.9*	14,429	*2.2*	(702)	*95.1*	14,912	*2.0*	(1,184)	*92.1*
Tramadol / Ryzolt	11,025	*1.5*	10,327	*1.6*	698	*106.8*	10,124	*1.4*	901	*108.9*
Adizem	7,833	*1.1*	8,758	*1.3*	(925)	*89.4*	8,154	*1.1*	(320)	*96.1*
Flutiform	7,314	*1.0*	0	*0.0*	7,314	*n/a*	7,676	*1.0*	(362)	*95.3*
Lodotra	5,220	*0.7*	4,484	*0.7*	736	*116.4*	5,228	*0.7*	(8)	*99.8*
Intermezzo	4,726	*0.7*	4,282	*0.7*	444	*110.4*	7,388	*1.0*	(2,662)	*64.0*
DepoCyte	3,824	*0.5*	7,722	*1.2*	(3,897)	*49.5*	3,715	*0.5*	109	*102.9*
Other Laxative	3,510	*0.5*	3,697	*0.6*	(188)	*94.9*	3,555	*0.5*	(45)	*98.7*
Uniphyl / Uniphyllin	2,920	*0.4*	3,094	*0.5*	(174)	*94.4*	2,885	*0.4*	35	*101.2*
Folotyn	227	*0.0*	0	*0.0*	227	*n/a*	229	*0.0*	(2)	*99.0*
Products excl Oxy	**725,479**	***100.0***	**656,488**	***100.0***	**68,992**	***110.5***	**736,780**	***100.0***	**(11,301)**	***98.5***
Products excl Oxy restated		*40.3*		*34.8*				*39.4*		
OxyContin	1,076,510	*59.7*	1,230,943	*65.2*	(154,434)	*87.5*	1,131,299	*60.6*	(54,789)	*95.2*
TOTALS	**1,801,989**	***100.0***	**1,887,431**	***100.0***	**(85,442)**	***95.5***	**1,868,079**	***100.0***	**(66,090)**	***96.5***

YTD SALES BY PRODUCT



June 2013


YTD SALES COMPARISON - BY PRODUCT (EXCL OXYCONTIN)
2013 ACTUAL vs 2012 ACTUAL (%)
2013 ACTUAL vs 2013 BUDGET (%)
All Other
Antiseptic
27%
Targin / Targinact
Norspan / BuTrans
17%
Lodotra
Levact
7%
Tramadol / Ryzolt
Palladone / Dilaudid
Senokot
Not Shown Due To Scale
vs 12 vs MYE
Intermezzo (65%) (36%)
DepoCyte (50%) 3%
(9)%
(4)%
2%
7%
All Other Analgesic
(3)%
MST
Other Laxative
Uniphyl / Uniphyllin
Colace
Adizem
(13)%


2013 YTD SALES vs 2012 YTD SALES BY PRODUCT (EXCL OXYCONTIN)
YTD Growth ($000s)
$27,500
$25,500
$23,500
$21,500
$19,500
$17,500
$15,500
$13,500
$11,500
$9,500
$7,500
$5,500
$3,500
$1,500
($500)
($2,500)
($4,500)
Targin / Targinact
Norspan / BuTrans
All Other
Levact
Antiseptic
Palladone / Dilaudid
Senokot
Lodotra
Tramadol / Ryzolt
Intermezzo
Uniphyl / Uniphyllin
Other Laxative
Colace
Adizem
All Other Analgesic
MST
DepoCyte

June 2013

SALES BY COUNTRY - YEAR TO DATE

	2013 Actual		2012 Actual		2013 vs 2012		2013 MYE		2013 vs MYE	
	Total US$'000	% of Total	Total US$'000	% of Total	US$'000	%	Total US$'000	% of Total	US$'000	%
Excluding OxyContin										
Germany (M. GmbH)	158,630	21.9	156,670	23.9	1,960	101.3	159,230	21.6	(600)	99.6
USA (Purdue)	109,224	15.1	100,796	15.4	8,428	108.4	121,728	16.5	(12,504)	89.7
UK (Napp)	95,134	13.1	93,555	14.3	1,579	101.7	94,623	12.8	511	100.5
Canada (Purdue)	86,639	11.9	78,198	11.9	8,441	110.8	85,104	11.6	1,535	101.8
Australia (M. Pty Ltd)	44,711	6.2	37,439	5.7	7,271	119.4	45,364	6.2	(654)	98.6
Nordics (Norpharma)	40,228	5.5	36,067	5.5	4,162	111.5	40,336	5.5	(108)	99.7
Italy (M. Srl)	27,953	3.9	17,671	2.7	10,282	158.2	28,074	3.8	(121)	99.6
France (M. SAS)	26,149	3.6	22,570	3.4	3,578	115.9	25,761	3.5	388	101.5
Austria (M. GesmbH)	22,053	3.0	21,669	3.3	385	101.8	22,004	3.0	49	100.2
Swiss Domestic (MMCO)	20,506	2.8	18,501	2.8	2,005	110.8	20,781	2.8	(275)	98.7
Spain (M. SL)	19,422	2.7	15,627	2.4	3,795	124.3	19,456	2.6	(35)	99.8
China (MCPC)	14,522	2.0	12,462	1.9	2,060	116.5	14,460	2.0	62	100.4
Korea (M. Korea Ltd)	12,225	1.7	6,225	0.9	6,001	196.4	12,216	1.7	10	100.1
Netherlands (M. P. BV)	11,613	1.6	10,652	1.6	961	109.0	11,806	1.6	(194)	98.4
Philippines (M Dist GmbH)	7,139	1.0	6,240	1.0	899	114.4	7,513	1.0	(374)	95.0
Eastern Europe (MMG)	6,601	0.9	5,887	0.9	714	112.1	6,633	0.9	(31)	99.5
Ireland (M. P. Ltd)	6,470	0.9	6,500	1.0	(30)	99.5	6,505	0.9	(35)	99.5
Other (inc NZ)	6,259	0.9	3,746	0.6	2,513	167.1	5,857	0.8	402	106.9
Belgium (M. CVA)	4,137	0.6	3,137	0.5	1,000	131.9	4,046	0.5	91	102.2
Thailand (Mundi. (T'land) Ltd)	3,020	0.4	0	0.0	3,020	n/a	2,534	0.3	486	119.2
Poland (Norpharma)	2,845	0.4	2,876	0.4	(31)	98.9	2,749	0.4	95	103.5
Products excl Oxy	**725,479**	**100.0**	**656,488**	**100.0**	**68,992**	**110.5**	**736,780**	**100.0**	**(11,301)**	**98.5**
Products excl Oxy restated		40.3		34.8				39.4		
OxyContin	1,076,510	59.7	1,230,943	65.2	(154,434)	87.5	1,131,299	60.6	(54,789)	95.2
TOTALS	**1,801,989**	**100.0**	**1,887,431**	**100.0**	**(85,442)**	**95.5**	**1,868,079**	**100.0**	**(66,090)**	**96.5**



June 2013 **OXYCONTIN SALES HISTORY**

	USA (Purdue Pharma LP)	Canada (Purdue Pharma)	Nordic (Norpharma / Mundipharma)	Germany (Mundipharma GmbH)	Ireland (Mundipharma Pharm. Ltd)	Australia (Mundipharma Pty Ltd)	UK (Napp Pharma. Ltd)	Neths. (Mundipharma Pharm. BV)	Switzerland (Mundipharma Medical Co)	E.Europe (Mundipharma Medical GmbH)	Austria (Mundipharma GesmbH)	Korea (Mundipharma Korea Ltd)	France (Mundipharma SAS)	Spain (Mundipharma SL)	Italy (Mundipharma Srl)	New Zealand (Mundipharma NZ Ltd)	SE Asia (P'pines, HK, Malaysia, S'pore)	China (MCPC)	Belgium (Mundipharma CVA)	Poland (Norpharma)	South Africa (Mundipharma Pty Ltd)	Total Monthly Sales	12 Mth Rolling Total	12 Mth Monthly Moving Average
Date of Launch >	Dec 95	Jun 96	Dec 96	Aug 98	Jan 99	Sep 99	Jan 00	Dec 00	Feb 01	Feb 01	Mar 01	Mar 01	Apr 02	Jun 04	Mar 05	Jul 05	Jul 05	Aug 04	Feb 07	Jul 08	Mar 12			
	US$'000	US$'000	US$'000	US$'000	US$'000	US$'000	US$'000	US$'000	US$'000	US$'000	US$'000	US$'000	US$'000	US$'000	US$'000	US$'000	US$'000	US$'000	US$'000	US$'000	US$'000	US$'000	US$'000	US$'000
1996	**47,982**	**122**	**12**																			**48,116**	**48,116**	**4,010**
1997	**133,255**	**1,014**	**240**																			**134,509**	**134,509**	**11,209**
1998	**273,219**	**2,614**	**646**	**2,669**																		**279,148**	**279,148**	**23,262**
1999	**562,570**	**5,111**	**1,541**	**10,956**	**228**																	**580,405**	**580,405**	**48,367**
2000	**951,446**	**9,583**	**2,620**	**14,612**	**326**	**1,663**	**2,320**	**22**														**982,592**	**982,592**	**81,883**
	96.8%	*1.0%*	*0.3%*	*1.5%*	*0.0%*	*0.2%*	*0.2%*	*0.0%*														*100.0%*		
2001	**1,232,159**	**18,349**	**4,783**	**21,915**	**553**	**3,985**	**6,639**	**351**	**41**	**92**	**262**	**1,419**										**1,290,548**	**1,290,548**	**107,546**
	95.5%	*1.4%*	*0.4%*	*1.7%*	*0.0%*	*0.3%*	*0.5%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.1%*										*100.0%*		
2002	**1,269,342**	**29,691**	**9,739**	**37,060**	**845**	**6,681**	**11,793**	**1,333**	**213**	**283**	**662**	**2,200**	**629**									**1,370,471**	**1,370,471**	**114,206**
	92.6%	*2.2%*	*0.7%*	*2.7%*	*0.1%*	*0.5%*	*0.9%*	*0.1%*	*0.0%*	*0.0%*	*0.0%*	*0.2%*	*0.0%*									*100.0%*		
2003	**1,619,821**	**52,889**	**17,213**	**62,176**	**1,233**	**10,809**	**20,052**	**3,196**	**1,097**	**945**	**948**	**3,607**	**1,652**									**1,795,638**	**1,795,638**	**149,637**
	90.2%	*2.9%*	*1.0%*	*3.5%*	*0.1%*	*0.6%*	*1.1%*	*0.2%*	*0.1%*	*0.1%*	*0.1%*	*0.2%*	*0.1%*									*100.0%*		
2004	**1,334,601**	**75,404**	**22,170**	**79,186**	**1,262**	**16,051**	**24,696**	**5,655**	**2,208**	**1,681**	**1,360**	**5,533**	**3,345**	**336**								**1,573,488**	**1,573,488**	**131,124**
	84.8%	*4.8%*	*1.4%*	*5.0%*	*0.1%*	*1.0%*	*1.6%*	*0.4%*	*0.1%*	*0.1%*	*0.1%*	*0.4%*	*0.2%*	*0.0%*								*100.0%*		
2005	**941,705**	**93,960**	**27,676**	**114,711**	**1,988**	**20,032**	**33,687**	**7,317**	**3,300**	**3,537**	**1,399**	**5,663**	**5,404**	**1,169**	**839**	**103**	**345**					**1,262,836**	**1,262,836**	**105,236**
	74.6%	*7.4%*	*2.2%*	*9.1%*	*0.2%*	*1.6%*	*2.7%*	*0.6%*	*0.3%*	*0.3%*	*0.1%*	*0.4%*	*0.4%*	*0.1%*	*0.1%*	*0.0%*	*0.0%*					*100.0%*		
2006	**605,123**	**124,231**	**32,382**	**130,001**	**1,869**	**24,704**	**42,330**	**9,420**	**4,551**	**4,437**	**1,852**	**8,629**	**7,209**	**1,927**	**3,104**	**505**	**644**					**1,002,915**	**1,002,915**	**83,576**
	60.3%	*12.4%*	*3.2%*	*13.0%*	*0.2%*	*2.5%*	*4.2%*	*0.9%*	*0.5%*	*0.4%*	*0.2%*	*0.9%*	*0.7%*	*0.2%*	*0.3%*	*0.1%*	*0.1%*					*100.0%*		
2007	**955,636**	**152,630**	**41,294**	**90,966**	**2,404**	**33,018**	**57,144**	**11,982**	**6,425**	**6,718**	**2,274**	**11,035**	**10,126**	**3,066**	**6,690**	**1,198**	**954**	**2,421**	**516**			**1,396,496**	**1,396,496**	**116,375**
	68.4%	*10.9%*	*3.0%*	*6.5%*	*0.2%*	*2.4%*	*4.1%*	*0.9%*	*0.5%*	*0.5%*	*0.2%*	*0.8%*	*0.7%*	*0.2%*	*0.5%*	*0.1%*	*0.1%*	*0.2%*	*0.0%*			*100.0%*		
2008	**2,114,078**	**164,773**	**44,031**	**69,907**	**2,717**	**36,032**	**52,130**	**13,052**	**8,914**	**8,635**	**2,657**	**8,663**	**13,958**	**5,333**	**10,242**	**1,612**	**1,316**	**4,444**	**1,628**	**8**		**2,564,130**	**2,564,130**	**213,677**
	82.4%	*6.4%*	*1.7%*	*2.7%*	*0.1%*	*1.4%*	*2.0%*	*0.5%*	*0.3%*	*0.3%*	*0.1%*	*0.3%*	*0.5%*	*0.2%*	*0.4%*	*0.1%*	*0.1%*	*0.2%*	*0.1%*	*0.0%*		*100.0%*		
2009	**2,457,763**	**181,732**	**45,943**	**62,779**	**2,876**	**42,270**	**56,581**	**9,269**	**10,037**	**8,874**	**2,665**	**9,523**	**18,718**	**6,764**	**17,688**	**2,261**	**1,556**	**6,308**	**2,278**	**24**		**2,945,909**	**2,945,909**	**245,492**
	83.4%	*6.2%*	*1.6%*	*2.1%*	*0.1%*	*1.4%*	*1.9%*	*0.3%*	*0.3%*	*0.3%*	*0.1%*	*0.3%*	*0.6%*	*0.2%*	*0.6%*	*0.1%*	*0.1%*	*0.2%*	*0.1%*	*0.0%*		*100.0%*		
2010	**2,267,670**	**205,224**	**40,016**	**50,960**	**2,965**	**54,863**	**53,388**	**14,691**	**11,468**	**10,799**	**1,973**	**10,219**	**22,902**	**8,206**	**24,384**	**3,396**	**1,864**	**8,509**	**3,257**	**134**		**2,796,889**	**2,796,889**	**233,074**
	81.1%	*7.3%*	*1.4%*	*1.8%*	*0.1%*	*2.0%*	*1.9%*	*0.5%*	*0.4%*	*0.4%*	*0.1%*	*0.4%*	*0.8%*	*0.3%*	*0.9%*	*0.1%*	*0.1%*	*0.3%*	*0.1%*	*0.0%*		*100.0%*		
2011	**2,045,908**	**215,457**	**45,460**	**43,576**	**3,229**	**66,497**	**62,363**	**17,209**	**13,608**	**9,165**	**1,342**	**10,222**	**28,057**	**6,556**	**24,876**	**3,954**	**2,402**	**13,779**	**4,140**	**1,829**		**2,619,627**	**2,619,627**	**218,302**
	78.1%	*8.2%*	*1.7%*	*1.7%*	*0.1%*	*2.5%*	*2.4%*	*0.7%*	*0.5%*	*0.3%*	*0.1%*	*0.4%*	*1.1%*	*0.3%*	*0.9%*	*0.2%*	*0.1%*	*0.5%*	*0.2%*	*0.1%*		*100.0%*		
Jan-12	114,958	18,212	3,195	2,821	214	6,122	5,657	1,344	1,063	22	28	916	2,229	511	2,422	363	264	1,290	236	96		161,963	2,599,498	216,625
Feb-12	127,009	23,526	3,769	2,834	233	4,873	4,722	1,430	994	267	35	766	2,221	508	1,600	347	222	1,462	337	121		177,278	2,592,208	216,017
Mar-12	225,184	21,549	3,272	2,991	227	5,701	5,765	1,354	1,060	1,186	46	732	2,396	458	1,294	255	206	1,637	377	224	27	275,940	2,593,572	216,131
Apr-12	149,161	11,872	2,383	2,816	235	5,635	5,378	1,296	973	309	44	754	2,510	545	1,899	319	340	1,458	277	308	28	188,539	2,546,823	212,235
May-12	199,012	10,601	2,597	2,880	246	5,272	6,687	1,453	1,023	449	46	808	2,608	481	1,964	400	183	1,682	365	295	52	239,106	2,581,510	215,126
Jun-12	145,696	10,952	2,275	3,095	229	6,363	6,726	1,564	1,057	636	42	864	2,618	647	1,215	310	135	1,748	219	122	30	186,544	2,512,838	209,403
Jul-12	155,532	14,185	2,530	3,068	217	5,439	5,264	1,507	1,011	524	40	879	2,742	443	2,736	340	229	1,757	381	307	71	199,200	2,511,317	209,276
Aug-12	196,367	12,156	2,509	2,754	241	5,530	6,006	1,832	935	562	39	695	2,636	193	881	309	180	1,918	301	319	57	236,418	2,528,614	210,718
Sep-12	129,031	9,447	2,348	2,925	238	5,240	5,522	1,538	883	671	34	752	2,242	372	883	307	295	2,147	251	185	82	165,391	2,474,168	206,181
Oct-12	154,821	13,409	2,211	2,897	232	5,580	5,894	1,494	1,071	800	49	694	2,617	309	1,736	333	187	2,048	287	303	86	197,054	2,481,796	206,816
Nov-12	195,245	13,450	1,665	3,037	275	6,266	6,503	1,071	1,040	875	37	645	2,846	361	983	373	244	2,242	187	258	87	237,692	2,503,294	208,608
Dec-12	196,457	9,007	1,428	2,728	204	4,273	5,358	860	918	467	34	451	2,863	263	500	311	206	1,948	160	114	107	228,661	2,493,786	207,815
2012	**1,988,473**	**168,365**	**30,182**	**34,847**	**2,792**	**66,295**	**69,482**	**16,742**	**12,029**	**6,768**	**474**	**8,956**	**30,530**	**5,090**	**18,113**	**3,967**	**2,691**	**21,336**	**3,379**	**2,652**	**625**	**2,493,786**	**2,493,786**	**207,815**
	79.7%	*6.8%*	*1.2%*	*1.4%*	*0.1%*	*2.7%*	*2.8%*	*0.7%*	*0.5%*	*0.3%*	*0.0%*	*0.4%*	*1.2%*	*0.2%*	*0.7%*	*0.2%*	*0.1%*	*0.9%*	*0.1%*	*0.1%*	*0.0%*	*100.0%*		
Jan-13	124,553	10,122	1,801	2,692	253	5,516	4,738	814	1,050	89	38	691	2,874	383	1,707	262	273	2,620	201	267	54	160,998	2,492,821	207,735
Feb-13	125,814	9,694	1,377	2,680	207	4,620	4,277	632	863	639	34	492	2,524	219	1,132	324	177	2,679	166	250	87	158,886	2,474,429	206,202
Mar-13	159,968	8,174	1,188	2,511	223	5,079	5,486	542	929	490	32	241	2,674	391	624	293	226	3,476	178	243	89	193,055	2,391,544	199,295
Apr-13	168,299	9,088	1,487	2,411	239	5,476	4,496	682	928	597	34	296	3,212	198	1,932	330	172	2,891	161	427	80	203,436	2,406,441	200,537
May-13	149,442	9,377	1,536	2,555	238	5,061	5,298	742	882	315	41	431	2,936	307	974	305	224	3,106	203	358	118	184,447	2,351,782	195,982
Jun-13	143,922	8,295	1,493	2,631	135	4,958	3,785	552	884	481	36	434	2,829	250	839	351	101	3,260	183	172	98	175,687	2,340,926	195,077
2013	**871,998**	**54,748**	**8,881**	**15,481**	**1,294**	**30,710**	**28,079**	**3,964**	**5,537**	**2,612**	**214**	**2,584**	**17,049**	**1,749**	**7,207**	**1,864**	**1,173**	**18,032**	**1,091**	**1,716**	**528**	**1,076,510**	**2,340,926**	**195,077**
	81.0%	*5.1%*	*0.8%*	*1.4%*	*0.1%*	*2.9%*	*2.6%*	*0.4%*	*0.5%*	*0.2%*	*0.0%*	*0.2%*	*1.6%*	*0.2%*	*0.7%*	*0.2%*	*0.1%*	*1.7%*	*0.1%*	*0.2%*	*0.0%*	*100.0%*		
GRAND TOTAL 1996 - 2013 YTD	**21,672,750**	**1,555,895**	**374,829**	**841,802**	**26,581**	**413,610**	**520,683**	**114,202**	**79,427**	**64,546**	**18,082**	**88,252**	**159,578**	**40,195**	**113,142**	**18,859**	**12,944**	**74,828**	**16,290**	**6,364**	**1,152**	**26,214,013**		

YEAR TO DATE JUNE 2013

	2013 Actual	2012 Actual	2013 MYE	2013 Actual vs 2012 Actual		2013 Actual vs. MYE	
	US$'000	US$'000	US$'000	US$'000	%	US$'000	%
Israel (Rafa Laboratories Ltd)							
OxyContin	1,148	1,299	1,246	(150)	*88.4*	(98)	*92.1*
Targin / Targinact	2,006	1,459	1,772	547	*137.5*	234	*113.2*
Other Oxycodone	610	546	516	64	*111.7*	93	*118.1*
Morphine	281	258	247	22	*108.6*	34	*113.8*
BuTrans	429	463	454	(34)	*92.6*	(25)	*94.4*
Adizem	106	96	86	10	*110.1*	20	*123.9*
Prioderm	145	200	145	(55)	*72.6*	0	*100.1*
Hedrin	884	657	685	227	*134.5*	199	*129.1*
Lodotra	5	0	5	4	*1041.1*	(0)	*97.2*
Non Mundipharma products	30,360	26,830	26,250	3,531	*113.2*	4,110	*115.7*
	35,973	**31,808**	**31,406**	**4,165**	***113.1***	**4,568**	***114.5***
India (Modi Mundipharma Ltd)							
Analgesic	5,831	5,360	6,078	471	*108.8*	(247)	*95.9*
Betadine	16,547	15,220	16,696	1,327	*n/a*	(149)	*99.1*
Respiratory	2,590	2,322	2,648	269	*111.6*	(58)	*97.8*
Cardiovascular	5,190	4,943	5,274	248	*105.0*	(84)	*98.4*
Laxative	266	11	241	255	*2375.8*	25	*110.6*
Non Mundipharma products	12,299	12,241	13,130	58	*100.5*	(830)	*93.7*
	42,724	**40,097**	**44,067**	**2,627**	***106.6***	**(1,342)**	***97.0***
Cyprus (Mundipharma Pharmaceuticals Ltd)							
Analgesic	389	323	338	66	*120.5*	51	*115.2*
Betadine	705	719	726	(14)	*98.0*	(21)	*97.1*
Respiratory	213	226	293	(13)	*94.2*	(80)	*72.7*
Cardiovascular	29	30	30	(1)	*96.8*	(1)	*96.7*
Laxative	36	33	34	2	*106.7*	1	*104.1*
Hedrin	100	85	92	15	*117.6*	8	*108.7*
Oncology	163	120	114	43	*135.5*	49	*143.1*
Non Mundipharma products	1,489	1,617	1,480	(128)	*92.1*	9	*100.6*
	3,124	**3,154**	**3,107**	**(30)**	***99.1***	**17**	***100.5***
TOTAL	**81,822**	**75,059**	**78,580**	**6,763**	***109.0***	**3,242**	***104.1***

MONTH OF JUNE 2013

	2013 Actual	2012 Actual	2013 MYE	2013 Actual vs 2012 Actual		2013 Actual vs. MYE	
	US$'000	US$'000	US$'000	US$'000	%	US$'000	%
Israel (Rafa Laboratories Ltd)							
OxyContin	215	170	184	45	*126.3*	31	*116.8*
Targin / Targinact	332	207	309	125	*160.6*	23	*107.4*
Other Oxycodone	96	79	79	17	*121.5*	17	*121.5*
Morphine	54	34	36	20	*159.8*	18	*149.0*
BuTrans	58	69	77	(11)	*83.4*	(20)	*74.8*
Adizem	27	11	13	17	*251.8*	14	*205.8*
Prioderm	6	18	18	(12)	*32.9*	(13)	*31.4*
Hedrin	130	40	77	90	*326.8*	53	*168.6*
Lodotra	1	0	1	1	*264.7*	0	*117.8*
Non Mundipharma products	4,896	3,958	4,266	938	*123.7*	630	*114.8*
	5,815	**4,586**	**5,062**	**1,229**	***126.8***	**753**	***114.9***
India (Modi Mundipharma Ltd)							
Analgesic	869	902	1,047	(32)	*96.4*	(177)	*83.1*
Betadine	2,654	2,661	2,796	(7)	*99.7*	(142)	*94.9*
Respiratory	466	349	446	117	*133.5*	19	*104.3*
Cardiovascular	952	819	995	134	*116.3*	(43)	*95.7*
Laxative	64	0	47	64		18	*137.4*
Non Mundipharma products	1,975	2,165	2,553	(190)	*91.2*	(578)	*77.3*
	6,981	**6,895**	**7,885**	**86**	***101.3***	**(904)**	***88.5***
Cyprus (Mundipharma Pharmaceuticals Ltd)							
Analgesic	81	39	49	42	*207.9*	32	*165.6*
Betadine	115	44	112	71	*259.4*	3	*103.0*
Respiratory	16	11	18	5	*147.6*	(1)	*92.3*
Cardiovascular	5	5	5	0	*100.6*	(0)	*99.1*
Laxative	5	5	5	(0)	*99.6*	0	*101.7*
Hedrin	18	9	13	9	*202.6*	5	*140.4*
Oncology	30	46	20	(16)	*64.8*	10	*151.2*
Non Mundipharma products	247	266	250	(19)	*92.8*	(3)	*98.9*
	518	**426**	**471**	**92**	***121.6***	**47**	***109.9***
TOTAL	**13,314**	**11,906**	**13,418**	**1,408**	***111.8***	**(104)**	***99.2***

From: Mahony, Edward
Sent: 2013年7月16日 15:13
To: Boer, Peter; Lewent, Judy; Pickett, Cecil; Costa, Paulo; Snyderman, Ralph; Sackler, Dr Raymond R; Sackler, Dr Richard; Sackler, Jonathan; Sackler, Dame Theresa; Sackler, Dr Kathe; Sackler, Mortimer D.A.; Sackler Lefcourt, Ilene; Sackler, David; Baker, Stuart D.; Sackler [redacted] Beverly; Stewart, John H. (US);[redacted] Gasdia, Russell; Landau, Dr. Craig;[redacted] Lundie, David; [redacted] Weinstein, Bert[redacted]ale, David
CC: Lowne, Jon; [redacted]
Subject: June 2013 Financial Statements
Attachments: June 2013 Financial Statement Cover Memo Final.docx; Copy of Financial Statements 06 30 2013 v2 (3).xlsm

Colleagues,

Attached for your information are the Purdue June 2013 financial statements.

We are happy to supply a hard copy upon request.

Ed

PURDUE

To: John Stewart

From: Ed Mahony

CC: [redacted]

Jon Lowne, [redacted] Executive Committee

Date: July 11, 2013

Subject: Year-to-date June 2013 financial results

Attached are the June year-to-date 2013 Purdue financial statements. Actual results are compared to the 2013 mid-year forecast, 2013 budget and 2012 actual results.

NET SALES

Net Sales for the six months ending June were $982.9 million --- $81.9 million lower than 2012, $210.5 million lower than budget and $47.9 million or 4.7% under the mid-year forecast. The reason for the under mid-year forecast sales performance is reductions in trade inventory in advance of the July 4th holiday buy. The underlying demand is tracking at or very close to the mid-year forecast.

OxyContin

OxyContin net sales for the six months ending June were $878.1 million --- $41.0 million below the mid-year forecast and $97.2 million lower than 2012. The variance vs. mid-year forecast is due to:

a. OxyContin demand – as reported by IMS -- is running in line with the mid-year forecast.
b. OxyContin trade inventory is running $39.9 million below the mid-year forecast. At the end of June, trade inventory was low – 1.6 months for wholesalers and pharmacy combined. Trade inventories should be back closer to 1.8 months when orders in house at the end of June were shipped in early July (net sales value $32 million).

Other influences of future demand:

a. In April 2013 Walgreens implemented a nationwide requirement that its pharmacists rigorously review and evaluate the appropriateness of Class 2 prescriptions and where they deem it appropriate - not filling prescriptions. Similar efforts are in various stages at other pharmacies. The result of this effort may increasingly depress future prescriptions. The Purdue management team will report on this and other environmental factors at the July 25, 2013 Board meeting.
b. The 2013 budget assumed that the analgesic sales force would have OxyContin as the primary focus in 50% of all calls up from 30% at the end of 2012. That would have resulted in 181 thousand primary OxyContin sales calls in the first 6 months of 2013. Due to vacancies and a slower than expected implementation of this change, OxyContin was the primary focus in about 117 thousand sales calls through the end of June, 64% of target. Q3 target lists have been issued to the field force and OxyContin primary sales calls are increasing to 44% of all calls --- approaching the 50% target when secondary calls are added at ½ the value of a primary.
c. McKinsey has been engaged to work with Sales & Marketing to identify opportunities to improve performance of OxyContin. A preliminary report of this work will be made in time for the July 25th Board meeting.

<u>Butrans</u>

Butrans net sales for the six months ending June were $52.2 million --- $7.1 million below the mid-year forecast and $11.2 million above 2012. The net sales miss is driven by contraction in trade inventory and prescriptions running slightly below the mid-year forecast. The mid-year forecast assumes full year Butrans net sales of $127 million, the same as budget. The analgesic sales force made 213 thousand primary Butrans sales calls through the end of June vs. budget of 182 thousand calls, or 117% of target.

<u>Intermezzo</u>

The mid-year forecast assumes full year Intermezzo net sales of $10.3 million versus budget of $44 million. Prescriptions as reported by IMS are in line with the mid-year forecast.

<u>Operating expenses</u>

Total operating expenses were $435.4 million:

	Year-to-date June				Variance 2013 actual vs.			
(million)	Actual	Forecast	Budget	Prior year	Forecast	2013 Budget	2012 Actual	2013 Forecast
G&A	$ 75.4	$ 80.1	$ 80.8	$ 75.7	$ (4.7)	$ (5.4)	$ (0.3)	$ 158.4
Legal Fees	36.5	28.9	29.1	27.3	7.6	7.4	9.2	54.5
R&D	151.9	152.7	199.1	159.0	(0.8)	(47.2)	(7.1)	327.2
R&D Other - Milestones and Alliances	9.4	9.1	3.3	0.9	0.3	6.1	8.5	11.0
S&P	147.6	149.2	158.2	146.3	(1.6)	(10.6)	1.3	288.3
New Health Care Reform Pharma Fee	15.9	15.9	15.9	15.0	-	-	0.9	31.8
Other - US	(1.3)	0.3	2.3	(0.8)	(1.6)	(3.6)	(0.5)	0.4
Total	**$ 435.4**	**$ 436.2**	**$ 488.7**	**$ 423.4**	**$ (0.8)**	**$ (53.3)**	**$ 12.0**	**$ 871.6**

1. G&A spend through June 30, 2013 was $75.4 million, which is:
    a. Lower than the 2013 mid-year forecast by $4.7 million primarily due to: $1.5 million favorable spend in External Affairs due to timing and favorable spend across other departments.
    b. Lower than 2012 by $0.3 million.
2. Redacted

[1] Since mid-2011 to the end of 2013 we estimate that Grunenthal will have spent $13-$14 million in legal fees on OxyContin related matters which they unfairly expect Purdue to reimburse.

3. R&D spend through June 30, 2013 was in line with the mid-year forecast and $47.2 million lower than budget:

	Year-to-date June			2013
	Actual	Budget	Variance	Budget
Oxycodone Naloxone	$ 42.1	$ 61.6	$ 19.5	$ 117.7
Hydrocodone QD TR	30.9	34.1	3.2	64.1
Butrans	8.1	32.5	24.4	53.1
OxyContin (primary pediatric)	10.7	17.4	6.7	34.0
Oxycodone IR TR	6.1	7.8	1.7	13.9
TRPV1 (Purdue)	6.4	11.6	5.2	25.4
ORL1	1.4	1.3	(0.2)	2.6
Discovery Projects	10.3	12.8	2.5	25.6
Market Support Projects/All other	35.8	32.8	(3.0)	66.5
Finance Underspend Estimate	-	(12.7)	(12.7)	(25.4)
Research and Development	**$ 151.9**	**$ 199.1**	**$ 47.2**	**$ 377.6**

Oxycodone Naloxone (ONU)
2013 June year-to-date spend is $19.5 million below budget due primarily to slower than expected enrollment in the two pain plus OIC efficacy studies. The slower enrollment has led to several significant protocol changes in an effort to bring the trial to an earlier completion including reducing sample size, increasing sites and more. As a result, spending for the full year is now expected to be approximately $35 million less than budget. This decrease was taken into account in the mid-year forecast.

Hydrocodone QD TR (HYD)
2013 June year-to-date spend is $3.2 million below budget due primarily to the timing of non-clinical spend. This favorability is expected to reverse over the balance of the year. The HYD team recently extended the open label safety study for six months in order to generate data regarding the safety of longer term opioid exposure. This extension, along with carryover from 2012, results in spending for the full year to be approximately $4.2 million higher than budget. This increase was taken into account in the mid-year forecast.

Butrans
2013 June year-to-date spend is $24.4 million below budget primarily due to a change in registration strategy for the higher strengths program from full clinical programs to analysis of existing worldwide data. As a result, spending for the full year is expected to be approximately $24 million less than budget. This decrease was taken into account in the mid-year forecast.

OxyContin (primarily pediatric)
2013 June year-to-date spend is $6.7 million below budget driven by favorability in pediatric studies and risk management. OTR 3001 Safety Study has a current enrollment of 98 patients with a target of 154 patients.

TRPV1 Lead (Purdue)
2013 June year-to-date spend is $5.2 million below budget driven by favorability in clinical and nonclinical spend which is expected to reverse in coming months.

4. S&P spend through June 30, 2013 was $147.6 million, which is:

   a. $1.6 million lower than the mid-year forecast due to timing of Intermezzo promotional spend.

   b. $10.6 million lower than budget due to:
      i. Lower expenses related to the contract sales force ($1.3 million) driven by vacancies (10%). A 60 day accrual for severance of $2.3 million was recorded on the termination date of May 14, 2013.
      ii. Lower OxyContin ($2.8 million) and Butrans ($3.0 million) promotional spend.
      iii. Lower people driven expenses ($2.8 million) due to lower sales bonus ($1.1 million) and vacancies (3.5%) in the Analgesic Sales Force ($1.7 million).
      iv. Lower all other ($0.6 million).

   c. $1.3 million higher than prior year primarily due to:
      i. Higher Intermezzo promotional spend ($6.0 million).
      ii. Lower spending in contract sales organization ($12.0 million) due to a reduction from 275 representatives in first half of 2012 to 90 through May 2013.
      iii. Higher people driven expenses primarily due to higher sales bonus ($2.9 million).
      iv. Higher all other ($4.4 million).

   d. 2013 June year-to-date calls were below goal driven by vacancies (averaging 3.5% versus budget of 2.5%) and lower calls per day (6.9 versus budget of 7.1).

Calls by Product
2013 Budget v. Actual
June YTD

Primary Calls	**Budget**	**Act**	**Var**
Butrans	181,986	213,267	31,280
OxyContin	181,986	117,820	(64,166)
Total Primary Calls	363,973	331,087	(32,886)
Secondary Calls	**Budget**	**Act**	**Var**
OxyContin	163,788	182,574	18,786
Butrans	163,788	111,833	(51,955)
Total Secondary Calls	327,575	294,406	(33,169)
Tertiary Calls	**Budget**	**Act**	**Var**
Intermezzo	127,390	226,959	99,568
Total Tertiary Calls	127,390	226,959	99,568
PDEs	**Budget**	**Act**	**Var**
Butrans	263,880	269,183	5,303
OxyContin	263,880	209,107	(54,773)
Intermezzo	12,739	22,696	9,957
Total PDEs	540,499	500,986	(39,513)
Calls	**Budget**	**Act**	**Var**
Butrans	345,774	325,099	(20,675)
OxyContin	345,774	300,394	(45,380)
Intermezzo	127,390	226,959	99,568
Total calls	818,938	852,452	33,514

Pre-tax earnings

Full year pre-tax earnings of $470.8 million are:

a. $25.0 million lower than the mid-year forecast due to lower gross profit ($38.8 million) on lower sales, higher incentives ($8.6 million) due to the Better Medicine Awards offset by lower ex-US expense of $22 million due to the timing of funding.

b. $9.4 million lower than budget due to lower gross profit ($183.3 million) on lower sales, higher incentives ($5.1 million), offset by lower operating expenses ($53.4 million) and the gain on Infinity stock ($124.6 million).

c. $2.7 million higher than 2012 primarily due to lower gross profit ($77.9 million) on lower sales, higher operating expenses ($12.0 million), lower ex-US royalty income ($22.2 million) and higher incentives Redacted offset by the gain on Infinity stock ($124.6 million).

Pearl Therapeutics

The 2013 forecast includes $80.3 million of cash funding to Pearl Therapeutics of which $30.3 million was included as Ex-US expense and $50 million was included as an investment relating to the purchase of Pearl stock. Since the Pearl transaction did not close, there will be variances in these line items versus the 2013 forecast.

Non-Tax Distributions

Year-to-date partner non-tax distributions were $357.6 million, made up of $216.7 million of Infinity shares and $140.9 million in cash, of which $10 million was re-invested in Rhodes.

Working Capital Highlights

Cash and Short Term Investments

At the end of June, unrestricted cash and short term investments totaled $831 million --- which is $7 million higher than forecast. This temporary higher-than-forecast cash balance is due to timing of payments. Actual cash payments during the month included Redacted Redacted the Better Medicine Awards ($9.1 million).

Accounts Receivable

1. The rolling 3 month average Day's Sales Outstanding ("DSO") was 33.4 days at June 30, 2013 which is 1.6 days lower than our target of 35 days, and 0.2 days higher than May 31. The month to month DSO can fluctuate according to timing of sales and the resultant due dates. Invoice collections remain strong at 99.9 % within 10 days of the due date. There were no bad debt write-offs in the first half of 2013.

2. Open deductions totaled $431,500 at June 30, 2013 or .002% of the total receivables versus $555,706 at December 31, 2012.

3. In all respects, we believe accounts receivable collections are excellent. We continue to monitor Rite Aid (balance at June 30 of $433,653) - results are improving and short term liquidity remains good as they continue to refinance debt.

Accounts Payable

1. Payables at June 30, 2013 totaled $35.2 million versus $28.1 million at May 31, 2013. Substantial quarterly rebates to be paid in July accounted for the increase.

2. The June 30, 2013 Day's Payable Outstanding ("DPO") was 53.06 for all rebate related payments vs. 52.73 days at December 31, 2012 (a 0.33 day increase). The DPO for all non-rebate related payments was 38.88 days at June 30, 2013 vs. 38.84 days at December 31, 2012 (an increase of 0.04 days). Fluctuations in the DPO can occur due to the mix of payment types. The DPO is measured semi-annually.

3. Early payment discounts of $443,814 or 98.2% of those available were earned during the first half of 2013.

Inventory

1. Purdue is carrying $87.4 million in inventory net of reserves. This balance has increased over prior year-end and June 2012 by $36.8 million and $30.8 million, respectively. The primary drivers are as follows:

   Versus year-end 2012 (increase of $36.8 million)

   a. Higher Oxycodone API ($30.1 million) primarily driven by accelerated receipts from Rhodes Technology at Rhodes request to position them to free up labor and equipment capacity for new product validations in the last half of 2013.
   b. Higher finished goods for Dilaudid ($2.0 million) and Slow-Mag ($1.6 million) due to timing of 3rd party receipts.
   c. Higher OxyContin finished goods ($1.5 million) as compared to year-end factory shutdown levels.

   Versus June 2012 (increase of $30.8 million)

   a. Higher Oxycodone API ($30.7 million) primarily driven by accelerated receipts from Rhodes Technology.

2. Oxycodone comprises $52.5 million of the $87.4 million total inventory. Details are provided in the table below:

	Jun-13		Jun-12	Y/E 2012
Oxycodone	**kg**	**million $'s**	**million $'s**	**million $'s**
Raw	11,659	$37.7	$7.0	$7.6
WIP	791	$2.6	$4.6	$2.1
Bulk	577	$1.9	$2.8	$4.4
FG	3,195	$10.3	$9.8	$9.0
Total Oxycodone	**16,222**	**$52.5**	**$24.2**	**$23.1**

3. At the end June, the average MOH inventory level for OxyContin finished goods is ~ 2.3 months (based on projected sales). Details are as follows:

OxyContin - Months on Hand Inventory
(100 count bottles only)

10mg	15mg	20mg	30mg	40mg	60mg	80mg	Total
2.0	2.0	2.9	2.0	1.8	2.4	2.6	2.3

4. The current OxyContin finished product on hand of 2.3 is slightly higher than prior year-end of 2.1, but is slightly lower than the target of 2.5 months.

Headcount

At the end of June, Purdue's headcount was 1,689 versus the forecast of 1,751, which included a target reduction of 25. The variance of 62 includes 56 actively recruited positions - 14 with offers outstanding and 42 being actively recruited.

Purdue U.S.
Financial Statements
June 2013

Purdue US - Financial Reporting Scorecard

Expressed in 000's

	June YTD				2013 YTD Actual versus			Full Year		
	2013 YTD Actual	2013 YTD Forecast	2013 YTD Budget	2012 YTD Actual	2013 YTD Forecast	2013 YTD Budget	2012 YTD Actual	2013 Forecast	2013 Budget	2012 Actual
Net Revenues	$ 982,916	$ 1,030,832	$ 1,193,444	$ 1,064,796	-4.9%	-21.4%	-8.3%	$ 2,107,208	$ 2,410,349	$ 2,200,922
Operating Profit Margin	$ 385,313	$ 434,783	$ 525,076	$ 483,771	-12.8%	-36.3%	-25.6%	$ 918,660	$ 1,124,604	$ 992,750
EBITDA	$ 486,816	$ 511,878	$ 496,214	$ 482,062	-5.1%	-1.9%	1.0%	$ 948,265	$ 1,066,878	$ 1,038,561
Net Profit Before Tax	$ 470,836	$ 495,875	$ 480,231	$ 468,124	-5.3%	-2.0%	0.6%	$ 916,260	$ 1,034,912	$ 1,010,856
Owner's Equity	$ 518,573	$ 581,944	$ 855,844	$ 624,308	-12.2%	-65.0%	-20.4%	$ 590,000	$ 705,232	$ 671,725
Non-tax Distributions	$ 357,626	$ 357,626	$ 120,250	$ 471,600	0.0%	66.4%	-31.9%	$ 575,600	$ 538,100	$ 471,643
Days Sales Outstanding	*33.2*	*35.0*	*35.0*	*35.4*	*on target*	*on target*	*on target*	*35.0*	*35.0*	*33.2*
Accounts Receivable Outstanding > 90 Days Past Due	*< 1%*	*< 1%*	*< 1%*	*< 1%*	*on target*	*on target*	*on target*	*< 1%*	*< 1%*	*< 1%*
Capital Spending	$ 12,887	$ 17,500	$ 17,500	$ 13,203	-35.8%	-35.8%	-2.5%	$ 35,000	$ 35,000	$ 30,467
Unrestricted Cash on Hand	$ 830,712	$ 823,778	$ 985,738	$ 787,797	0.8%	-18.7%	5.2%	$ 576,056	$ 600,000	$ 755,593
Available Liquidity	$ 830,712	$ 823,778	$ 985,738	$ 787,797	0.8%	-18.7%	5.2%	$ 576,056	$ 600,000	$ 755,593
Available Liquidity - Average Months Sales	*5.1*	*4.8*	*5.0*	*4.4*	+0.3 months	+0.1 months	+0.7 months	*3.3*	*3.0*	*4.1*
Headcount	1,689	1,751	1,784	1,672	- 11 heads	-11 heads	+17 heads	1,751	1,784	1,666

PURDUE US - Profit and Loss Statement
Period Ended June 30, 2013
Expressed in 000's

	June YTD								2013 YTD Actual versus			Full Year					
	2013 YTD Actual	% Sales	2013 YTD Forecast	% Sales	2013 YTD Budget	% Sales	2012 YTD Actual	% Sales	2013 YTD Forecast	2013 YTD Budget	2012 YTD Actual	2013 Forecast	% Sales	2013 Budget	% Sales	2012 Actual	% Sales
GROSS BRANDED PRODUCT SALES	**$ 1,305,344**		**$ 1,387,452**		**$ 1,592,806**		**$ 1,437,996**		**$ (82,108)**	**$ (287,462)**	**$ (132,652)**	**$ 2,821,387**		**$ 3,228,472**		**$ 3,004,905**	
Fee for Service	(26,947)	2.1%	(28,804)	2.1%	(32,242)	2.0%	(36,754)	2.6%	1,857	5,295	9,807	(57,957)	2.1%	(65,338)	2.0%	(69,313)	2.3%
Discounts and Allowances	(20,634)	1.6%	(27,723)	2.0%(2)	(34,138)	2.1%	(24,769)	1.7%	7,089	13,504	4,135	(54,066)	1.9%	(88,198)	2.7%	(134,032)	4.5%
Patient Savings Card Discount	(21,633)	1.7%	(21,642)	1.6%	(16,502)	1.0%	(11,243)	0.8%	9	(5,131)	(10,390)	(41,334)	1.5%	(34,537)	1.1%	(25,104)	0.8%
Rebates on Branded Sales	(227,165)	17.4%	(244,780)	17.6%	(284,139)	17.8%	(271,335)	18.9%	17,615	56,974	44,170	(488,581)	17.3%	(566,117)	17.5%	(517,606)	17.2%
Proposed Regulation Adjustment for Medicaid Rebates (1)	(28,598)	2.2%	(34,497)	2.5%	(33,167)	2.1%	(30,062)	2.1%	5,899	4,569	1,464	(73,892)	2.6%	(65,584)	2.0%	(60,383)	2.0%
Other	2,549		826		826		963		1,723	1,723	1,586	1,651		1,651		2,455	
NET REVENUES	**982,916**		**1,030,832**		**1,193,444**		**1,064,796**		**(47,916)**	**(210,528)**	**(81,880)**	**2,107,208**		**2,410,349**		**2,200,922**	
Cost of Goods Sold	(67,025)	5.1%	(72,270)	5.2%	(80,585)	5.1%	(69,008)	4.8%	5,245	13,560	1,983	(149,240)	5.3%	(162,211)	5.0%	(148,475)	4.9%
Royalty Expense	(62,080)	4.8%	(65,454)	4.7%	(75,251)	4.7%	(62,874)	4.4%	3,374	13,171	794	(122,339)	4.3%	(131,575)	4.1%	(120,268)	4.0%
Shipping and Warehousing	(5,078)	0.4%	(5,618)	0.4%	(5,583)	0.4%	(6,306)	0.4%	540	505	1,228	(11,356)	0.4%	(10,807)	0.3%	(11,814)	0.4%
TOTAL COST OF GOODS SOLD	**(134,183)**		**(143,342)**		**(161,419)**		**(138,188)**		**9,159**	**27,236**	**4,005**	**(282,935)**		**(304,592)**		**(280,557)**	
GROSS PROFIT	**848,733**		**887,490**		**1,032,025**		**926,608**		**(38,757)**	**(183,292)**	**(77,875)**	**1,824,273**		**2,105,757**		**1,920,365**	
Redacted																	
Research and Development	(151,868)	15.5%	(152,712)	14.8%	(199,104)	16.7%	(159,043)	14.9%	844	47,236	7,175	(327,248)	15.5%	(377,347)	15.7%	(312,513)	14.2%
Research and Development Other - Milestones and Alliances	(9,426)		(9,106)		(3,346)		(851)		(320)	(6,080)	(8,575)	(10,952)		(6,692)		(2,284)	
Sales and Promotion	(147,618)	15.0%	(149,179)	14.5%	(158,163)	13.3%	(146,305)	13.7%	1,561	10,545	(1,313)	(288,313)	13.7%	(309,913)	12.9%	(303,110)	13.8%
Health Care Reform Fee	(15,900)	1.6%	(15,900)	1.5%	(15,900)	1.3%	(15,000)	1.4%	-	-	(900)	(31,800)	1.5%	(31,800)	1.3%	(31,251)	1.4%
Other US	1,276		(279)		(2,425)		889		1,555	3,701	387	(439)		(4,940)		(17,933)	
OPERATING EXPENSES	(435,408)		(436,143)		(488,782)		(423,399)		735	53,374	(12,009)	(871,653)		(942,093)		(882,603)	
OPERATING MARGIN BEFORE INCENTIVES AND SETTLEMEN	**413,325**		**451,347**		**543,243**		**503,209**		**(38,022)**	**(129,918)**	**(89,884)**	**952,620**		**1,163,664**		**1,037,762**	
Incentive Bonus	(26,292)	2.7%	(17,652)	1.7%	(21,155)	1.8%	(20,242)	1.9%	(8,640)	(5,137)	(6,050)	(35,618)	1.7%	(42,618)	1.8%	(34,285)	1.6%
Insurance Income	180		2,988		2,988		638		(2,808)	(2,808)	(458)	3,558		3,558		3,520	
Redacted																	
OPERATING PROFIT MARGIN	**385,313**	**39.2%**	**434,783**	**42.2%**	**525,076**	**44.0%**	**483,771**	**45.4%**	**(49,470)**	**(139,763)**	**(98,458)**	**918,660**	**43.6%**	**1,124,604**	**46.7%**	**992,750**	**45.1%**
Royalty Income - ex US	22,384		20,346	(3)	20,346		44,631		2,038	2,038	(22,247)	40,692		40,692		83,961	
Ex US Expenses	(60,422)		(82,443)	(4)	(63,799)		(60,126)		22,021	3,377	(296)	(164,889)		(127,600)		(65,063)	
Gain on Infinity Stock	124,581		124,581		-		-		-	124,581	124,581	124,581		-		-	
One Time Charges / Other Items	(1,142)		(1,478)		(1,478)		(1,080)		336	336	(62)	(2,956)		(2,956)		(2,146)	
Interest Income (Expense), net	122		86		86		928		36	36	(806)	172		172		1,354	
TOTAL OTHER ITEMS	85,523		61,092		(44,845)		(15,647)		24,431	130,368	101,170	(2,400)		(89,692)		18,106	
PROFIT BEFORE TAX	**470,836**		**495,875**		**480,231**		**468,124**		**(25,039)**	**(9,395)**	**2,712**	**916,260**		**1,034,912**		**1,010,856**	
Tax Provision for Corporations	(1,475)		(2,337)		(2,337)		(254)		862	862	(1,221)	(4,674)		(4,674)		(2,548)	
PROFIT AFTER TAX	**$ 469,361**	47.8%	**$ 493,538**	47.9%	**$ 477,894**	40.0%	**$ 467,870**	43.9%	**$ (24,177)**	**$ (8,533)**	**$ 1,491**	**$ 911,586**	43.3%	**$ 1,030,238**	42.7%	**$ 1,008,308**	45.8%

(1) The Proposed Rule was issued in Q1 2012, which when finalized could result in a higher rebate rate on the new formulation of OxyContin.
(2) Discounts and Allowances as a % of sales is below forecast due to trade inventory reduction higher than forecast results in VCB accrual reversals ($2.3 million) and a favorable Intermezzo pull through adjustment to recognize the difference between demand and Purdue factory slaes ($2.6
(3) Decrease from prior year is due to a lower royalty rate at the end of 2012 upon patent expiration.
(4) The 2013 forecast includes $80.3 million of cash funding to Pearl Therapeutics of which $30.3 million was included as an Ex-US expense and $50 million was included as an investment relating to the purchase of Pearl stock. Since the Pearl transaction did not close, there will be variances in these line items versus the 2013 forecast.

PURDUE US - Profit and Loss Statement Ratios

	ACTUAL						2013
	2007	2008	2009	2010	2011	2012	FORECAST
GROSS BRANDED PRODUCT SALES	100%	100%	100%	100%	100%	100%	100%
Fee for Service	-2.1%	-1.5%	-2.2%	-2.5%	-2.5%	-2.3%	-2.1%
Discounts and Allowances	-3.5%	-3.1%	-2.2%	-1.6%	-1.9%	-4.5% (1)	-1.9%
Patient Savings Card Discount	0.0%	-0.5%	-0.6%	-0.5%	-0.5%	-0.8%	-1.5%
Rebates on Branded Sales	-12.4%	-13.4%	-15.1%	-19.9%	-18.4%	-17.2%	-17.3%
Proposed Regulation Adjustment for Medicaid Rebates	0.0%	0.0%	0.0%	-1.3%	-2.3%	-2.0%	-2.6%
Other	8.2% (2)	0.9%	1.5%	1.2%	0.4%	0.1%	0.1%
NET REVENUES	82.0%	81.5%	79.9%	74.3%	74.4%	73.2%	74.6%
Cost of Goods Sold	-8.5% (3)	-5.9%	-5.6%	-5.2%	-5.6%	-4.9%	-5.3%
Royalty Expense	-0.4%	-0.1%	-0.4%	-2.3% (4)	-3.9%	-4.0%	-4.3%
Shipping and Warehousing	-0.9%	-0.5%	-0.5%	-0.5%	-0.4%	-0.4%	-0.4%
TOTAL COST OF GOODS SOLD	-9.8%	-6.5%	-6.4%	-7.9%	-9.9%	-9.3%	-10.0%
GROSS PROFIT	**72.2%**	**75.0%**	**73.5%**	**66.3%**	**64.5%**	**63.8%**	**64.6%**
General and Administrative (incl Legal Dept, excl Legal Fees)	-11.7%	-6.0%	-5.4%	-5.9%	-6.6%	-7.0%	-7.5%
Redacted							
Research and Development	-11.0%	-5.8%	-5.5%	-7.1%	-12.1%	-14.2%	-15.5%
Research and Development Other - Milestones and Alliances	-0.5%	-0.4%	-2.5%	-0.4%	0.0%	-0.1%	-0.5%
Sales and Promotion	-11.9%	-6.5%	-6.5%	-8.4%	-10.3%	-13.8%	-13.7%
Health Care Reform Fee	0.0%	0.0%	0.0%	0.0%	-1.2%	-1.4%	-1.5%
Other US	-0.7%	-0.7%	-0.4%	0.7%	-0.1%	-0.8%	0.0%
OPERATING EXPENSES	-42.4%	-23.1%	-23.1%	-23.3%	-33.0%	-40.1%	-41.4%
OPERATING MARGIN BEFORE INCENTIVES AND SETTLEMENTS	**29.8%**	**51.9%**	**50.4%**	**43.1%**	**53.8%**	**47.2%**	**45.2%**
Incentive Bonus	-4.3%	-1.5%	-1.4%	-1.7%	-1.5%	-1.6%	-1.7%
Insurance Income	3.5%	0.6%	0.4%	0.7%	1.4%	0.2%	0.2%
Redacted							
OPERATING PROFIT MARGIN	**28.8%**	**48.8%**	**47.8%**	**41.3%**	**53.4%**	**45.1%**	**43.6%**
Royalty Income - ex US	6.6%	3.4%	3.2%	3.7%	4.1%	3.8%	1.9%
Ex US Expenses	-0.7%	-6.0%	-5.1%	-5.7%	-5.8%	-3.0%	-7.8%
One Time Charges / Other Items	-0.2%	-0.1%	0.0%	-1.1%	-0.1%	-0.1%	-0.1%
Interest Income (Expense), net	3.4%	0.7%	0.0%	0.0%	0.0%	0.1%	0.0%
TOTAL OTHER ITEMS	9.1%	-2.0%	-1.8%	-3.1%	-1.8%	0.8%	-6.0%
PROFIT BEFORE TAX	**37.9%**	**46.9%**	**45.9%**	**38.2%**	**51.6%**	**45.9%**	**43.5%**

Income statement line items as a percent of gross sales

Income statement line items as a percent of net sales

(1) 2012 Discounts and Allowances ratio is higher than history due to an increase in OxyContin return reserves.
(2) 2007 Other ratio is higher than history due to the termination of the OxyContin AG distribution agreement during 2007.
(3) 2007 Cost of Goods Sold was higher due to a higher sales mix of lower margin products.
(4) Starting mid 2010 royalties on the new OxyContin formula became due.

PURDUE US - Balance Sheet

Expressed in 000's

	Footnotes	June 30, 2013 Actual	December 31, 2013 Forecast	December 31, 2013 Budget	December 31, 2012 Actual
ASSETS					
CURRENT ASSETS					
Cash and cash equivalents		$ 830,712	$ 576,056	$ 600,000	$ 755,593
Accounts receivable	(1)	118,134	136,623	150,613	187,137
Due from associated companies	(2)	20,424	13,673	13,673	31,819
Other receivables	(3)	7,619	7,250	8,350	2,957
Inventories	(4)	87,433	42,881	42,881	50,631
Prepaid expenses and other assets	(5)	15,404	23,670	28,670	22,144
Restricted cash - current	(6)	23,932	4,800	-	23,927
TOTAL CURRENT ASSETS		**1,103,658**	**804,953**	**844,187**	**1,074,208**
Property and equipment, net	(7)	149,680	159,119	163,447	149,483
Investments in associated companies	(8)	20,459	69,111	14,936	7,871
Due from associated companies		3,000	3,250	3,250	3,000
Restricted cash - long term	(6)	17,203	21,700	21,700	17,205
Goodwill		23,396	23,396	23,396	23,396
Product rights, trademarks and other intangibles, net	(9)	169,829	166,409	165,982	173,249
Other assets	(10)	21,881	21,247	21,247	22,523
Investment in Infinity common stock	(11)	-	-	138,772	189,545
Deferred income taxes		19,788	17,425	17,425	19,788
TOTAL ASSETS		**$ 1,528,894**	**$ 1,286,610**	**$ 1,414,342**	**$ 1,680,268**
LIABILITIES AND EQUITY					
CURRENT LIABILITIES					
Accounts payable		77,205	81,600	94,100	71,181
Accrued expenses and taxes payable	(12)	671,460	360,628	360,628	694,721
Due to associated companies		20,976	13,000	13,000	12,392
TOTAL CURRENT LIABILITIES		**769,641**	**455,228**	**467,728**	**778,294**
Other liabilities		240,680	241,382	241,382	230,249
TOTAL LIABILITIES		**1,010,321**	**696,610**	**709,110**	**1,008,543**
EQUITY					
Capital stock - common		9	9	9	9
Additional paid in capital		1,982	1,982	1,982	1,982
Subscription receivable		(999)	(999)	(999)	(999)
Accumulated other comprehensive income		(139,935)	(128,436)	(128,436)	(139,935)
Unrealized gain on Infinity stock	(11)	-	-	60,232	97,469
Retained earnings and partners' capital		657,516	717,444	772,444	713,199
TOTAL EQUITY	(13)	**518,573**	**590,000**	**705,232**	**671,725**
TOTAL LIABILITIES AND EQUITY		**$ 1,528,894**	**$ 1,286,610**	**$ 1,414,342**	**$ 1,680,268**

PURDUE US - Balance Sheet Footnotes

Expressed in 000's

(1) Accounts receivable is $69.0 million lower than prior year end primarily due to decrease in trade receivables of $75.4 million as a result of lower June sales as compared to December.

(2) Decrease from prior year end is primarily due to a lower Ex-US royalty receivable due to lower royalty rates upon patent expiration in 2012.

(3) Increase from prior year end of $4.6 million in other receivables balance is primarily due an increase in net amount receivable from Express Scripts related to IPAP program ($4.4 million).

(4) Increase from prior year end of $36.8 million in inventory balance is due to higher Oxycodone API ($30.1 million) driven by accelerated receipts from Rhodes Tech which increased capacity for new product validations, higher finished goods for Dilaudid ($2.0 million) and Slow-Mag ($1.6 million) due to timing of third party receipts, and higher OxyContin finished goods ($1.5 million) as compared to year end factory shutdown levels.

(5) The balance in the prepaids fluctuates according to payment patterns on major contracts, larger items include: prepaid software ($3.1 million), prepaid clinical outsourcing ($1.9 million), prepaid REMS security deposit ($1.2 million) and $4.2 million in prepaid S&P.

(6) All remaining settlements have been paid out from the Qualified Settlement Trust (QST). As of June 30, the entire balance of $23.9 million of the QST is classified as current reflecting the fact that the balance of the QST is expected to be returned to Purdue in 2014. Long term restricted cash relates to cash collateralized insurance letters of credit.

(7) Change in Property and equipment is as follows:

Balance @ 01/01/13	149,483
Capital expenditures	12,887
Loss on disposals	(8)
Depreciation	(12,682)
Balance @ 06/30/13	149,680

(8) Investments represent cash investments net of losses in Lucien, Germany and Japan.

Balance @ 01/01/13	7,871
Cash investments in Lucien & Japan, net	51,815
Equity losses in Lucien & Japan	(51,815)
100% of Germany losses	(7,500)
Cash investment in Germany	20,088
Balance @ 06/30/13	20,459

The 2013 forecast includes $80.3 million of cash funding to Pearl Therapeutics of which $30.3 million was included as an Ex-US expense and $50 million was included as an investment relating to the purchase of Pearl stock. Since the Pearl transaction did not close, there will be variances in these line items versus the 2013 forecast.

(9) The balance as of June 30, 2013 consists of:

Dilaudid product rights	85,707
Shire assets (Colace, PeriColace and Slow-mag)	64,917
Grunenthal milestones (OxyContin)	16,412
Abbott/McGinity patent (OxyContin)	2,317
Butrans milestone	476
Total	169,829

(10) Other assets balance of $21.8 million includes the payments made by Purdue (covering UBS free rent related to floors 2-8, commission and closing costs) to OSR in prior years ($12.5 million) which are being amortized over the lease term of floors 9 and 10 and a $6 million lease deposit paid to OSR to be returned in 2016.

(11) On April 9, 2013 Purdue distributed 5,416,565 shares of Infinity stock to its owners who then sold the shares for $40 per share ($216.7 million).

(12) Accrued expenses and taxes payable of $671.5 million includes $178.1 million in accrued rebates, $343.3 million in accrued Medicaid and Medicaid Part D ($197.9 million relating to the proposed CMS rule), Redacted $25.8 million in salaries and bonuses, and $16.5 million for the Health Care Reform Fee. The decrease from prior year end of $23.3 million is primarily due to decrease in wholesaler inventory rebates ($44.9 million) as a result of decreased estimates of trade inventory, offset by increase in rebate accruals of $17.2 million due to timing.

(13) Equity rollforward:

Balance @ 01/01/13	671,725
Cash contributions	490
Cash distributions (tax and non-tax)	(308,871)
Infinity Distribution	(216,663)
Reversal of unrealized gain on Infinity Distribution	(97,469)
Net Income	469,361
Balance @ 06/30/13	518,573

PURDUE US - Statement of Cash Flows

Expressed in 000's

	June 30, 2013 Actual	December 31, 2013 Forecast	December 31, 2013 Budget	December 31, 2012 Actual
Operating activities				
Net income	$ 469,361	$ 911,586	$ 1,030,238	$ 1,008,308
Adjustments to reconcile net income to net cash provided by operating activities:				
Depreciation and amortization	16,102	32,177	32,138	29,059
Distribution of Infinity stock	216,663	216,663	-	-
Gain on Investment in Infinity	(124,581)	(124,581)	-	(24,742)
Impairment of intangible asset	-	-	-	20,000
Deferred income taxes	-	2,363	-	(2,600)
Loss on unconsolidated, associated companies	59,315	163,066	128,621	101,005
Loss on disposal of assets	8	27	-	27
Changes to working capital	17,042	(271,230)	(212,281) (1)	88,604
Long-term assets and liabilities	11,067	23,903	27,431	22,730
Total cash provided by operating activities	**664,977**	**953,974**	**1,006,147**	**1,242,391**
Investing activities				
Capital expenditures	(12,887)	(35,000)	(35,000)	(30,467)
Purchase of product marketing rights and other intangible	-	-	-	(29,982)
Restricted cash, net	(3)	14,632	22,472	17,337
Investments in associated companies, net	(71,903)	(224,306) (2)	(134,605)	(89,089)
Investment in Infinity stock	-	-	-	(27,500)
Total cash used in investing activities	**(84,793)**	**(244,674)**	**(147,133)**	**(159,701)**
Financing activities				
Payments from associates, net	19,979	18,504	6,792	(2,703)
Capital contributions	490	-	-	-
Distributions to partners for required tax payments	(167,908)	(331,772)	(444,000)	(459,245)
Distributions to partners non-tax	(140,963)	(358,906)	(538,077)	(471,643)
Distribution of Infinity stock	(216,663)	(216,663)	-	-
Total cash used in financing activities	**(505,065)**	**(888,837)**	**(975,285)**	**(933,591)**
Increase (decrease) in cash and cash equivalents	75,119	(179,537)	(116,271)	149,099
Cash and cash equivalents:				
Unrestricted cash at the beginning of the period	755,593	755,593	716,271	606,494
Unrestricted cash at the end of the period	**$ 830,712**	**$ 576,056**	**$ 600,000**	**$ 755,593**

(1) Budget assumes payout of Medicaid rebates related to the CMS proposed rule of $183 million.
(2) The 2013 forecast includes $80.3 million of cash funding to Pearl Therapeutics of which $30.3 million was included as an Ex-US expense and $50 million was included as an investment relating to the purchase of Pearl stock. Since the Pearl transaction did not close, there will be variances in these line items versus the 2013 forecast.

Sales Summary Gross to Net by Product

Expressed in 000's

	June YTD				2013 YTD Actual versus			Full Year		
	2013 YTD Actual	**2013 YTD Forecast**	**2013 YTD Budget**	**2012 YTD Actual**	**2013 YTD Forecast**	**2013 YTD Budget**	**2012 YTD Actual**	**2013 Forecast**	**2013 Budget**	**2012 Actual**
OxyContin										
Gross Sales	$ 1,190,966	$ 1,259,221	$ 1,452,291	$ 1,334,061	$ (68,255)	$ (261,325)	$ (143,095)	$ 2,553,108	$ 2,916,463	$ 2,777,064
Fee for Service	(25,119)	(26,657)	(29,829)	(34,560)	1,538	4,710	9,441	(53,399)	(59,887)	(65,876)
Sales Discounts and Allowances	(21,627)	(25,322)	(30,901)	(19,768)	3,695	9,274	(1,859)	(44,826)	(72,658)	(116,425)
Savings Cards Discounts	(17,293)	(17,149)	(11,407)	(7,762)	(144)	(5,886) (2)	(9,531) (1)	(31,522)	(22,813)	(18,330)
Rebates	(220,221)	(236,448)	(275,977)	(266,590)	16,227	55,756	46,369	(471,555)	(547,870)	(509,597)
Proposed Regulation Adjustment for Medicaid Rebates	(28,598)	(34,497)	(33,167)	(30,062)	5,899	4,569	1,464	(73,892)	(65,584)	(60,383)
OxyContin Net Sales	**878,108**	**919,148**	**1,071,010**	**975,319**	**(41,040)**	**(192,902)**	**(97,211)**	**1,877,914**	**2,147,651**	**2,006,453**
Butrans										
Gross Sales	$ 63,949	$ 72,958	$ 72,958	$ 48,929	(9,009)	$ (9,009)	$ 15,020	$ 160,025	$ 160,025	$ 112,887
Fee for Service	(1,380)	(1,588)	(1,571)	(1,355)	208	191	(25)	(3,448)	(3,432)	(2,693)
Sales Discounts and Allowances	(1,125)	(1,522)	(1,738)	(821)	397	613	(304)	(6,609)	(6,826)	(13,726)
Savings Cards Discounts	(3,673)	(3,775)	(4,001)	(3,380)	102	328	(293)	(8,392)	(8,574)	(6,198)
Rebates	(5,589)	(6,753)	(6,687)	(2,372)	1,164	1,098	(3,217)	(14,326)	(14,341)	(6,139)
Butrans Net Sales	**52,182**	**59,320**	**58,961**	**41,001**	**(7,138)**	**(6,779)**	**11,181**	**127,250**	**126,852**	**84,131**
Intermezzo										
Gross Sales	$ 4,906	$ 7,687	$ 19,971	$ 13,853	(2,781)	$ (15,065)	$ (8,947)	$ 13,893	$ 57,622	$ 16,556
Fee for Service	(124)	(153)	(398)	(352)	29	274	228	(276)	(1,147)	(352)
Sales Discounts and Allowances	2,708	91	(399)	(9,920)	2,617 (3)	3,107	12,628	(1,096)	(6,914)	(9,908)
Savings Cards Discounts	(667)	(718)	(1,094)	(101)	51	427	(566)	(1,421)	(3,150)	(576)
Rebates	(467)	(530)	(689)	(190)	63	222	(277)	(728)	(2,365)	(138)
Intermezzo Net Sales	**6,356**	**6,377**	**17,391**	**3,290**	**(21)**	**(11,035)**	**3,066**	**10,372**	**44,046**	**5,582**
Total for All Products										
Gross Sales	$ 1,305,344	$ 1,387,452	1,592,806	$ 1,437,996	(82,108)	$ (287,462)	$ (132,652)	$ 2,821,387	$ 3,228,472	$ 3,004,905
Fee for Service	(26,947)	(28,804)	(32,242)	(36,754)	1,857	5,295	9,807	(57,957)	(65,338)	(69,313)
Sales Discounts and Allowances	(20,634)	(27,723)	(34,138)	(24,769)	7,089	13,504	4,135	(54,066)	(88,198)	(134,032)
Savings Cards Discounts	(21,633)	(21,642)	(16,502)	(11,243)	9	(5,131)	(10,390)	(41,334)	(34,537)	(25,104)
Rebates	(227,165)	(244,780)	(284,139)	(271,335)	17,615	56,974	44,170	(488,581)	(566,117)	(517,606)
Proposed Regulation Adjustment for Medicaid Rebates	(28,598)	(34,497)	(33,167)	(30,062)	5,899	4,569	1,464	(73,892)	(65,584)	(60,383)
Other	2,549	826	826	963	1,723	1,723	1,586	1,651	1,651	2,455
Total Net Sales	**$ 982,916**	**$ 1,030,832**	**$ 1,193,444**	**$ 1,064,796**	**$ (47,916)**	**$ (212,251)**	**$ (83,466)**	**$ 2,107,208**	**$ 2,410,349**	**$ 2,200,922**

(1) The increase in year-to-date June 2013 actual expense versus prior year-to-date actual is due to (1) higher redemption rates largely due to the fact that the eVoucher program only initiated in March 2012 and the 65 and over age limit on the eVoucher program was lifted in 2013 and (2) the card limit was increased from $70 to $90 which increased the average cost per redemption.

(2) The variance to budget, which was adjusted for in the Mid Year Forecast, primarily relates to the lifting of the age limit of 65 on the eVoucher program.

(3) Due to favorable Intermezzo pull though adjustment to recognize the difference between demand and Purdue factory sales. The forecast assumed demand would equal Purdue sales. Year to date factory sales were lower than demand by $2.5 million.

Gross Sales Summary by Product

Expressed in 000's

	June YTD				2013 YTD Actual versus			Full Year		
	2013 YTD Actual	**2013 YTD Forecast**	**2013 YTD Budget**	**2012 YTD Actual**	**2013 YTD Forecast**	**2013 YTD Budget**	**2012 YTD Actual**	**2013 Forecast**	**2013 Budget**	**2012 Actual**
10 mg	$ 66,565	$ 69,820	$ 78,175	$ 72,162	$ (3,255)	$ (11,610)	$ (5,597)	$ 142,460	$ 156,987	$ 152,741
15 mg	17,356	17,030	18,834	15,330	326	(1,478)	2,026	35,840	37,814	33,992
20 mg	171,467	184,463	209,131	194,365	(12,996)	(37,664)	(22,898)	377,709	419,948	402,472
30 mg	98,178	101,912	118,244	94,674	(3,734)	(20,066)	3,504	214,549	237,429	205,335
40 mg	254,286	272,904	309,840	298,560	(18,618)	(55,554)	(44,274)	555,777	622,343	618,704
60 mg	155,406	162,487	193,633	158,670	(7,081)	(38,227)	(3,264)	338,266	388,817	340,746
80 mg	427,708	450,603	524,432	496,604	(22,895)	(96,724)	(68,896)	888,506	1,053,124	1,023,074
Gross OxyContin Sales	**1,190,966**	**1,259,219**	**1,452,289**	**1,330,365**	**(68,253)**	**(261,323)**	**(139,399)**	**2,553,107**	**2,916,462**	**2,777,064**
Dilaudid Tablets	$ 4,886	$ 6,006	$ 6,006	$ 7,268	$ (1,120)	$ (1,120)	$ (2,382)	$ 11,856	$ 11,856	$ 14,191
Dilaudid Ampules	1,591	2,307	2,307	3,772	(716)	(716)	(2,181)	4,328	4,328	8,272
Dilaudid Vials	339	425	425	683	(86)	(86)	(344)	797	797	1,306
Gross Dilaudid Sales	**6,816**	**8,738**	**8,738**	**11,723**	**(1,922)**	**(1,922)**	**(4,907)**	**16,981**	**16,981**	**23,769**
Betadine First Aid	$ 2,078	$ 2,016	$ 2,016	$ 1,952	$ 62	$ 62	$ 126	$ 4,027	$ 4,027	$ 4,118
Betadine Hospital	2,314	2,193	2,193	2,290	121	121	24	4,401	4,401	4,653
Betadine Veterinary	482	409	409	450	73	73	32	830	830	850
Gross Betadine Sales	**4,874**	**4,618**	**4,618**	**4,692**	**256**	**256**	**182**	**9,258**	**9,258**	**9,621**
Colace	$ 11,847	$ 12,835	$ 12,835	$ 12,398	$ (988)	$ (988)	$ (551)	$ 25,669	$ 25,669	$ 25,891
Peri-Colace	2,106	2,354	2,354	2,260	(248)	(248)	(154)	4,708	4,708	4,403
Gross Colace / Peri-Colace Sales	**13,953**	**15,189**	**15,189**	**14,658**	**(1,236)**	**(1,236)**	**(705)**	**30,377**	**30,377**	**30,294**
Senokot-S	$ 6,094	$ 4,822	$ 4,822	$ 5,511	$ 1,272	$ 1,272	$ 583	$ 9,648	$ 9,648	$ 11,220
Senokot	4,906	4,631	4,631	4,933	275	275	(27)	9,263	9,263	10,000
Gross Senokot Sales	**11,000**	**9,453**	**9,453**	**10,444**	**1,547**	**1,547**	**556**	**18,911**	**18,911**	**21,220**
Butrans	$ 63,949	$ 72,958	$ 72,958	$ 48,929	$ (9,009)	$ (9,009)	$ 15,020	$ 160,025	$ 160,025	$ 112,887
Intermezzo	4,906	7,687	19,971	13,853	(2,781)	(15,065)	(8,947)	13,892	57,622	16,556
MS Contin	5,649	5,937	5,937	6,394	(288)	(288)	(745)	11,642	11,642	12,974
Ryzolt	(521)	-	-	(6,250)	(521)	(521)	5,729	-	-	(6,924)
Slow-Mag	2,760	2,720	2,720	2,272	40	40	488	5,316	5,316	5,554
Betasept	998	933	933	978	65	65	20	1,878	1,878	1,971
Discontinued Products	(6)	-	-	(62)	(6)	(6)	56	-	-	(81)
GROSS BRANDED SALES	**1,305,344**	**1,387,452**	**1,592,806**	**1,437,996**	**(82,108)**	**(287,462)**	**(132,652)**	**2,821,387**	**3,228,472**	**3,004,905**
Fee for Service	(26,947)	(28,804)	(32,242)	(36,754)	1,857	5,295	9,807	(57,957)	(65,338)	(69,313)
Discounts and Allowances	(20,634)	(27,723)	(34,138)	(24,769)	7,089	13,504	4,135	(54,066)	(88,198)	(134,032)
Savings Card Discount	(21,633)	(21,642)	(16,502)	(11,243)	9	(5,131)	(10,390)	(41,334)	(34,537)	(25,104)
Rebates	(227,165)	(244,780)	(284,139)	(271,335)	17,615	56,974	44,170	(488,581)	(566,117)	(517,606)
Proposed Regulation Adj for Medicaid Rebates	(28,598)	(34,497)	(33,167)	(30,062)	5,899	4,569	1,464	(73,892)	(65,584)	(60,383)
Other	2,549	826	826	963	1,723	1,723	1,586	1,651	1,651	2,455
NET BRANDED SALES	**$ 982,916**	**$ 1,030,832**	**$ 1,193,444**	**$ 1,064,796**	**$ (47,916)**	**$ (210,528)**	**$ (81,880)**	**$ 2,107,208**	**$ 2,410,349**	**$ 2,200,922**

Sales Variance to Forecast

Expressed in 000's

Gross Sales:		
● Impact of trade inventories lower than forecast (1)	$ (66,280)	
● Lower OxyContin demand versus forecast (1)	(1,975)	
Lower OxyContin Sales		$ (68,255)
● Butrans sales due to lower trade inventory and demand		(9,009)
● Intermezzo due to lower trade inventory.		(2,782)
● All other		(2,062)
Subtotal - Gross sales variance		(82,108)
Deductions:		
● Lower variable deductions due to lower sales		34,192
Net Branded Sales Variance		$ (47,916)

(1) Each of these factors is based on estimates provided by IMS and customers.

General and Administrative Summary

Expressed in 000's

	June YTD				2013 YTD Actual versus			Full Year			HEADCOUNT				
	2013 YTD Actual	2013 YTD Forecast	2013 YTD Budget	2012 YTD Actual	2013 YTD Forecast	2013 YTD Budget	2012 YTD Actual	2013 Forecast	2013 Budget	2012 Actual	2013 YTD Actual	2013 Budget	Var to Budget	2012 Actual	Comments
Finance	$ 6,611	$ 6,781	$ 6,781	$ 6,605	$ (170)	$ (170)	$ 6	$ 13,520	$ 13,520	$ 13,324	60	64	4	62	$0.2 million favorable for open positions and timing of software maintenance.
Information Technology	16,122	17,012	17,858	15,890	(890)	(1,736)	232	35,217	35,466	32,262	92	102	10	96	$0.4 million favorable due to open positions, $0.5 million favorable timing of software and hardware maintenance.
Corporate Procurement	1,671	1,760	1,760	1,528	(89)	(89)	143	3,500	3,500	3,215	12	14	2	13	$0.1 million favorable due to two open positions.
Insurance	1,373	1,608	1,746	1,425	(235)	(373)	(52)	3,192	3,492	2,846	-	-	-	-	$0.2 million favorable due to lower negotiated property premium rates, lower than anticipated business interruption insurance, and timing of clinical trial insurance.
IPAP	1,819	1,852	1,950	1,726	(33)	(131)	93	3,704	3,900	3,747	-	-	-	-	
Subtotal - Mahony	27,596	29,013	30,095	27,174	(1,417)	(2,499)	422	59,133	59,878	55,394	164	180	16	171	
Human Resources	3,076	3,272	3,313	3,033	(196)	(237)	43	6,546	6,587	5,900	23	24	1	23	$0.2 million favorable due to an open position, and timing of training and consulting.
EHS Corporate	1,313	1,353	1,325	1,107	(40)	(12)	206	2,599	2,587	2,286	6	6	-	6	
Administration Building	3,975	4,000	4,075	4,011	(25)	(100)	(36)	8,132	8,322	8,156	34	34	-	34	
Stamford Facilities	11,331	11,455	11,420	10,848	(124)	(89)	483	22,734	22,837	22,062	-	-	-	-	$0.1 million favorable due to lower operating expenses as compared to the budget. This is trued up at year end.
Facilities Allocation Out	(11,420)	(11,420)	(11,420)	(11,324)	-	-	(96)	(22,837)	(22,837)	(22,649)	-	-	-	-	
Subtotal - Long	8,275	8,660	8,713	7,675	(385)	(438)	600	17,174	17,496	15,755	63	64	1	63	
Public Affairs	2,598	3,176	3,176	2,421	(578)	(578)	177	7,129	7,129	5,218	4	4	-	4	$0.6 million favorable due to timing of various consulting projects and special promotion project payments.
Federal Government Affairs	1,722	1,754	1,754	1,838	(32)	(32)	(116)	3,495	3,495	3,473	2	2	-	2	
State Government Affairs	5,096	6,029	6,029	5,178	(933)	(933)	(82)	11,522	11,522	10,659	12	12	-	12	$0.9 million favorable due to timing of organizational grant payments vs. a straight line budget assumption.
Subtotal - External Affairs	9,416	10,959	10,959	9,437	(1,543)	(1,543)	(21)	22,146	22,146	19,350	18	18	-	18	
Redacted															
Purdue Pharma Fund	901	961	961	671	(60)	(60)	230	1,922	1,922	969	-	-	-	-	
DEA Compliance	20	25	184	273	(5)	(164)	(253)	25	362	448	-	1	1	1	This department was disbanded. $20k minimal carryover expense.
Redacted															
Executive Administration	3,818	3,892	3,566	3,263	(74)	252	555	7,634	7,133	7,012	6	7	1	6	
General underspend	-	(360)	(450)	-	360	450	-	(721)	(901)	-	-	-	-	-	
Subtotal - Executive Administration	3,818	3,532	3,116	3,263	286	702	555	6,913	6,232	7,012	6	7	1	6	
Depreciation and Occupancy	8,236	8,236	8,236	8,611	-	-	(375)	16,471	16,471	17,116	-	-	-	-	
Quality	3,828	4,380	4,380	3,500	(552)	(552)	328	8,757	8,757	7,438	31	35	4	31	$0.6 million favorable for open positions, consulting and travel.
Security	2,760	2,935	2,970	3,084	(175)	(210)	(324)	5,828	5,897	5,465	15	15	-	15	$0.2 million favorable for timing of grants and timing of new hire.
Corporate Compliance	1,615	1,963	2,033	1,761	(348)	(418)	(146)	3,536	3,606	3,384	10	12	2	11	$0.3 million favorable due to timing of Axentis license fees delayed until Q3.
Business Development	1,379	1,681	1,681	1,595	(302)	(302)	(216)	3,442	3,442	3,181	7	7	-	7	$0.3 million favorable due to minimal consulting project spend to date.
Employee Benefits	143	723	(436)	2,063	(580)	579	(1,920)	(1,701)	(1,447)	4,726	-	-	-	-	$0.6 million favorable for medical expense running favorable to plan.
Fleet	(265)	(582)	19	(571)	317	(284)	306	(609)	-	(349)	-	-	-	-	$0.3 million unfavorable due to high auto liability claims.
Subtotal - Other	17,696	19,336	18,883	20,043	(1,640)	(1,187)	(2,347)	35,724	36,726	40,961	63	69	6	64	
Total General and Administrative	$ 75,370	$ 80,088	$ 80,788	$ 75,748	$ (4,718)	$ (5,418)	$ (378)	$ 158,426	$ 160,426	$ 154,259	360	385	25	368	

Legal Fees Summary

Redacted

Research and Development

Expressed in 000's

	June YTD				2013 YTD Actual versus			Full Year			HEADCOUNT				
	2013 YTD Actual	2013 YTD Forecast	2013 YTD Budget	2012 YTD Actual	2013 YTD Forecast	2013 YTD Budget	2012 YTD Actual	2013 Forecast	2013 Budget	2012 Actual	2013 YTD Actual	2013 Forecast	Var to Budget	2012 Actual	Comments
Clinical Program	$ 64,699	$ 66,579	$ 108,048	$ 71,940	$ (1,880)	$ (43,349)	$ (7,241)	$ 134,212	$ 191,025	$ 137,238	-	-	-	-	$1.9 million favorability as a result of timing due to: OTR - $1.8 million due to lower CRO service costs in the OTR3001 pediatric study. BUP - $1.6 million due primarily to slower than expected enrollment in pediatric PREA study BUP3031 coupled with lower CRO service cost in tQTC study BUP1025. These underspends are offset in part by: ONU - $2.3 million due primarily to higher than expected CRO service costs incurred in the ONU3704 Pain and OIC pivotal study. There was increased operational focus on protocol revisions and patient recruitment efforts in the program in Q2 driving the higher-than expected costs.
Non-Clinical	20,271	22,548	24,924	26,888	(2,277)	(4,653)	(6,617)	56,220	50,134	52,748	51	55	4	50	$2.3 million of underspend is primarily due to timing of outsourcing in TRPV1 ($0.5 million), SUP ($0.4 million, BUP ($0.3 million), and HYD ($0.4 million), and ONU ($0.5 million).
Medical Research	14,761	15,941	16,570	12,658	(1,180)	(1,809)	2,103	34,180	33,455	27,394	70	78	8	62	$1.2 million favorability primarily due to timing of consulting spend.
Discovery Research	10,798	10,973	12,107	10,315	(175)	(1,309)	483	24,500	24,522	20,728	52	53	1	46	$0.2 million of favorability relates to timing of infrastructure costs (repairs and maintenance).
Health Policy	8,355	8,717	8,348	9,214	(362)	7	(859)	16,572	16,502	16,693	41	41	-	39	$0.4 million favorability due to timing of special programs $0.2 million, medical education grants $0.1 million, $0.1 million in people costs, $0.2 million in outside service/consulting offset by ($0.2) million in library subscription & information services.
Risk Management	6,749	7,925	8,025	4,976	(1,176)	(1,276)	1,773	16,146	16,246	12,050	14	14	-	11	$1.2 million favorability due to timing of studies & classwide REMS spend vs. budget phasing.
Drug Safety	4,295	5,055	5,455	5,033	(760)	(1,160)	(738)	10,722	11,122	9,476	33	39	6	35	$0.8 underspend driven by $0.2 million in lower adverse event processing, $0.1 million staff extender expenses YTD and $0.5 million favorable in people and people related costs.
Regulatory	5,549	6,224	7,084	5,286	(675)	(1,535)	263	15,043	15,423	10,560	25	27	2	24	$0.7 million favorability driven by $0.6 million in lower submission processing expense driven by delay in ONU NDA submission processing, $0.2 million in consulting partially offset by ($0.1) million in software due to timing of invoices.
Tech Transfer	2,214	2,594	3,103	2,297	(380)	(889)	(83)	4,066	8,075	4,575	-	-	-	-	$0.5 million favorability is due to timing of OCI, HYD, and TRPV1 batches.
Medical Affairs	1,086	2,235	2,035	324	(1,149)	(949)	762	4,342	4,142	1,205	3	4	1	2	$1.1 million favorability due to underspend relating to Investigator Initiated Studies and staff extenders.
Shionogi Collaboration	1,575	1,498	2,125	2,338	77	(550)	(763)	1,250	4,249	1,450	-	-	-	-	$0.1 million unfavorable variance relates to phasing of the collaboration budget.
R&D Innovation	1,138	1,720	2,597	221	(582)	(1,459)	917	6,247	5,310	1,057	3	3	-	1	$0.6 million favorability due to timing of consulting spend related to exploratory projects.
Health Outcomes	2,042	1,925	2,744	172	117	(702)	1,870	6,265	5,654	2,179	5	5	-	-	($0.1) million unfavorability due to ($0.2) million in peoples cost offset by $0.1 million in outsides services relating to advisory boards and various consulting projects.
Project Management	2,569	2,630	2,630	2,034	(61)	(61)	535	5,149	5,148	4,549	19	20	1	138	
Outsource Management	640	751	751	695	(111)	(111)	(55)	1,488	1,488	1,314	6	6	-	8	
Stamford Occupancy and Depreciatior	5,339	5,339	5,339	4,706	-	-	633	10,678	10,678	9,412	-	-	-	-	
Cranbury Occupancy	(212)	(76)	(71)	(54)	(136)	(141)	(158)	(157)	(151)	(115)	14	14	-	10	
Underspend Estimate	-	(9,866)	(12,710)	-	9,866	12,710	-	(19,675)	(25,675)	-	-	-	-	-	
Total Research and Development	$ 151,868	$ 152,712	$ 199,104	$ 159,043	$ (844)	$ (47,236)	$ (7,175)	$ 327,248	$ 377,347	$ 312,513	336	359	23	301	

Other US

Expressed in 000's

	June YTD				2013 YTD Actual versus			Full Year			
	2013 YTD Actual	2013 YTD Forecast	2013 YTD Budget	2012 YTD Actual	2013 YTD Forecast	2013 YTD Budget	2012 YTD Actual	2013 Forecast	2013 Budget	2012 Actual	Comments
Other Income (Expense):											
Purdue Pharma Tech	$ 1,136	$ 842	$ 842	$ 1,600	$ 294	$ 294	$ (464)	$ 1,683	$ 1,683	$ 2,689	Purdue Pharma Tech (PP Tech) provides EHS, security and other services to Purdue at cost plus markup. PP Tech is consolidated in these financials - its margin is shown here.
Amortization expense - Dilaudid	(1,243)	(1,243)	(1,243)	(1,243)	-	-	-	(2,486)	(2,486)	(2,485)	Balance represents amortization of marketing rights of Dilaudid acquired in 2007 and 2008 for approximately $100 million which is being amortized over its estimated useful life of 40 years.
Reversal of use tax	189	-	-	307	189	189	(118)	-	-	307	Sales and use taxes are recorded automatically when invoices are processed. When tax should not have been charged the tax is not paid and the credit is captured here.
Trust expenses	(80)	(50)	(50)	(160)	(30)	(30)	80	(100)	(100)	(328)	Redacted
Norwell rent income (Totowa)	375	375	375	374	-	-	1	750	750	749	
Purchase discounts	411	350	350	361	61	61	50	700	700	898	
Depreciation - Norwell & Other	(106)	(110)	(110)	(103)	4	4	(3)	(220)	(220)	(290)	Primarily represents depreciation on Norwell.
Depreciation savings	-	500	500	-	(500)	(500)	-	1,000	1,000	-	Budget expected favorability (underspend) here.
Intermezzo milestone amortization / write off	-	-	-	(312)	-	-	312	-	-	(20,000)	Balance represents write off of two $10 million milestone payments made upon the Orange Book listings of Intermezzo patents. Amounts were written off in 2012 based on declining sales projections.
President's reserve	-	(1,450)	(2,950)	-	1,450	2,950	-	(2,900)	(5,900)	-	
Miscellaneous	594	507	(139)	65	87	733	529	1,134	(366)	527	
Net Other Income (Expense)	$ 1,276	$ (279)	$ (2,425)	$ 889	$ 1,555	$ 3,701	$ 387	$ (439)	$ (4,939)	$ (17,933)	

Headcount Summary

	June 2013 Actual	2013 Forecast	Variance to Forecast	2013 Budget	2012 Actual
G&A	360	385	25	382	368
R&D	336	359	23	360	334
Marketing / Sales Support	75	81	6	87	77
Field Sales	651	671	20	673	625
Total S&P	726	752	26	760	702
Totowa	17	18	1	18	18
Supply Chain Operations	58	60	2	60	57
Wilson	192	201	9	201	187
Total Technical Operations	267	279	12	279	262
President's Reserve	-	1	1	3	-
Targeted headcount reduction (1)	-	(25)	(25)	-	-
Total Headcount	1,689	1,751	62	1,784	1,666

(1) Management is evaluating all open positions and intends to close a number of those positions. The expectation is 20 to 25 positions will be closed with a 2013 savings of $1.2 to $1.5 million.

Message

From: Mahony, Edward [redacted]

Sent: 7/16/2013 3:12:34 PM

To: Boer, Peter [redacted] Lewent, Judy [redacted] Costa, Paulo [redacted]; Snyderman, Ralph [redacted] Sackler, Dr Raymond R [redacted]; Sackler, Dr Richard [/O=PURDUE/OU=EXTERNAL [redacted] Sackler, Jonathan [redacted] Sackler, Dame Theresa [redacted] Sackler, Dr Kathe [redacted] Sackler, Mortimer D.A. [redacted] Sackler Lefcourt, Ilene [redacted] Sackler, David [redacted] Baker, Stuart D. [redacted] Sackler, Beverly [redacted] Stewart, John H. (US) [redacted] Gasdia, Russell [redacted] Landau, Dr. Craig [redacted] Lundie, David [redacted] Weinstein, Bert [redacted]

CC: Lowne, Jon [redacted]

BCC: Stewart, John H. (US) [redacted]

Subject: June 2013 Financial Statements

Attachments: June 2013 Financial Statement Cover Memo Final.docx; Copy of Financial Statements 06 30 2013 v2 (3).xlsm

Colleagues,

Attached for your information are the Purdue June 2013 financial statements.

We are happy to supply a hard copy upon request.

Ed

PURDUE

To: John Stewart

From: Ed Mahony

CC: [redacted]

Jon Lowne, [redacted] Executive Committee

Date: July 11, 2013

Subject: Year-to-date June 2013 financial results

Attached are the June year-to-date 2013 Purdue financial statements. Actual results are compared to the 2013 mid-year forecast, 2013 budget and 2012 actual results.

NET SALES

Net Sales for the six months ending June were $982.9 million --- $81.9 million lower than 2012, $210.5 million lower than budget and $47.9 million or 4.7% under the mid-year forecast. The reason for the under mid-year forecast sales performance is reductions in trade inventory in advance of the July 4th holiday buy. The underlying demand is tracking at or very close to the mid-year forecast.

OxyContin

OxyContin net sales for the six months ending June were $878.1 million --- $41.0 million below the mid-year forecast and $97.2 million lower than 2012. The variance vs. mid-year forecast is due to:

a. OxyContin demand – as reported by IMS -- is running in line with the mid-year forecast.
b. OxyContin trade inventory is running $39.9 million below the mid-year forecast. At the end of June, trade inventory was low – 1.6 months for wholesalers and pharmacy combined. Trade inventories should be back closer to 1.8 months when orders in house at the end of June were shipped in early July (net sales value $32 million).

Other influences of future demand:

a. In April 2013 Walgreens implemented a nationwide requirement that its pharmacists rigorously review and evaluate the appropriateness of Class 2 prescriptions and where they deem it appropriate - not filling prescriptions. Similar efforts are in various stages at other pharmacies. The result of this effort may increasingly depress future prescriptions. The Purdue management team will report on this and other environmental factors at the July 25, 2013 Board meeting.
b. The 2013 budget assumed that the analgesic sales force would have OxyContin as the primary focus in 50% of all calls up from 30% at the end of 2012. That would have resulted in 181 thousand primary OxyContin sales calls in the first 6 months of 2013. Due to vacancies and a slower than expected implementation of this change, OxyContin was the primary focus in about 117 thousand sales calls through the end of June, 64% of target. Q3 target lists have been issued to the field force and OxyContin primary sales calls are increasing to 44% of all calls --- approaching the 50% target when secondary calls are added at ½ the value of a primary.
c. McKinsey has been engaged to work with Sales & Marketing to identify opportunities to improve performance of OxyContin. A preliminary report of this work will be made in time for the July 25th Board meeting.

Butrans

Butrans net sales for the six months ending June were $52.2 million --- $7.1 million below the mid-year forecast and $11.2 million above 2012. The net sales miss is driven by contraction in trade inventory and prescriptions running slightly below the mid-year forecast. The mid-year forecast assumes full year Butrans net sales of $127 million, the same as budget. The analgesic sales force made 213 thousand primary Butrans sales calls through the end of June vs. budget of 182 thousand calls, or 117% of target.

Intermezzo

The mid-year forecast assumes full year Intermezzo net sales of $10.3 million versus budget of $44 million. Prescriptions as reported by IMS are in line with the mid-year forecast.

Operating expenses

Total operating expenses were $435.4 million:

[EMBED Excel.Sheet.12]

1. G&A spend through June 30, 2013 was $75.4 million, which is:
    a. Lower than the 2013 mid-year forecast by $4.7 million primarily due to: $1.5 million favorable spend in External Affairs due to timing and favorable spend across other departments.
    b. Lower than 2012 by $0.3 million.
2. Redacted
3. R&D spend through June 30, 2013 was in line with the mid-year forecast and $47.2 million lower than budget:

[EMBED Excel.Sheet.12]Oxycodone Naloxone (ONU)

2013 June year-to-date spend is $19.5 million below budget due primarily to slower than expected enrollment in the two pain plus OIC efficacy studies. The slower enrollment has led to several significant protocol changes in an effort to bring the trial to an earlier completion including reducing sample size, increasing sites and more. As a result, spending for the full year is now expected to be approximately $35 million less than budget. This decrease was taken into account in the mid-year forecast.

[1] Since mid-2011 to the end of 2013 we estimate that Grunenthal will have spent $13-$14 million in legal fees on OxyContin related matters which they unfairly expect Purdue to reimburse.

<u>Hydrocodone QD TR (HYD)</u>
2013 June year-to-date spend is $3.2 million below budget due primarily to the timing of non-clinical spend. This favorability is expected to reverse over the balance of the year. The HYD team recently extended the open label safety study for six months in order to generate data regarding the safety of longer term opioid exposure. This extension, along with carryover from 2012, results in spending for the full year to be approximately $4.2 million higher than budget. This increase was taken into account in the mid-year forecast.

<u>Butrans</u>
2013 June year-to-date spend is $24.4 million below budget primarily due to a change in registration strategy for the higher strengths program from full clinical programs to analysis of existing worldwide data. As a result, spending for the full year is expected to be approximately $24 million less than budget. This decrease was taken into account in the mid-year forecast.

<u>OxyContin (primarily pediatric)</u>
2013 June year-to-date spend is $6.7 million below budget driven by favorability in pediatric studies and risk management. OTR 3001 Safety Study has a current enrollment of 98 patients with a target of 154 patients.

<u>TRPV1 Lead (Purdue)</u>
2013 June year-to-date spend is $5.2 million below budget driven by favorability in clinical and nonclinical spend which is expected to reverse in coming months.

4. S&P spend through June 30, 2013 was $147.6 million, which is:

   a. $1.6 million lower than the mid-year forecast due to timing of Intermezzo promotional spend.

   b. $10.6 million lower than budget due to:
      i. Lower expenses related to the contract sales force ($1.3 million) driven by vacancies (10%). A 60 day accrual for severance of $2.3 million was recorded on the termination date of May 14, 2013.
      ii. Lower OxyContin ($2.8 million) and Butrans ($3.0 million) promotional spend.
      iii. Lower people driven expenses ($2.8 million) due to lower sales bonus ($1.1 million) and vacancies (3.5%) in the Analgesic Sales Force ($1.7 million).
      iv. Lower all other ($0.6 million).

   c. $1.3 million higher than prior year primarily due to:
      i. Higher Intermezzo promotional spend ($6.0 million).
      ii. Lower spending in contract sales organization ($12.0 million) due to a reduction from 275 representatives in first half of 2012 to 90 through May 2013.
      iii. Higher people driven expenses primarily due to higher sales bonus ($2.9 million).
      iv. Higher all other ($4.4 million).

   d. 2013 June year-to-date calls were below goal driven by vacancies (averaging 3.5% versus budget of 2.5%) and lower calls per day (6.9 versus budget of 7.1).

Calls by Product
2013 Budget v. Actual
June YTD

Primary Calls	Budget	Act	Var
Butrans	181,986	213,267	31,280
OxyContin	181,986	117,820	(64,166)
Total Primary Calls	363,973	331,087	(32,886)
Secondary Calls	**Budget**	**Act**	**Var**
OxyContin	163,788	182,574	18,786
Butrans	163,788	111,833	(51,955)
Total Secondary Calls	327,575	294,406	(33,169)
Tertiary Calls	**Budget**	**Act**	**Var**
Intermezzo	127,390	226,959	99,568
Total Tertiary Calls	127,390	226,959	99,568
PDEs	**Budget**	**Act**	**Var**
Butrans	263,880	269,183	5,303
OxyContin	263,880	209,107	(54,773)
Intermezzo	12,739	22,696	9,957
Total PDEs	540,499	500,986	(39,513)
Calls	**Budget**	**Act**	**Var**
Butrans	345,774	325,099	(20,675)
OxyContin	345,774	300,394	(45,380)
Intermezzo	127,390	226,959	99,568
Total calls	818,938	852,452	33,514

Pre-tax earnings
Full year pre-tax earnings of $470.8 million are:

a. $25.0 million lower than the mid-year forecast due to lower gross profit ($38.8 million) on lower sales, higher incentives ($8.6 million) due to the Better Medicine Awards offset by lower ex-US expense of $22 million due to the timing of funding.

b. $9.4 million lower than budget due to lower gross profit ($183.3 million) on lower sales, higher incentives ($5.1 million), offset by lower operating expenses ($53.4 million) and the gain on Infinity stock ($124.6 million).

c. $2.7 million higher than 2012 primarily due to lower gross profit ($77.9 million) on lower sales, higher operating expenses ($12.0 million), lower ex-US royalty income ($22.2 million) and higher incentives and settlements ($8.6 million) offset by the gain on Infinity stock ($124.6 million).

Pearl Therapeutics
The 2013 forecast includes $80.3 million of cash funding to Pearl Therapeutics of which $30.3 million was included as Ex-US expense and $50 million was included as an investment relating to the purchase of Pearl stock. Since the Pearl transaction did not close, there will be variances in these line items versus the 2013 forecast.

Non-Tax Distributions
Year-to-date partner non-tax distributions were $357.6 million, made up of $216.7 million of Infinity shares and $140.9 million in cash, of which $10 million was re-invested in Rhodes.

Working Capital Highlights

Cash and Short Term Investments
At the end of June, unrestricted cash and short term investments totaled $831 million --- which is $7 million higher than forecast. This temporary higher-than-forecast cash balance is due to timing of payments. Actual cash payments during the month included Board approved payments related to the Pike County settlement ($4 million) and the Better Medicine Awards ($9.1 million).

Accounts Receivable

1. The rolling 3 month average Day's Sales Outstanding ("DSO") was 33.4 days at June 30, 2013 which is 1.6 days lower than our target of 35 days, and 0.2 days higher than May 31. The month to month DSO can fluctuate according to timing of sales and the resultant due dates. Invoice collections remain strong at 99.9 % within 10 days of the due date. There were no bad debt write-offs in the first half of 2013.

2. Open deductions totaled $431,500 at June 30, 2013 or .002% of the total receivables versus $555,706 at December 31, 2012.

3. In all respects, we believe accounts receivable collections are excellent. We continue to monitor Rite Aid (balance at June 30 of $433,653) - results are improving and short term liquidity remains good as they continue to refinance debt.

Accounts Payable

1. Payables at June 30, 2013 totaled $35.2 million versus $28.1 million at May 31, 2013. Substantial quarterly rebates to be paid in July accounted for the increase.

2. The June 30, 2013 Day's Payable Outstanding ("DPO") was 53.06 for all rebate related payments vs. 52.73 days at December 31, 2012 (a 0.33 day increase). The DPO for all non-rebate related payments was 38.88 days at June 30, 2013 vs. 38.84 days at December 31, 2012 (an increase of 0.04 days). Fluctuations in the DPO can occur due to the mix of payment types. The DPO is measured semi-annually.

3. Early payment discounts of $443,814 or 98.2% of those available were earned during the first half of 2013.

Inventory

1. Purdue is carrying $87.4 million in inventory net of reserves. This balance has increased over prior year-end and June 2012 by $36.8 million and $30.8 million, respectively. The primary drivers are as follows:

   Versus year-end 2012 (increase of $36.8 million)

   a. Higher Oxycodone API ($30.1 million) primarily driven by accelerated receipts from Rhodes Technology at Rhodes request to position them to free up labor and equipment capacity for new product validations in the last half of 2013.

   b. Higher finished goods for Dilaudid ($2.0 million) and Slow-Mag ($1.6 million) due to timing of 3rd party receipts.

c. Higher OxyContin finished goods ($1.5 million) as compared to year-end factory shutdown levels.

Versus June 2012 (increase of $30.8 million)

a. Higher Oxycodone API ($30.7 million) primarily driven by accelerated receipts from Rhodes Technology.

2. Oxycodone comprises $52.5 million of the $87.4 million total inventory. Details are provided in the table below:

	Jun-13		Jun-12	Y/E2012
Oxycodone	**kg**	**million $'s**	**million $'s**	**million $'s**
Raw	11,659	$37.7	$7.0	$7.6
WIP	791	$2.6	$4.6	$2.1
Bulk	577	$1.9	$2.8	$4.4
FG	3,195	$10.3	$9.8	$9.0
Total Oxycodone	**16,222**	**$52.5**	**$24.2**	**$23.1**

3. At the end June, the average MOH inventory level for OxyContin finished goods is ~ 2.3 months (based on projected sales). Details are as follows:

OxyContin - Months on Hand Inventory
(100 count bottles only)

10mg	15mg	20mg	30mg	40mg	60mg	80mg	Total
2.0	2.0	2.9	2.0	1.8	2.4	2.6	2.3

4. The current OxyContin finished product on hand of 2.3 is slightly higher than prior year-end of 2.1, but is slightly lower than the target of 2.5 months.

Headcount

At the end of June, Purdue's headcount was 1,689 versus the forecast of 1,751, which included a target reduction of 25. The variance of 62 includes 56 actively recruited positions - 14 with offers outstanding and 42 being actively recruited.

	A	B	C	D	E	F	G	H	I	J	K
1		Year-to-date June					Variance 2013 actual vs.				
2	(million)	Actual	Forecast	Budget	Prior year		Forecast	2013 Budget	2012 Actual		2013 Forecast
3	G&A	$ 75.4	$ 80.1	$ 80.8	$ 75.7		$ (4.7)	$ (5.4)	$ (0.3)		$ 158.4
4											
5	R&D	151.9	152.7	199.1	159.0		(0.8)	(47.2)	(7.1)		327.2
6	R&D Other - Milestones and Alliances	9.4	9.1	3.3	0.9		0.3	6.1	8.5		11.0
7	S&P	147.6	149.2	158.2	146.3		(1.6)	(10.6)	1.3		288.3
8	New Health Care Reform Pharma Fee	15.9	15.9	15.9	15.0		-	-	0.9		31.8
9	Other - US	(1.3)	0.3	2.3	(0.8)		(1.6)	(3.6)	(0.5)		0.4
10	**Total**	**$ 435.4**	**$ 436.2**	**$ 488.7**	**$ 423.4**		**$ (0.8)**	**$ (53.3)**	**$ 12.0**		**$ 871.6**

Produced Natively

▷ 9
25
24

0	3NWHL27I	TRUE	TRUE	SAPBEXq(	0	0	FALSE
0	3TS7A3EG	TRUE	TRUE	SAPBEXq(	2	3	FALSE
0	3NWHL27I	TRUE	TRUE	SAPBEXq(	2	3	FALSE
0	3NWHL27I	TRUE	TRUE	SAPBEXq(	2	3	FALSE
0	415IDLQ2(	TRUE	TRUE	SAPBEXq(	0	0	FALSE
0	415IDLQ2(	TRUE	TRUE	SAPBEXq(	2	3	FALSE
0	415IDLQ2(	TRUE	TRUE	SAPBEXq(	2	4	FALSE
0	415IDLQ2(	TRUE	TRUE	SAPBEXq(	4	4	FALSE
0	415IDLQ2(	TRUE	TRUE	SAPBEXq(	4	4	FALSE
0	415IDLQ2(	TRUE	TRUE	SAPBEXq(	4	4	FALSE
0	415IDLQ2(	TRUE	TRUE	SAPBEXq(	4	2	FALSE
0	415IDLQ2(	TRUE	TRUE	SAPBEXq(	4	2	FALSE
0	3NWHL27I	TRUE	TRUE	SAPBEXq(	0	0	FALSE
0	3NWHL27I	TRUE	TRUE	SAPBEXq(	0	0	FALSE
0	3NWHL27I	TRUE	TRUE	SAPBEXq(	0	0	FALSE
0	3NWHL27I	TRUE	TRUE	SAPBEXq(	0	0	FALSE
0	3NWHL27I	TRUE	TRUE	SAPBEXq(	0	0	FALSE
0	3N4R74C4	TRUE	TRUE	SAPBEXq(	4	3	FALSE
0	3TS7A3EG	TRUE	TRUE	SAPBEXq(	2	3	FALSE
0	415IDLQ2(	TRUE	TRUE	SAPBEXq(	4	3	FALSE
0	3NWHL27I	TRUE	TRUE	SAPBEXq(	0	0	FALSE
0	3NWHL27I	TRUE	TRUE	SAPBEXq(	2	3	FALSE
0	3NWHL27I	TRUE	TRUE	SAPBEXq(	2	3	FALSE
0	415IDLQ2(	TRUE	TRUE	SAPBEXq(	2	3	FALSE
0	415IDLQ2(	TRUE	TRUE	SAPBEXq(	2	4	FALSE

FALSE	FALSE	TRUE	FALSE	0
TRUE	FALSE	TRUE	FALSE	0
TRUE	FALSE	TRUE	FALSE	0
TRUE	FALSE	TRUE	FALSE	0
FALSE	FALSE	TRUE	FALSE	1
TRUE	FALSE	TRUE	FALSE	0
TRUE	FALSE	TRUE	FALSE	0
TRUE	FALSE	TRUE	FALSE	0
TRUE	FALSE	TRUE	FALSE	0
TRUE	FALSE	TRUE	FALSE	0
TRUE	FALSE	TRUE	FALSE	0
TRUE	FALSE	TRUE	FALSE	0
FALSE	FALSE	TRUE	FALSE	0
FALSE	FALSE	TRUE	FALSE	0
FALSE	FALSE	TRUE	FALSE	0
FALSE	FALSE	TRUE	FALSE	0
FALSE	FALSE	TRUE	FALSE	0
TRUE	FALSE	TRUE	FALSE	0
TRUE	FALSE	TRUE	FALSE	0
TRUE	FALSE	TRUE	FALSE	0
FALSE	FALSE	TRUE	FALSE	0
TRUE	FALSE	TRUE	FALSE	0
TRUE	FALSE	TRUE	FALSE	0
TRUE	FALSE	TRUE	FALSE	0
TRUE	FALSE	TRUE	FALSE	0

5	TRUE	FALSE	FALSE	FALSE	FALSE	
5	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE
5	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE
5	TRUE	FALSE	FALSE	FALSE	FALSE	
5	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE
5	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE
5	TRUE	FALSE	FALSE	FALSE	FALSE	
5	TRUE	FALSE	FALSE	FALSE	FALSE	
5	TRUE	FALSE	FALSE	FALSE	FALSE	
5	TRUE	FALSE	FALSE	FALSE	FALSE	
5	TRUE	FALSE	FALSE	FALSE	FALSE	
5	TRUE	FALSE	FALSE	FALSE	FALSE	
5	TRUE	FALSE	FALSE	FALSE	FALSE	
5	TRUE	FALSE	FALSE	FALSE	FALSE	
5	TRUE	FALSE	FALSE	FALSE	FALSE	
5	TRUE	FALSE	FALSE	FALSE	FALSE	
5	TRUE	FALSE	FALSE	FALSE	FALSE	
5	TRUE	FALSE	FALSE	FALSE	FALSE	
5	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE
5	TRUE	FALSE	FALSE	FALSE	FALSE	
5	TRUE	FALSE	FALSE	FALSE	FALSE	
5	TRUE	FALSE	FALSE	FALSE	FALSE	
5	TRUE	FALSE	FALSE	FALSE	FALSE	
5	TRUE	FALSE	FALSE	FALSE	FALSE	
5	TRUE	FALSE	FALSE	FALSE	FALSE	

175
59

23	0COSTCE	Cost cente	X		
23	0COORDE	Order	X		
23	0COMP_C	Company (	X		
23	415IDIQJB	Key Figure		X	X
23	0COSTELI	Cost Eleme	X		X
23	0PROFIT_	Profit Cent	X		Y
22	3TS7A2RE	Key Figure		X	
22	ZDEPTNAI	Departmen	X		
22	ZEMPLYT'	Employee	X		
22	ZSTART	Start Date	X		
22	ZFULLPAF	Full Time/ I	X		
22	0COMP_C	Company (	X		
22	ZEFFCDA	Effective D	X		
22	Z_EVP	EVP	X		
22	0FUNC_AI	PS Functio	X		
22	ZFUNCGR	PS Functio	X		
22	ZUNIONST	Union Statu	X		
22	ZLOCATN	Location N	X		
22	ZFLSASTA	FLSA Statu	X		
22	Z_NAME	Employee I	X		
22	ZEMP_UN	Job Title	X		
22	ZHDCNTS	Headcount	X		
22	ZDEP_CO	PS Departr	X		
22	0COSTCE	Cost cente	X		Y
21	0COSTELI	Cost Eleme	X		
21	0COORDE	Order	X		
21	0COMP_C	Company (	X		
21	0FISCPER	Fiscal year	X		
21	3YXK63C1	2005 Budg		X	X
21	0COSTCE	Cost cente	X		X
21	0PROFIT_	Profit Cent	X		Y
20	0COSTELI	Cost Eleme	X		
20	0PROFIT_	Profit Cent	X		
20	0COORDE	Order	X		
20	0COORDE	Order type	X		
20	3NWHLOE	Key Figure		X	X
20	0COSTCE	Cost cente	X		Y
19	0COSTELI	Cost Eleme	X		
19	0PROFIT_	Profit Cent	X		

19	0COORDE	Order	X		
19	0COORDE	Order type	X		
19	3NWHLOE	Key Figure		X	X
19	0COSTCE	Cost cente	X		Y
18	0COSTEL	Cost Elem	X		
18	0PROFIT_	Profit Cent	X		
18	0COORDE	Order	X		
18	0COORDE	Order type	X		
18	3NWHLOE	Key Figure		X	X
18	0COSTCE	Cost cente	X		Y
17	0COSTEL	Cost Elem	X		
17	0PROFIT_	Profit Cent	X		
17	0COORDE	Order	X		
17	0COORDE	Order type	X		
17	3NWHLOE	Key Figure		X	X
17	0COSTCE	Cost cente	X		Y
16	0COSTEL	Cost Elem	X		
16	0PROFIT_	Profit Cent	X		
16	0COORDE	Order	X		
16	0COORDE	Order type	X		
16	3NWHLOE	Key Figure		X	X
16	0COSTCE	Cost cente	X		Y
15	0COORDE	Order	X		
15	0COMP_C	Company (	X		
15	415IDIQJB	Key Figure		X	X
15	0COSTCE	Cost cente	X		X
15	0PROFIT_	Profit Cent	X		Y
15	0COSTEL	Cost Elem	X		Y
14	0COORDE	Order	X		
14	0COMP_C	Company (	X		
14	415IDIQJB	Key Figure		X	X
14	0COSTCE	Cost cente	X		X
14	0PROFIT_	Profit Cent	X		Y
14	0COSTEL	Cost Elem	X		Y
13	0COORDE	Order	X		
13	0COMP_C	Company (	X		
13	415IDIQJB	Key Figure		X	X
13	0COSTCE	Cost cente	X		X
13	0PROFIT_	Profit Cent	X		Y
13	0COSTEL	Cost Elem	X		Y
12	0COORDE	Order	X		
12	0COMP_C	Company (	X		
12	415IDIQJB	Key Figure		X	X
12	0COSTCE	Cost cente	X		X
12	0PROFIT_	Profit Cent	X		Y
12	0COSTEL	Cost Elem	X		Y
11	0COORDE	Order	X		
11	0COMP_C	Company (	X		
11	415IDIQJB	Key Figure		X	X
11	0COSTCE	Cost cente	X		X
11	0PROFIT_	Profit Cent	X		Y
11	0COSTEL	Cost Elem	X		Y

10	0COSTCE	Cost cente	X		
10	0COORDE	Order	X		
10	0COMP_C	Company (	X		
10	415IDIQJB	Key Figure		X	X
10	0PROFIT_	Profit Cent	X		Y
10	0COSTELI	Cost Eleme	X		Y
9	0COSTCE	Cost cente	X		
9	0COSTELI	Cost Eleme	X		
9	0COORDE	Order	X		
9	0COMP_C	Company (	X		
9	415IDIQJB	Key Figure		X	X
9	0PROFIT_	Profit Cent	X		Y
8	0COSTCE	Cost cente	X		
8	0COSTELI	Cost Eleme	X		
8	0COMP_C	Company (	X		
8	415IDIQJB	Key Figure		X	X
8	0PROFIT_	Profit Cent	X		Y
8	0COORDE	Order	X		Y
7	0COSTELI	Cost Eleme	X		
7	0PROFIT_	Profit Cent	X		
7	0COORDE	Order	X		
7	0COORDE	Order type	X		
7	3NWHLOE	Key Figure		X	X
7	0COSTCE	Cost cente	X		Y
6	0COSTELI	Cost Eleme	X		
6	0PROFIT_	Profit Cent	X		
6	0COORDE	Order	X		
6	0COORDE	Order type	X		
6	3NWHLOE	Key Figure		X	X
6	0COSTCE	Cost cente	X		Y
5	3TS7A2RE	Key Figure		X	
5	ZDEPTNAI	Departmen	X		
5	ZEMPLYT	Employee	X		
5	ZSTART	Start Date	X		
5	ZFULLPAF	Full Time/ I	X		
5	0COMP_C	Company (	X		
5	ZEFFCDA	Effective D	X		
5	Z_EVP	EVP	X		
5	0FUNC_AI	PS Functio	X		
5	ZFUNCGR	PS Functio	X		
5	ZUNIONST	Union Statu	X		
5	ZLOCATN	Location N	X		
5	ZFLSASTA	FLSA Statu	X		
5	Z_NAME	Employee I	X		
5	ZEMP_UN	Job Title	X		
5	ZHDCNTS	Headcount	X		
5	ZDEP_CO	PS Departr	X		
5	0COSTCE	Cost cente	X		Y
4	0COSTELI	Cost Eleme	X		
4	0PROFIT_	Profit Cent	X		
4	0COORDE	Order	X		
4	0COORDE	Order type	X		

4	3NWHLOE	Key Figure		X	X
4	0COSTCE	Cost cente	X		Y
24	0COSTELI	Cost Eleme	X		
24	0PROFIT_	Profit Cent	X		
24	0COORDE	Order	X		
24	0COORDE	Order type	X		
24	3NWHLOE	Key Figure		X	X
24	0COSTCE	Cost cente	X		Y
26	0COSTELI	Cost Eleme	X		
26	0PROFIT_	Profit Cent	X		
26	0COORDE	Order	X		
26	0COORDE	Order type	X		
26	3NWHLOE	Key Figure		X	X
26	0COSTCE	Cost cente	X		Y
25	0COSTELI	Cost Eleme	X		
25	0PROFIT_	Profit Cent	X		
25	0COORDE	Order	X		
25	0COORDE	Order type	X		
25	3NWHLOE	Key Figure		X	X
25	0COSTCE	Cost cente	X		Y
27	0COSTCE	Cost cente	X		
27	0COSTELI	Cost Eleme	X		
27	0COORDE	Order	X		
27	0COMP_C	Company (	X		
27	415IDIQJB	Key Figure		X	X
27	0PROFIT_	Profit Cent	X		Y
28	0COSTCE	Cost cente	X		
28	0COORDE	Order	X		
28	0COMP_C	Company (	X		
28	415IDIQJB	Key Figure		X	X
28	0PROFIT_	Profit Cent	X		Y
28	0COSTELI	Cost Eleme	X		Y

0001	Research a	U	0
0002			0
0003			0
0001	FY Plan	U	
0002			0
0001			0
0001	Headcount	U	
0002			2
0003	Full Time	U	1
0004			2
0005			1
0006			0
0007	6/30/2013		2
0008			1
0009			0
0010			1
0011			1
0012		U	2
0013			0
0014			2
0015		U	1
0016	Open		1
0017			1
0001	Research a		1
0001			0
0002			0
0003			0
0004			1
0001	2013 Wkg Budget	U	
0002	Research a		0
0001			0
0001	Direct Spei	C	1
0002			0
0003			0
0004			2
0001	Current Ye	U	
0001	Research a		0
0001	Direct Spei	C	1
0002			0

0003			0
0004			2
0001	Current Ye	U	
0001	Research a		0
0001	]Annual Bo	C	1
0002			0
0003			0
0004			2
0001	Current Ye	U	
0001	Research a		0
0001	]Annual Bo	C	1
0002			0
0003			0
0004			2
0001	Current Ye	U	
0001	Research a		0
0001	]Annual Bo	C	1
0002			0
0003			0
0004			2
0001	*	U	
0001	Research a		0
0001			0
0002			0
0001	YTD Var $	U	
0002	Research a	U	0
0001	FAAH Infin		6
0002			1
0001			0
0002			0
0001	YTD Var $	U	
0002	Research a	U	0
0001	PurdueTRF		6
0002			1
0001			0
0002			0
0001	FY Plan	U	
0002	Research a	U	0
0001	Risk Mgt P		0
0002			1
0001			0
0002			0
0001	YTD Actua	U	
0002	Research a	U	0
0001	Risk Mgt P		0
0002			1
0001			0
0002			0
0001	FY Plan	U	
0002	Research a	U	0
0001	Risk Mgt P		0
0002			1

0001	Drug Safet	U	0
0002		U	0
0003		U	0
0001	*	U	
0001		U	0
0002	People Cos	U	1
0001	Research a	U	0
0002			0
0003			0
0004			0
0001	*	U	
0001			0
0001	Clinical Prc	U	0
0002			0
0003			0
0001	*	U	
0001			0
0002			0
0001	Direct Sper	C	1
0002			0
0003			0
0004			2
0001	*	U	
0001	Medical Re		0
0001	Annual Bor	C	1
0002			0
0003			0
0004			2
0001	*	U	
0001	Research a		0
0001	Headcount	U	
0002			2
0003	Full Time	U	1
0004			2
0005			1
0006			0
0007	6/30/2013		2
0008			1
0009			0
0010			1
0011			1
0012		U	2
0013			0
0014			2
0015		U	1
0016	Actual		1
0017			1
0001	Research a		1
0001	]Annual Bo	C	1
0002			0
0003			0
0004			2

0001	*	U	
0001	Research a		0
0001	]Annual Bo	C	1
0002			0
0003			0
0004			2
0001	*	U	
0001	Research a		0
0001	Direct Sper	C	1
0002			0
0003			0
0004			2
0001	*	U	
0001	Medical Re		0
0001	Annual Bor	C	1
0002			0
0003			0
0004			2
0001	*	U	
0001	Research a		0
0001	Research a	U	0
0002			0
0003			0
0004			0
0001	*	U	
0001			0
0001	Drug Safet	U	0
0002		U	0
0003		U	0
0001	*	U	
0001		U	0
0002	People Cos	U	1

02	X	PURDPUR	00000000	K	0COSTCE	A
00			00000000	K	0COORDE	A
00			00000000	K	0COMP_C	A
00				K	415IDIQJB	A
03	X	PURDFA_/	00000000	K	0COSTELI	A
02		PURDRD_	00000000	K	0PROFIT_	A
00				K	3TS7A2RE	A
00			00000000	K	ZDEPTNAI	A
00			00000000	K	ZEMPLYT`	A
00			00000000	K	ZSTART	A
00			00000000	K	ZFULLPAF	A
00			00000000	K	0COMP_C	A
00			00000000	F	ZEFFCDA`	A
00			00000000	K	Z_EVP	A
00			00000000	K	0FUNC_AI	A
00			00000000	K	ZFUNCGR	A
00			00000000	K	ZUNIONST	A
00			00000000	K	ZLOCATN	A
00			00000000	K	ZFLSASTA	A
00			00000000	K	Z_NAME	A
00			00000000	K	ZEMP_UN	A
00			00000000	K	ZHDCNTS	A
00			00000000	K	ZDEP_CO	A
02	X	PURDPUR	00000000	K	0COSTCE	A
03	X	PURDOPE	00000000	K	0COSTELI	A
00			00000000	K	0COORDE	A
00			00000000	K	0COMP_C	A
00			00000000	K	0FISCPER	A
00				K	3YXK63C1	A
02	X	PURDPUR	00000000	K	0COSTCE	A
00			00000000	K	0PROFIT_	A
03		PURDOPE	00000000	K	0COSTELI	A
00			00000000	K	0PROFIT_	A
00			00000000	K	0COORDE	A
00			00000000	K	0COORDE	A
00				K	3NWHLOE	A
02	X	PURDPUR	00000000	K	0COSTCE	A
03		PURDOPE	00000000	K	0COSTELI	A
00			00000000	K	0PROFIT_	A

00			00000000	K	0COORDE	A
00			00000000	K	0COORDE	A
00				K	3NWHLOE	A
02	X	PURDPUR	00000000	K	0COSTCE	A
03		PURDOPE	00000000	K	0COSTEL	A
00			00000000	K	0PROFIT_	A
00			00000000	K	0COORDE	A
00			00000000	K	0COORDE	A
00				K	3NWHLOE	A
02	X	PURDPUR	00000000	K	0COSTCE	A
03		PURDOPE	00000000	K	0COSTEL	A
00			00000000	K	0PROFIT_	A
00			00000000	K	0COORDE	A
00			00000000	K	0COORDE	A
00				K	3NWHLOE	A
02	X	PURDPUR	00000000	K	0COSTCE	A
03		PURDOPE	00000000	K	0COSTEL	A
00			00000000	K	0PROFIT_	A
00			00000000	K	0COORDE	A
00			00000000	K	0COORDE	A
00				K	3NWHLOE	A
02	X	PURDPUR	00000000	K	0COSTCE	A
00			00000000	K	0COORDE	A
00			00000000	K	0COMP_C	A
00				K	415IDIQJB	A
02	X	PURDPUR	00000000	K	0COSTCE	A
02		PURDRD_	00000000	K	0PROFIT_	A
03	X	PURDFA_	00000000	K	0COSTEL	A
00			00000000	K	0COORDE	A
00			00000000	K	0COMP_C	A
00				K	415IDIQJB	A
02	X	PURDPUR	00000000	K	0COSTCE	A
02		PURDRD_	00000000	K	0PROFIT_	A
03	X	PURDFA_	00000000	K	0COSTEL	A
00			00000000	K	0COORDE	A
00			00000000	K	0COMP_C	A
00				K	415IDIQJB	A
02	X	PURDPUR	00000000	K	0COSTCE	A
02		PURDRD_	00000000	K	0PROFIT_	A
02	X	PURDFA_	00000000	K	0COSTEL	A
00			00000000	K	0COORDE	A
00			00000000	K	0COMP_C	A
00				K	415IDIQJB	A
02	X	PURDPUR	00000000	K	0COSTCE	A
02		PURDRD_	00000000	K	0PROFIT_	A
02	X	PURDFA_	00000000	K	0COSTEL	A
00			00000000	K	0COORDE	A
00			00000000	K	0COMP_C	A
00				K	415IDIQJB	A
02	X	PURDPUR	00000000	K	0COSTCE	A
02		PURDRD_	00000000	K	0PROFIT_	A
02	X	PURDFA_	00000000	K	0COSTEL	A

02	X	PURDPUR	00000000	K	0COSTCE	A
00			00000000	K	0COORDE	A
00			00000000	K	0COMP_C	A
00				K	415IDIQJB	A
02		PURDRD_	00000000	K	0PROFIT_	A
03		PURDFA_/	00000000	K	0COSTELI	A
02	X	PURDPUR	00000000	K	0COSTCE	A
03	X	PURDFA_/	00000000	K	0COSTELI	A
00			00000000	K	0COORDE	A
00			00000000	K	0COMP_C	A
00				K	415IDIQJB	A
02		PURDRD_	00000000	K	0PROFIT_	A
02	X	PURDPUR	00000000	K	0COSTCE	A
03	X	PURDFA_/	00000000	K	0COSTELI	A
00			00000000	K	0COMP_C	A
00				K	415IDIQJB	A
02		PURDRD_	00000000	K	0PROFIT_	A
00			00000000	K	0COORDE	A
03		PURDOPE	00000000	K	0COSTELI	A
00			00000000	K	0PROFIT_	A
00			00000000	K	0COORDE	A
00			00000000	K	0COORDE	A
00				K	3NWHLOE	A
02	X	PURDPUR	00000000	K	0COSTCE	A
03		PURDOPE	00000000	K	0COSTELI	A
00			00000000	K	0PROFIT_	A
00			00000000	K	0COORDE	A
00			00000000	K	0COORDE	A
00				K	3NWHLOE	A
02	X	PURDPUR	00000000	K	0COSTCE	A
00				K	3TS7A2RE	A
00			00000000	K	ZDEPTNAI	A
00			00000000	K	ZEMPLYT	A
00			00000000	K	ZSTART	A
00			00000000	K	ZFULLPAF	A
00			00000000	K	0COMP_C	A
00			00000000	F	ZEFFCDA	A
00			00000000	K	Z_EVP	A
00			00000000	K	0FUNC_AF	A
00			00000000	K	ZFUNCGR	A
00			00000000	K	ZUNIONST	A
00			00000000	K	ZLOCATN	A
00			00000000	K	ZFLSASTA	A
00			00000000	K	Z_NAME	A
00			00000000	K	ZEMP_UN	A
00			00000000	K	ZHDCNTS	A
00			00000000	K	ZDEP_CO	A
02	X	PURDPUR	00000000	K	0COSTCE	A
03		PURDOPE	00000000	K	0COSTELI	A
00			00000000	K	0PROFIT_	A
00			00000000	K	0COORDE	A
00			00000000	K	0COORDE	A

00				K	3NWHLOE	A
02	X	PURDPUR	00000000	K	0COSTCE	A
03		PURDOPE	00000000	K	0COSTELI	A
00			00000000	K	0PROFIT_	A
00			00000000	K	0COORDE	A
00			00000000	K	0COORDE	A
00				K	3NWHLOE	A
02	X	PURDPUR	00000000	K	0COSTCE	A
03		PURDOPE	00000000	K	0COSTELI	A
00			00000000	K	0PROFIT_	A
00			00000000	K	0COORDE	A
00			00000000	K	0COORDE	A
00				K	3NWHLOE	A
02	X	PURDPUR	00000000	K	0COSTCE	A
03		PURDOPE	00000000	K	0COSTELI	A
00			00000000	K	0PROFIT_	A
00			00000000	K	0COORDE	A
00			00000000	K	0COORDE	A
00				K	3NWHLOE	A
02	X	PURDPUR	00000000	K	0COSTCE	A
02	X	PURDPUR	00000000	K	0COSTCE	A
03	X	PURDFA_/	00000000	K	0COSTELI	A
00			00000000	K	0COORDE	A
00			00000000	K	0COMP_C	A
00				K	415IDIQJB	A
02		PURDRD_	00000000	K	0PROFIT_	A
02	X	PURDPUR	00000000	K	0COSTCE	A
00			00000000	K	0COORDE	A
00			00000000	K	0COMP_C	A
00				K	415IDIQJB	A
02		PURDRD_	00000000	K	0PROFIT_	A
03		PURDFA_/	00000000	K	0COSTELI	A

H	0COSTCE	A	00000000	0000
H			00000000	0000
H			00000000	0000
			00000000	0000
H	0COSTELI	A	00000000	0000
H	0PROFIT_	A	00000000	0000
			00000000	0000
H			00000000	0000
H			00000000	0000
H			00000000	0000
H			00000000	0000
H			00000000	0000
H			00000000	0000
H			00000000	0000
H			00000000	0000
H			00000000	0000
H			00000000	0000
H			00000000	0000
H			00000000	0000
H			00000000	0000
H			00000000	0000
H			00000000	0000
H			00000000	0000
H	0COSTCE	A	00000000	0000
H	0COSTELI	A	00000000	0000
H			00000000	0000
H			00000000	0000
H			00000000	0000
			00000000	0000
H	0COSTCE	A	00000000	0000
H			00000000	0000
H	0COSTELI	A	00000000	0000
H			00000000	0000
H			00000000	0000
H			00000000	0000
			00000000	0000
H	0COSTCE	A	00000000	0000
H	0COSTELI	A	00000000	0000
H			00000000	0000

H			00000000	0000
H			00000000	0000
			00000000	0000
H	0COSTCE	A	00000000	0000
H	0COSTELI	A	00000000	0000
H			00000000	0000
H			00000000	0000
H			00000000	0000
			00000000	0000
H	0COSTCE	A	00000000	0000
H	0COSTELI	A	00000000	0000
H			00000000	0000
H			00000000	0000
H			00000000	0000
			00000000	0000
H	0COSTCE	A	00000000	0000
H	0COSTELI	A	00000000	0000
H			00000000	0000
H			00000000	0000
H			00000000	0000
			00000000	0000
H	0COSTCE	A	00000000	0000
H			00000000	0000
H			00000000	0000
			00000000	0000
H	0COSTCE	A	00000000	0000
H	0PROFIT_	A	00000000	0000
H	0COSTELI	A	00000000	0000
H			00000000	0000
H			00000000	0000
			00000000	0000
H	0COSTCE	A	00000000	0000
H	0PROFIT_	A	00000000	0000
H	0COSTELI	A	00000000	0000
H			00000000	0000
H			00000000	0000
			00000000	0000
H	0COSTCE	A	00000000	0000
H	0PROFIT_	A	00000000	0000
H	0COSTELI	A	00000000	0000
H			00000000	0000
H			00000000	0000
			00000000	0000
H	0COSTCE	A	00000000	0000
H	0PROFIT_	A	00000000	0000
H	0COSTELI	A	00000000	0000
H			00000000	0000
H			00000000	0000
			00000000	0000
H	0COSTCE	A	00000000	0000
H	0PROFIT_	A	00000000	0000
H	0COSTELI	A	00000000	0000

H	0COSTCE	A	00000000	0000
H			00000000	0000
H			00000000	0000
			00000000	0000
H	0PROFIT_	A	00000000	0000
H	0COSTELI	A	00000000	0000
H	0COSTCE	A	00000000	0000
H	0COSTELI	A	00000000	0000
H			00000000	0000
H			00000000	0000
			00000000	0000
H	0PROFIT_	A	00000000	0000
H	0COSTCE	A	00000000	0000
H	0COSTELI	A	00000000	0000
H			00000000	0000
			00000000	0000
H	0PROFIT_	A	00000000	0000
H			00000000	0000
H	0COSTELI	A	00000000	0000
H			00000000	0000
H			00000000	0000
H			00000000	0000
			00000000	0000
H	0COSTCE	A	00000000	0000
H	0COSTELI	A	00000000	0000
H			00000000	0000
H			00000000	0000
H			00000000	0000
			00000000	0000
H	0COSTCE	A	00000000	0000
			00000000	0000
H			00000000	0000
H			00000000	0000
H			00000000	0000
H			00000000	0000
H			00000000	0000
H			00000000	0000
H			00000000	0000
H			00000000	0000
H			00000000	0000
H			00000000	0000
H			00000000	0000
H			00000000	0000
H			00000000	0000
H			00000000	0000
H			00000000	0000
H			00000000	0000
H	0COSTCE	A	00000000	0000
H	0COSTELI	A	00000000	0000
H			00000000	0000
H			00000000	0000
H			00000000	0000

			00000000	0000
H	0COSTCE	A	00000000	0000
H	0COSTELI	A	00000000	0000
H			00000000	0000
H			00000000	0000
H			00000000	0000
			00000000	0000
H	0COSTCE	A	00000000	0000
H	0COSTELI	A	00000000	0000
H			00000000	0000
H			00000000	0000
H			00000000	0000
			00000000	0000
H	0COSTCE	A	00000000	0000
H	0COSTELI	A	00000000	0000
H			00000000	0000
H			00000000	0000
H			00000000	0000
			00000000	0000
H	0COSTCE	A	00000000	0000
H	0COSTCE	A	00000000	0000
H	0COSTELI	A	00000000	0000
H			00000000	0000
H			00000000	0000
			00000000	0000
H	0PROFIT_	A	00000000	0000
H	0COSTCE	A	00000000	0000
H			00000000	0000
H			00000000	0000
			00000000	0000
H	0PROFIT_	A	00000000	0000
H	0COSTELI	A	00000000	0000

	0	1	2	1	1	1
	0			1	1	1
	0			1	1	1
X	0	1		0	0	0
	0		1	1	1	1
	0		2	1	1	1
X	0			0	0	0
	0			1	1	1
	0	1		1	1	1
	0			1	1	1
	0			1	1	1
	0			1	1	1
	0	1		1	1	1
	0			1	1	1
	0			1	1	1
	0			1	1	1
	0			1	1	1
	0			1	1	1
	0			1	1	1
	0			1	1	1
	0			1	1	1
	0	1		1	1	1
	0			1	1	1
	0	1	1	1	1	1
	0		1	1	1	1
	0			1	1	1
	0			1	1	1
	0			1	1	1
X	0	1		0	0	0
	0	1	2	1	1	1
	0			1	1	1
	0	1	1	1	1	1
	0			1	1	1
	0			1	1	1
	0			1	1	1
X	0	1		0	0	0
	0	1	1	1	1	1
	0	1	1	1	1	1
	0			1	1	1

	0			1	1	1
	0			1	1	1
X	0	1		0	0	0
	0	1	1	1	1	1
	0	X	1	1	1	1
	0			1	1	1
	0			1	1	1
	0			1	1	1
X	0	1		0	0	0
	0	1	1	1	1	1
	0	X	1	1	1	1
	0			1	1	1
	0			1	1	1
	0			1	1	1
X	0	1		0	0	0
	0	1	1	1	1	1
	0	X	1	1	1	1
	0			1	1	1
	0			1	1	1
	0			1	1	1
X	0	X		0	0	0
	0	1	1	1	1	1
	0			1	1	1
	0			1	1	1
X	0	1		0	0	0
	0	1	2	1	1	1
	0	1	2	1	1	1
	0		1	1	1	1
	0			1	1	1
	0			1	1	1
X	0	1		0	0	0
	0	1	2	1	1	1
	0	1	2	1	1	1
	0		1	1	1	1
	0			1	1	1
	0			1	1	1
X	0	1		0	0	0
	0	1	2	1	1	1
	0	X	2	1	1	1
	0		1	1	1	1
	0			1	1	1
	0			1	1	1
X	0	1		0	0	0
	0	1	2	1	1	1
	0	X	2	1	1	1
	0		1	1	1	1
	0			1	1	1
	0			1	1	1
X	0	1		0	0	0
	0	1	2	1	1	1
	0	X	2	1	1	1
	0		1	1	1	1

	0	1	2	1	1	1
	0			1	1	1
	0			1	1	1
X	0	X		0	0	0
	0		2	1	1	1
	0	1	1	1	1	1
	0	1	2	1	1	1
	0		1	1	1	1
	0			1	1	1
	0			1	1	1
X	0	X		0	0	0
	0		2	1	1	1
	0	1	2	1	1	1
	0		1	1	1	1
	0			1	1	1
X	0	X		0	0	0
	0		2	1	1	1
	0			1	1	1
	0	1	1	1	1	1
	0			1	1	1
	0			1	1	1
	0			1	1	1
X	0	X		0	0	0
	0	1	2	1	1	1
	0	1	1	1	1	1
	0			1	1	1
	0			1	1	1
	0			1	1	1
X	0	X		0	0	0
	0	1	2	1	1	1
X	0			0	0	0
	0			1	1	1
	0	1		1	1	1
	0			1	1	1
	0			1	1	1
	0			1	1	1
	0	1		1	1	1
	0			1	1	1
	0			1	1	1
	0			1	1	1
	0			1	1	1
	0			1	1	1
	0			1	1	1
	0			1	1	1
	0			1	1	1
	0	1		1	1	1
	0			1	1	1
	0	1	1	1	1	1
	0	X	1	1	1	1
	0			1	1	1
	0			1	1	1
	0			1	1	1

X	0	X		0	0	0
	0	1	1	1	1	1
	0	X	1	1	1	1
	0			1	1	1
	0			1	1	1
	0			1	1	1
X	0	X		0	0	0
	0	1	1	1	1	1
	0	1	1	1	1	1
	0			1	1	1
	0			1	1	1
	0			1	1	1
X	0	X		0	0	0
	0	1	2	1	1	1
	0	1	1	1	1	1
	0			1	1	1
	0			1	1	1
	0			1	1	1
X	0	X		0	0	0
	0	1	2	1	1	1
	0	1	2	1	1	1
	0		1	1	1	1
	0			1	1	1
	0			1	1	1
X	0	X		0	0	0
	0		2	1	1	1
	0	1	2	1	1	1
	0			1	1	1
	0			1	1	1
X	0	X		0	0	0
	0		2	1	1	1
	0	1	1	1	1	1

0	0		0	415IDHO4
0	0	2	0	415IDI3HQ
0	0	2	0	415IDIB69
0	0			415IDIQJB
0	0		0	415IDIIUS
14	0		0	415IDHVT
0	0			3TS7A2RE
0	0	2	0	3TS7AANL
6	0	2	0	3TS7A0EW
0	0	2	0	3TS7A11Y
0	0	2	0	3TS7C9HS
0	0	2	0	3TS7A19M
0	0	2	0	3TS7A1HB
0	0	2	0	3TS7A1OZ
0	0	2	0	3TS7A2C1
0	0	2	0	3TS7A2JP
0	0	2	0	3TV4TF6M
0	0	2	0	3TS7A0U9
0	0	2	0	4FKUV9W
4	0	2	0	3TS7A078
5	0	2	0	3TS7A0ML
2	0	2	0	3TS7C33D
3	0	2	0	3TS282M4
0	0		0	3TS7A1W
9	0		0	3N4R72UC
0	0	2	0	3QK6SJEF
0	0	2	0	3QK6SJME
0	0	2	0	3XT8WF0E
0	0			3YXK63C1
0	0		0	3R79R6WI
5	0	2	0	3QK6SJ71
0	0		0	3NWHL1S
0	0	2	0	3QMO8IK1
0	0	2	0	3QVESVEI
0	0	2	0	3QVESVM
0	0			3NWHLOE
1	0		0	3ODX7E5C
0	0		0	3NWHL1S
0	0	2	0	3QMO8IK1

0	0	2	0	3QVESVEI
0	0	2	0	3QVESVM
0	0			3NWHLOE
1	0		0	3ODX7E5(
0	0		0	3NWHL1S:
0	0	2	0	3QMO8IK1
0	0	2	0	3QVESVEI
0	0	2	0	3QVESVM
0	0			3NWHLOE
1	0		0	3ODX7E5(
0	0		0	3NWHL1S:
0	0	2	0	3QMO8IK1
0	0	2	0	3QVESVEI
0	0	2	0	3QVESVM
0	0			3NWHLOE
1	0		0	3ODX7E5(
0	0		0	3NWHL1S:
0	0	2	0	3QMO8IK1
0	0	2	0	3QVESVEI
0	0	2	0	3QVESVM
0	0			3NWHLOE
1	0		0	3ODX7E5(
0	0	2	0	415IDI3HQ
0	0	2	0	415IDIB69
0	0			415IDIQJB
0	0		0	415IDHO4
14	0		0	415IDHVT
0	0		0	415IDIIUS
0	0	2	0	415IDI3HQ
0	0	2	0	415IDIB69
0	0			415IDIQJB
0	0		0	415IDHO4
14	0		0	415IDHVT
0	0		0	415IDIIUS
0	0	2	0	415IDI3HQ
0	0	2	0	415IDIB69
0	0			415IDIQJB
0	0		0	415IDHO4
14	0		0	415IDHVT
0	0		0	415IDIIUS
0	0	2	0	415IDI3HQ
0	0	2	0	415IDIB69
0	0			415IDIQJB
0	0		0	415IDHO4
14	0		0	415IDHVT
0	0		0	415IDIIUS
0	0	2	0	415IDI3HQ
0	0	2	0	415IDIB69
0	0			415IDIQJB
0	0		0	415IDHO4
14	0		0	415IDHVT
0	0		0	415IDIIUS

0	0		0	415IDHO4(
0	0	2	0	415IDI3HQ
0	0	2	0	415IDIB69T
0	0			415IDIQJB
14	0		0	415IDHVT7
0	0		0	415IDIIUS5
0	0		0	415IDHO4(
0	0		0	415IDIIUS5
0	0	2	0	415IDI3HQ
0	0	2	0	415IDIB69T
0	0			415IDIQJB
14	0		0	415IDHVT7
0	0		0	415IDHO4(
0	0		0	415IDIIUS5
0	0	2	0	415IDIB69T
0	0			415IDIQJB
14	0		0	415IDHVT7
0	0	2	0	415IDI3HQ
0	0		0	3NWHL1S:
0	0	2	0	3QMO8IK1
0	0	2	0	3QVESVEI
0	0	2	0	3QVESVM
0	0			3NWHLOE
1	0		0	3ODX7E5(
0	0		0	3NWHL1S:
0	0	2	0	3QMO8IK1
0	0	2	0	3QVESVEI
0	0	2	0	3QVESVM
0	0			3NWHLOE
1	0		0	3ODX7E5(
0	0			3TS7A2RE
0	0	2	0	3TS7AANL
6	0	2	0	3TS7A0EW
0	0	2	0	3TS7A11Y
0	0	2	0	3TS7C9HS
0	0	2	0	3TS7A19M
0	0	2	0	3TS7A1HB
0	0	2	0	3TS7A1OZ
0	0	2	0	3TS7A2C1
0	0	2	0	3TS7A2JP
0	0	2	0	3TV4TF6M
0	0	2	0	3TS7A0U9
0	0	2	0	4FKUV9W
4	0	2	0	3TS7A078(
5	0	2	0	3TS7A0ML
2	0	2	0	3TS7C33D
3	0	2	0	3TS282M4
0	0		0	3TS7A1W(
0	0		0	3NWHL1S:
0	0	2	0	3QMO8IK1
0	0	2	0	3QVESVEI
0	0	2	0	3QVESVM

0	0			3NWHLOE
1	0		0	3ODX7E5(
0	0		0	3NWHL1S:
0	0	2	0	3QMO8IK1
0	0	2	0	3QVESVEI
0	0	2	0	3QVESVM
0	0			3NWHLOE
1	0		0	3ODX7E5(
0	0		0	3NWHL1S:
0	0	2	0	3QMO8IK1
0	0	2	0	3QVESVEI
0	0	2	0	3QVESVM
0	0			3NWHLOE
1	0		0	3ODX7E5(
0	0		0	3NWHL1S:
0	0	2	0	3QMO8IK1
0	0	2	0	3QVESVEI
0	0	2	0	3QVESVM
0	0			3NWHLOE
1	0		0	3ODX7E5(
0	0		0	415IDHO4(
0	0		0	415IDIIUS5
0	0	2	0	415IDI3HQ
0	0	2	0	415IDIB69
0	0			415IDIQJB
14	0		0	415IDHVT
0	0		0	415IDHO4(
0	0	2	0	415IDI3HQ
0	0	2	0	415IDIB69
0	0			415IDIQJB
14	0		0	415IDHVT
0	0		0	415IDIIUS5

0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000

0000

0000

0000
0000
0000
0000
0000
0000

0000

0000
0000
0000
0000
0000

0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000

0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000

0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000

0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000
0000

266							
13							
23	415IDIQJB	415IDKNO	FY Plan	0001		S	L
23	415IDIQJB	415IDJSX	YTD Actua	0002	Y	S	L
23	415IDIQJB	415IDK0M	YTD Plan	0003	Y	S	L
23	415IDIQJB	415IDK8A	YTD Var $	0004	Y	F	L
23	415IDIQJB	415IDLAP	Prior Yr Ac	0005	Y	S	L
23	415IDIQJB	415IDIY7U	Month Act	0006	Y	S	L
23	415IDIQJB	415IDJ5W	Month Plar	0007	Y	S	L
23	415IDIQJB	415IDJDK	Month Var	0008	Y	F	L
23	415IDIQJB	4EMZXR3	FY Original	0009	Y	S	L
23	415IDIQJB	415IDJL9E	Month Var	0010	Y	F	L
23	415IDIQJB	415IDKFZI	YTD Var %	0011	Y	F	L
23	415IDIQJB	415IDKVCI	% Spent	0012	Y	F	L
23	415IDIQJB	415IDL313	$ To Go	0013	Y	F	L
22	3TS7A2RE	3TS7AJEJ	Headcount	0001		S	L
21	3YXK63C1	3YXK64TS	2013 Wkg Budget	0001		S	L
21	3YXK63C1	3YXK63RE	YTD June 2013 Actual	0002	Y	S	L
21	3YXK63C1	3YXK63Z2	YTD June 2013 LE	0003	Y	S	L
21	3YXK63C1	3YXK646R	YTD $ Var	0004	Y	F	L
21	3YXK63C1	3YXK64EF	YTD % Va	0005	Y	F	L
21	3YXK63C1	3YXK64M4	2013 LE	0006	Y	S	L
21	3YXK63C1	3YXK651H	Var $	0007	Y	F	L
21	3YXK63C1	3YXK6595	Var %	0008	Y	F	L
21	3YXK63C1	3YXK66BK	2012 Actual	0009	Y	S	L
21	3YXK63C1	4MS97EZA	2011 Actual	0010	Y	S	L
21	3YXK63C1	4EJW1TO	FY Original	0011	Y	S	L
20	3NWHLOE	3OW23W	Current Ye	0001		S	L
20	3NWHLOE	3OW2282	Current Ye	0002	Y	S	L
20	3NWHLOE	3OW228AI	Current Ye	0003	Y	S	L
20	3NWHLOE	3WRKQLC	Current Ye	0004	Y	F	L
20	3NWHLOE	3OW2295	Previous Y	0005	Y	S	L
20	3NWHLOE	3WRKQLV	Current Ye	0006	Y	F	L
20	3NWHLOE	3OW227V	Current Ye	0007	Y	S	L
20	3NWHLOE	3OW7W9	Current Ye	0008	Y	S	L
20	3NWHLOE	3WRKQL8	Current Ye	0009	Y	F	L
20	3NWHLOE	3WRKQLG	Curent Yea	0010	Y	F	L
19	3NWHLOE	3OW23W	Current Ye	0001		S	L
19	3NWHLOE	3OW2282	Current Ye	0002	Y	S	L
19	3NWHLOE	3OW228AI	Current Ye	0003	Y	S	L
19	3NWHLOE	3WRKQLC	Current Ye	0004	Y	F	L

19	3NWHLOE	3OW2295	Previous Y	0005	Y	S	L
19	3NWHLOE	3WRKQLV	Current Ye	0006	Y	F	L
19	3NWHLOE	3OW227V	Current Ye	0007	Y	S	L
19	3NWHLOE	3OW7W9	Current Ye	0008	Y	S	L
19	3NWHLOE	3WRKQL8	Current Ye	0009	Y	F	L
19	3NWHLOE	3WRKQLG	Curent Yea	0010	Y	F	L
18	3NWHLOE	3OW23W(	Current Ye	0001		S	L
18	3NWHLOE	3OW2282	Current Ye	0002	Y	S	L
18	3NWHLOE	3OW228AI	Current Ye	0003	Y	S	L
18	3NWHLOE	3WRKQLC	Current Ye	0004	Y	F	L
18	3NWHLOE	3OW2295	Previous Y	0005	Y	S	L
18	3NWHLOE	3WRKQLV	Current Ye	0006	Y	F	L
18	3NWHLOE	3OW227V	Current Ye	0007	Y	S	L
18	3NWHLOE	3OW7W9	Current Ye	0008	Y	S	L
18	3NWHLOE	3WRKQL8	Current Ye	0009	Y	F	L
18	3NWHLOE	3WRKQLG	Curent Yea	0010	Y	F	L
17	3NWHLOE	3OW23W(	Current Ye	0001		S	L
17	3NWHLOE	3OW2282	Current Ye	0002	Y	S	L
17	3NWHLOE	3OW228AI	Current Ye	0003	Y	S	L
17	3NWHLOE	3WRKQLC	Current Ye	0004	Y	F	L
17	3NWHLOE	3OW2295	Previous Y	0005	Y	S	L
17	3NWHLOE	3WRKQLV	Current Ye	0006	Y	F	L
17	3NWHLOE	3OW227V	Current Ye	0007	Y	S	L
17	3NWHLOE	3OW7W9	Current Ye	0008	Y	S	L
17	3NWHLOE	3WRKQL8	Current Ye	0009	Y	F	L
17	3NWHLOE	3WRKQLG	Curent Yea	0010	Y	F	L
16	3NWHLOE	3OW2282	Current Ye	0001		S	L
16	3NWHLOE	3OW228AI	Current Ye	0002		S	L
16	3NWHLOE	3WRKQLC	Current Ye	0003		F	L
16	3NWHLOE	3OW23W(	Current Ye	0004		S	L
16	3NWHLOE	3OW2295	Previous Y	0005		S	L
16	3NWHLOE	3WRKQLV	Current Ye	0006	Y	F	L
16	3NWHLOE	3OW227V	Current Ye	0007	Y	S	L
16	3NWHLOE	3OW7W9	Current Ye	0008	Y	S	L
16	3NWHLOE	3WRKQL8	Current Ye	0009	Y	F	L
16	3NWHLOE	3WRKQLG	Curent Yea	0010	Y	F	L
15	415IDIQJB	415IDK8A	YTD Var $	0001		F	L
15	415IDIQJB	415IDJSX	YTD Actua	0002	Y	S	L
15	415IDIQJB	415IDK0M	YTD Plan	0003	Y	S	L
15	415IDIQJB	415IDKNO	FY Plan	0004	Y	S	L
15	415IDIQJB	415IDLAP	Prior Yr Ac	0005	Y	S	L
15	415IDIQJB	415IDIY7U	Month Act	0006	Y	S	L
15	415IDIQJB	415IDJ5W	Month Plar	0007	Y	S	L
15	415IDIQJB	415IDJDK	Month Var	0008	Y	F	L
15	415IDIQJB	4EMZXR3	FY Original	0009	Y	S	L
15	415IDIQJB	415IDJL9E	Month Var	0010	Y	F	L
15	415IDIQJB	415IDKFZI	YTD Var %	0011	Y	F	L
15	415IDIQJB	415IDKVC	% Spent	0012	Y	F	L
15	415IDIQJB	415IDL313	$ To Go	0013	Y	F	L
14	415IDIQJB	415IDK8A	YTD Var $	0001		F	L
14	415IDIQJB	415IDJSX	YTD Actua	0002	Y	S	L
14	415IDIQJB	415IDK0M	YTD Plan	0003	Y	S	L

14	415IDIQJB	415IDKNO	FY Plan	0004	Y	S	L
14	415IDIQJB	415IDLAPI	Prior Yr Ac	0005	Y	S	L
14	415IDIQJB	415IDIY7U	Month Actu	0006	Y	S	L
14	415IDIQJB	415IDJ5WI	Month Plar	0007	Y	S	L
14	415IDIQJB	415IDJDK\	Month Var	0008	Y	F	L
14	415IDIQJB	4EMZXR3'	FY Original	0009	Y	S	L
14	415IDIQJB	415IDJL9E	Month Var	0010	Y	F	L
14	415IDIQJB	415IDKFZI	YTD Var %	0011	Y	F	L
14	415IDIQJB	415IDKVCI	% Spent	0012	Y	F	L
14	415IDIQJB	415IDL313	$ To Go	0013	Y	F	L
13	415IDIQJB	415IDKNO	FY Plan	0001		S	L
13	415IDIQJB	415IDJSX)	YTD Actua	0002	Y	S	L
13	415IDIQJB	415IDK0M	YTD Plan	0003	Y	S	L
13	415IDIQJB	415IDK8AZ	YTD Var $	0004	Y	F	L
13	415IDIQJB	415IDLAPI	Prior Yr Ac	0005	Y	S	L
13	415IDIQJB	415IDIY7U	Month Actu	0006	Y	S	L
13	415IDIQJB	415IDJ5WI	Month Plar	0007	Y	S	L
13	415IDIQJB	415IDJDK\	Month Var	0008	Y	F	L
13	415IDIQJB	4EMZXR3'	FY Original	0009	Y	S	L
13	415IDIQJB	415IDJL9E	Month Var	0010	Y	F	L
13	415IDIQJB	415IDKFZI	YTD Var %	0011	Y	F	L
13	415IDIQJB	415IDKVCI	% Spent	0012	Y	F	L
13	415IDIQJB	415IDL313	$ To Go	0013	Y	F	L
12	415IDIQJB	415IDJSX)	YTD Actua	0001		S	L
12	415IDIQJB	415IDK0M	YTD Plan	0002	Y	S	L
12	415IDIQJB	415IDK8AZ	YTD Var $	0003	Y	F	L
12	415IDIQJB	415IDKNO	FY Plan	0004	Y	S	L
12	415IDIQJB	415IDLAPI	Prior Yr Ac	0005	Y	S	L
12	415IDIQJB	415IDIY7U	Month Actu	0006	Y	S	L
12	415IDIQJB	415IDJ5WI	Month Plar	0007	Y	S	L
12	415IDIQJB	415IDJDK\	Month Var	0008	Y	F	L
12	415IDIQJB	4EMZXR3'	FY Original	0009	Y	S	L
12	415IDIQJB	415IDJL9E	Month Var	0010	Y	F	L
12	415IDIQJB	415IDKFZI	YTD Var %	0011	Y	F	L
12	415IDIQJB	415IDKVCI	% Spent	0012	Y	F	L
12	415IDIQJB	415IDL313	$ To Go	0013	Y	F	L
11	415IDIQJB	415IDKNO	FY Plan	0001		S	L
11	415IDIQJB	415IDJSX)	YTD Actua	0002	Y	S	L
11	415IDIQJB	415IDK0M	YTD Plan	0003	Y	S	L
11	415IDIQJB	415IDK8AZ	YTD Var $	0004	Y	F	L
11	415IDIQJB	415IDLAPI	Prior Yr Ac	0005	Y	S	L
11	415IDIQJB	415IDIY7U	Month Actu	0006	Y	S	L
11	415IDIQJB	415IDJ5WI	Month Plar	0007	Y	S	L
11	415IDIQJB	415IDJDK\	Month Var	0008	Y	F	L
11	415IDIQJB	4EMZXR3'	FY Original	0009	Y	S	L
11	415IDIQJB	415IDJL9E	Month Var	0010	Y	F	L
11	415IDIQJB	415IDKFZI	YTD Var %	0011	Y	F	L
11	415IDIQJB	415IDKVCI	% Spent	0012	Y	F	L
11	415IDIQJB	415IDL313	$ To Go	0013	Y	F	L
10	415IDIQJB	415IDJSX)	YTD Actua	0001		S	L
10	415IDIQJB	415IDK0M	YTD Plan	0002		S	L
10	415IDIQJB	415IDK8AZ	YTD Var $	0003		F	L

10	415IDIQJB	415IDKNO	FY Plan	0004		S	L
10	415IDIQJB	415IDLAPI	Prior Yr Ac	0005		S	L
10	415IDIQJB	415IDIY7U	Month Actu	0006	Y	S	L
10	415IDIQJB	415IDJ5WI	Month Plar	0007	Y	S	L
10	415IDIQJB	415IDJDK\	Month Var	0008	Y	F	L
10	415IDIQJB	4EMZXR3'	FY Original	0009	Y	S	L
10	415IDIQJB	415IDJL9E	Month Var	0010	Y	F	L
10	415IDIQJB	415IDKFZI	YTD Var %	0011	Y	F	L
10	415IDIQJB	415IDKVCI	% Spent	0012	Y	F	L
10	415IDIQJB	415IDL313	$ To Go	0013	Y	F	L
9	415IDIQJB	415IDJSX)	YTD Actua	0001		S	L
9	415IDIQJB	415IDK0M(	YTD Plan	0002		S	L
9	415IDIQJB	415IDK8AZ	YTD Var $	0003		F	L
9	415IDIQJB	415IDKNO	FY Plan	0004		S	L
9	415IDIQJB	415IDLAPI	Prior Yr Ac	0005		S	L
9	415IDIQJB	415IDIY7U	Month Actu	0006	Y	S	L
9	415IDIQJB	415IDJ5WI	Month Plar	0007	Y	S	L
9	415IDIQJB	415IDJDK\	Month Var	0008	Y	F	L
9	415IDIQJB	4EMZXR3'	FY Original	0009	Y	S	L
9	415IDIQJB	415IDJL9E	Month Var	0010	Y	F	L
9	415IDIQJB	415IDKFZI	YTD Var %	0011	Y	F	L
9	415IDIQJB	415IDKVCI	% Spent	0012	Y	F	L
9	415IDIQJB	415IDL313	$ To Go	0013	Y	F	L
8	415IDIQJB	415IDIY7U	Month Actu	0001	Y	S	L
8	415IDIQJB	415IDJ5WI	Month Plar	0002	Y	S	L
8	415IDIQJB	415IDJDK\	Month Var	0003	Y	F	L
8	415IDIQJB	415IDJL9E	Month Var	0004	Y	F	L
8	415IDIQJB	415IDJSX)	YTD Actua	0005		S	L
8	415IDIQJB	415IDK0M(	YTD Plan	0006		S	L
8	415IDIQJB	415IDK8AZ	YTD Var $	0007	Y	F	L
8	415IDIQJB	415IDKFZI	YTD Var %	0008	Y	F	L
8	415IDIQJB	415IDKNO	FY Plan	0009	Y	S	L
8	415IDIQJB	415IDKVCI	% Spent	0010	Y	F	L
8	415IDIQJB	415IDL313	$ To Go	0011	Y	F	L
8	415IDIQJB	415IDLAPI	Prior Yr Ac	0012	Y	S	L
8	415IDIQJB	4EMZXR3'	FY Original	0013		S	L
7	3NWHLOE	3OW2282T	Current Ye	0001		S	L
7	3NWHLOE	3OW228AI	Current Ye	0002		S	L
7	3NWHLOE	3WRKQLC	Current Ye	0003		F	L
7	3NWHLOE	3OW23W(	Current Ye	0004		S	L
7	3NWHLOE	3OW2957	Previous Y	0005		S	L
7	3NWHLOE	3WRKQLV	Current Ye	0006	Y	F	L
7	3NWHLOE	3OW227V4	Current Ye	0007	Y	S	L
7	3NWHLOE	3OW7W9\	Current Ye	0008	Y	S	L
7	3NWHLOE	3WRKQL8	Current Ye	0009	Y	F	L
7	3NWHLOE	3WRKQLG	Curent Yea	0010	Y	F	L
6	3NWHLOE	3OW2282T	Current Ye	0001		S	L
6	3NWHLOE	3OW228AI	Current Ye	0002		S	L
6	3NWHLOE	3WRKQLC	Current Ye	0003		F	L
6	3NWHLOE	3OW23W(	Current Ye	0004		S	L
6	3NWHLOE	3OW2957	Previous Y	0005		S	L
6	3NWHLOE	3WRKQLV	Current Ye	0006	Y	F	L

6	3NWHLOE	3OW227V	Current Ye	0007	Y	S	L
6	3NWHLOE	3OW7W9	Current Ye	0008	Y	S	L
6	3NWHLOE	3WRKQL8	Current Ye	0009	Y	F	L
6	3NWHLOE	3WRKQL	Curent Ye	0010	Y	F	L
5	3TS7A2RE	3TS7AJEJ	Headcount	0001		S	L
4	3NWHLOE	3OW2282	Current Ye	0001		S	L
4	3NWHLOE	3OW228AI	Current Ye	0002		S	L
4	3NWHLOE	3WRKQLC	Current Ye	0003		F	L
4	3NWHLOE	3OW23W	Current Ye	0004		S	L
4	3NWHLOE	3OW2295	Previous Y	0005		S	L
4	3NWHLOE	3WRKQLV	Current Ye	0006	Y	F	L
4	3NWHLOE	3OW227V	Current Ye	0007	Y	S	L
4	3NWHLOE	3OW7W9	Current Ye	0008	Y	S	L
4	3NWHLOE	3WRKQL8	Current Ye	0009	Y	F	L
4	3NWHLOE	3WRKQL	Curent Ye	0010	Y	F	L
24	3NWHLOE	3OW2282	Current Ye	0001		S	L
24	3NWHLOE	3OW228AI	Current Ye	0002		S	L
24	3NWHLOE	3WRKQLC	Current Ye	0003		F	L
24	3NWHLOE	3OW23W	Current Ye	0004		S	L
24	3NWHLOE	3OW2295	Previous Y	0005		S	L
24	3NWHLOE	3WRKQLV	Current Ye	0006	Y	F	L
24	3NWHLOE	3OW227V	Current Ye	0007	Y	S	L
24	3NWHLOE	3OW7W9	Current Ye	0008	Y	S	L
24	3NWHLOE	3WRKQL8	Current Ye	0009	Y	F	L
24	3NWHLOE	3WRKQL	Curent Ye	0010	Y	F	L
26	3NWHLOE	3OW2282	Current Ye	0001		S	L
26	3NWHLOE	3OW228AI	Current Ye	0002		S	L
26	3NWHLOE	3WRKQLC	Current Ye	0003		F	L
26	3NWHLOE	3OW23W	Current Ye	0004		S	L
26	3NWHLOE	3OW2295	Previous Y	0005		S	L
26	3NWHLOE	3WRKQLV	Current Ye	0006	Y	F	L
26	3NWHLOE	3OW227V	Current Ye	0007	Y	S	L
26	3NWHLOE	3OW7W9	Current Ye	0008	Y	S	L
26	3NWHLOE	3WRKQL8	Current Ye	0009	Y	F	L
26	3NWHLOE	3WRKQL	Curent Ye	0010	Y	F	L
25	3NWHLOE	3OW2282	Current Ye	0001		S	L
25	3NWHLOE	3OW228AI	Current Ye	0002		S	L
25	3NWHLOE	3WRKQLC	Current Ye	0003		F	L
25	3NWHLOE	3OW23W	Current Ye	0004		S	L
25	3NWHLOE	3OW2295	Previous Y	0005		S	L
25	3NWHLOE	3WRKQLV	Current Ye	0006	Y	F	L
25	3NWHLOE	3OW227V	Current Ye	0007	Y	S	L
25	3NWHLOE	3OW7W9	Current Ye	0008	Y	S	L
25	3NWHLOE	3WRKQL8	Current Ye	0009	Y	F	L
25	3NWHLOE	3WRKQL	Curent Ye	0010	Y	F	L
27	415IDIQJB	415IDJSX	YTD Actua	0001		S	L
27	415IDIQJB	415IDK0M	YTD Plan	0002		S	L
27	415IDIQJB	415IDK8A	YTD Var $	0003		F	L
27	415IDIQJB	415IDKNO	FY Plan	0004		S	L
27	415IDIQJB	415IDLAP	Prior Yr Ac	0005		S	L
27	415IDIQJB	415IDIY7U	Month Act	0006	Y	S	L
27	415IDIQJB	415IDJ5W	Month Pla	0007	Y	S	L

27	415IDIQJB	415IDJDK\	Month Var	0008	Y	F	L
27	415IDIQJB	4EMZXR3'	FY Original	0009	Y	S	L
27	415IDIQJB	415IDJL9E	Month Var	0010	Y	F	L
27	415IDIQJB	415IDKFZI	YTD Var %	0011	Y	F	L
27	415IDIQJB	415IDKVCI	% Spent	0012	Y	F	L
27	415IDIQJB	415IDL313	$ To Go	0013	Y	F	L
28	415IDIQJB	415IDJSX)	YTD Actua	0001		S	L
28	415IDIQJB	415IDK0M(	YTD Plan	0002		S	L
28	415IDIQJB	415IDK8AZ	YTD Var $	0003		F	L
28	415IDIQJB	415IDKNO	FY Plan	0004		S	L
28	415IDIQJB	415IDLAPI	Prior Yr Ac	0005		S	L
28	415IDIQJB	415IDIY7U	Month Actu	0006	Y	S	L
28	415IDIQJB	415IDJ5WI	Month Plar	0007	Y	S	L
28	415IDIQJB	415IDJDK\	Month Var	0008	Y	F	L
28	415IDIQJB	4EMZXR3'	FY Original	0009	Y	S	L
28	415IDIQJB	415IDJL9E	Month Var	0010	Y	F	L
28	415IDIQJB	415IDKFZI	YTD Var %	0011	Y	F	L
28	415IDIQJB	415IDKVCI	% Spent	0012	Y	F	L
28	415IDIQJB	415IDL313	$ To Go	0013	Y	F	L

X	IOBJ	0AMOUNT	Amount
X	IOBJ	0AMOUNT	Amount
X	IOBJ	0AMOUNT	Amount
X			
X	IOBJ	0AMOUNT	Amount
X	IOBJ	0AMOUNT	Amount
X	IOBJ	0AMOUNT	Amount
X			
X	IOBJ	0AMOUNT	Amount
X			
X			
X			
X			
X			
X	IOBJ	0AMOUNT	Amount
X	IOBJ	0AMOUNT	Amount
X	IOBJ	0AMOUNT	Amount
X	IOBJ	0AMOUNT	Amount
X	IOBJ	0AMOUNT	Amount
X	IOBJ	0AMOUNT	Amount
X	IOBJ	0AMOUNT	Amount
X			
X			
X			
X			
X			
X			
X			
X			
X			

X			
X			
X			
X			
X			
X			
X			
X			
X			
X			
X			
X			
X			
X			
X			
X			
X			
X			
X			
X			
X			
X			
X	IOBJ	0AMOUNT	Amount
X	IOBJ	0AMOUNT	Amount
X	IOBJ	0AMOUNT	Amount
X	IOBJ	0AMOUNT	Amount
X	IOBJ	0AMOUNT	Amount
X	IOBJ	0AMOUNT	Amount
X			
X	IOBJ	0AMOUNT	Amount
X			
X			
X			
X			
X			
X	IOBJ	0AMOUNT	Amount
X	IOBJ	0AMOUNT	Amount

X	IOBJ	0AMOUNT	Amount
X	IOBJ	0AMOUNT	Amount
X	IOBJ	0AMOUNT	Amount
X	IOBJ	0AMOUNT	Amount
X			
X	IOBJ	0AMOUNT	Amount
X			
X			
X			
X			
X	IOBJ	0AMOUNT	Amount
X	IOBJ	0AMOUNT	Amount
X	IOBJ	0AMOUNT	Amount
X			
X	IOBJ	0AMOUNT	Amount
X	IOBJ	0AMOUNT	Amount
X	IOBJ	0AMOUNT	Amount
X			
X	IOBJ	0AMOUNT	Amount
X			
X			
X			
X			
X	IOBJ	0AMOUNT	Amount
X	IOBJ	0AMOUNT	Amount
X			
X	IOBJ	0AMOUNT	Amount
X	IOBJ	0AMOUNT	Amount
X	IOBJ	0AMOUNT	Amount
X	IOBJ	0AMOUNT	Amount
X			
X	IOBJ	0AMOUNT	Amount
X			
X			
X			
X			
X	IOBJ	0AMOUNT	Amount
X	IOBJ	0AMOUNT	Amount
X	IOBJ	0AMOUNT	Amount
X			
X	IOBJ	0AMOUNT	Amount
X	IOBJ	0AMOUNT	Amount
X	IOBJ	0AMOUNT	Amount
X			
X	IOBJ	0AMOUNT	Amount
X			
X			
X			
X			
X	IOBJ	0AMOUNT	Amount
X	IOBJ	0AMOUNT	Amount
X			

X	IOBJ	0AMOUNT	Amount
X	IOBJ	0AMOUNT	Amount
X	IOBJ	0AMOUNT	Amount
X	IOBJ	0AMOUNT	Amount
X			
X	IOBJ	0AMOUNT	Amount
X			
X			
X			
X			
X	IOBJ	0AMOUNT	Amount
X	IOBJ	0AMOUNT	Amount
X			
X	IOBJ	0AMOUNT	Amount
X	IOBJ	0AMOUNT	Amount
X	IOBJ	0AMOUNT	Amount
X	IOBJ	0AMOUNT	Amount
X			
X	IOBJ	0AMOUNT	Amount
X			
X			
X			
X			
X	IOBJ	0AMOUNT	Amount
X	IOBJ	0AMOUNT	Amount
X			
X			
X	IOBJ	0AMOUNT	Amount
X	IOBJ	0AMOUNT	Amount
X			
X			
X	IOBJ	0AMOUNT	Amount
X			
X			
X	IOBJ	0AMOUNT	Amount
X	IOBJ	0AMOUNT	Amount
X			
X			
X			
X			
X			
X			
X			
X			
X			
X			

X			
X			
X			
X			
X			
X			
X			
X			
X			
X			
X			
X			
X			
X			
X			
X			
X			
X			
X			
X			
X			
X			
X			
X			
X			
X	IOBJ	0AMOUNT	Amount
X	IOBJ	0AMOUNT	Amount
X			
X	IOBJ	0AMOUNT	Amount
X	IOBJ	0AMOUNT	Amount
X	IOBJ	0AMOUNT	Amount
X	IOBJ	0AMOUNT	Amount

X			
X	IOBJ	0AMOUNT	Amount
X			
X			
X			
X			
X	IOBJ	0AMOUNT	Amount
X	IOBJ	0AMOUNT	Amount
X			
X	IOBJ	0AMOUNT	Amount
X	IOBJ	0AMOUNT	Amount
X	IOBJ	0AMOUNT	Amount
X	IOBJ	0AMOUNT	Amount
X			
X	IOBJ	0AMOUNT	Amount
X			
X			
X			
X			

878
14

23	0COSTCEI	0BUS_ARE	Business a	0000	X	0
23	0COSTCEI	0COMP_C	Company c	0000	X	0
23	0COSTCEI	0LOGSYS	Source Sys	0000	X	1
23	0COSTCEI	0OBJ_CUF	Object curr	0000	X	0
23	0COSTCEI	0PROFIT_	Profit Cent	0000	X	0
23	0COSTCEI	0RESP_PE	Person res	0000	X	2
23	0COSTCEI	ZCOSTCT	Cost Cente	0000	X	1
23	0PROFIT_	0COMP_C	Company c	0000	X	0
23	0PROFIT_	0LOGSYS	Source Sys	0000	X	1
23	0PROFIT_	0OBJ_CUF	Object curr	0000	X	0
23	0PROFIT_	0RESP_PE	Person res	0000	X	2
23	0PROFIT_	0SOURSY	Source sys	0000	X	2
23	0COORDE	0BUS_ARE	Business a	0000	X	0
23	0COORDE	0COMP_C	Company c	0000	X	0
23	0COORDE	0COORD_	Order type	0000	X	2
23	0COORDE	0CO_ARE/	Controlling	0000	X	0
23	0COORDE	0IM_SIZE	Scale (IM)	0000	X	1
23	0COORDE	0LOGSYS	Source Sys	0000	X	1
23	0COORDE	0OBJ_CUF	Object curr	0000	X	0
23	0COORDE	0ORDCAT	Order Cate	0000	X	2
23	0COORDE	0PLANT	Plant	0000	X	0
23	0COORDE	0PROFIT_	Profit Cent	0000	X	0
23	0COORDE	0REQU_C	Req.cost c	0000	X	0
23	0COORDE	0RESP_C(	Resp. cost	0000	X	0
23	0COORDE	0STATUSS	BW Status	0000	X	2
23	0COORDE	0WBS_ELI	WBS elem	0000	X	0
23	0COMP_C	0CHRT_A(	Chart of ac	0000	X	0
23	0COMP_C	0COMPAN	Company	0000	X	0
23	0COMP_C	0COUNTR	Country	0000	X	0
23	0COMP_C	0CURREN	Currency	0000	X	0
23	0COMP_C	0C_CTR_A	Credit Con	0000	X	0
23	0COMP_C	0FISCVAR	Fiscal Year	0000	X	2
23	0COMP_C	0LOGSYS	Source Sys	0000	X	1
23	0COMP_C	0OFPER	Open FY P	0000	X	1
23	0COMP_C	0OFPER3	Open Posti	0000	X	2
23	0COMP_C	0OFYEAR	Open Fisca	0000	X	2
23	0COMP_C	0RETROP	Post to Pre	0000	X	2
23	0COMP_C	0SOURSY	Source sys	0000	X	2
23	0COSTELI	0CSTELMI	CElem cate	0000	X	2

23	0COSTELI	0LOGSYS	Source Sys	0000	X	1
23	0COSTELI	0SEM_POS	Planning It	0000	X	1
23	0COSTELI	0UNIT	Unit of Mea	0000	X	0
22	0COMP_C	0CHRT_AC	Chart of ac	0000	X	0
22	0COMP_C	0COMPAN	Company	0000	X	0
22	0COMP_C	0COUNTR	Country	0000	X	0
22	0COMP_C	0CURREN	Currency	0000	X	0
22	0COMP_C	0C_CTR_A	Credit Con	0000	X	0
22	0COMP_C	0FISCVAR	Fiscal Year	0000	X	2
22	0COMP_C	0LOGSYS	Source Sys	0000	X	1
22	0COMP_C	0SOURSY	Source sys	0000	X	2
22	0COSTCEI	0BUS_ARE	Business a	0000	X	0
22	0COSTCEI	0COMP_C	Company c	0000	X	0
22	0COSTCEI	0LOGSYS	Source Sys	0000	X	1
22	0COSTCEI	0OBJ_CUF	Object curr	0000	X	0
22	0COSTCEI	0PROFIT_	Profit Cent	0000	X	0
22	0COSTCEI	0RESP_PE	Person res	0000	X	2
22	0COSTCEI	ZCOSTCT	Cost Cente	0000	X	1
22	0COMP_C	0OFPER	Open FY P	0001	X	1
22	0COMP_C	0OFPER3	Open Posti	0002	X	2
22	0COMP_C	0OFYEAR	Open Fisca	0003	X	2
22	0COMP_C	0RETROP	Post to Pre	0004	X	2
21	0COSTCEI	0BUS_ARE	Business a	0000	X	0
21	0COSTCEI	0COMP_C	Company c	0000	X	0
21	0COSTCEI	0LOGSYS	Source Sys	0000	X	1
21	0COSTCEI	0OBJ_CUF	Object curr	0000	X	0
21	0COSTCEI	0PROFIT_	Profit Cent	0000	X	0
21	0COSTCEI	0RESP_PE	Person res	0000	X	2
21	0COSTCEI	ZCOSTCT	Cost Cente	0000	X	1
21	0COSTELI	0CSTELMI	CElem cate	0000	X	2
21	0COSTELI	0LOGSYS	Source Sys	0000	X	1
21	0COSTELI	0SEM_POS	Planning It	0000	X	1
21	0COSTELI	0UNIT	Unit of Mea	0000	X	0
21	0PROFIT_	0COMP_C	Company c	0000	X	0
21	0PROFIT_	0LOGSYS	Source Sys	0000	X	1
21	0PROFIT_	0OBJ_CUF	Object curr	0000	X	0
21	0PROFIT_	0RESP_PE	Person res	0000	X	2
21	0PROFIT_	0SOURSY	Source sys	0000	X	2
21	0COORDE	0BUS_ARE	Business a	0000	X	0
21	0COORDE	0COMP_C	Company c	0000	X	0
21	0COORDE	0COORD_	Order type	0001		0
21	0COORDE	0CO_ARE/	Controlling	0000	X	0
21	0COORDE	0IM_SIZE	Scale (IM)	0000	X	1
21	0COORDE	0LOGSYS	Source Sys	0000	X	1
21	0COORDE	0OBJ_CUF	Object curr	0000	X	0
21	0COORDE	0ORDCAT	Order Cate	0000	X	2
21	0COORDE	0PLANT	Plant	0000	X	0
21	0COORDE	0PROFIT_	Profit Cent	0000	X	0
21	0COORDE	0REQU_C	Req.cost c	0000	X	0
21	0COORDE	0RESP_C(	Resp. cost	0000	X	0
21	0COORDE	0STATUSS	BW Status	0000	X	2
21	0COORDE	0WBS_ELI	WBS elem	0000	X	0

21	0COMP_C	0CHRT_A(	Chart of ac	0000	X	0
21	0COMP_C	0COMPAN	Company	0000	X	0
21	0COMP_C	0COUNTR	Country	0000	X	0
21	0COMP_C	0CURREN	Currency	0000	X	0
21	0COMP_C	0C_CTR_A	Credit Con	0000	X	0
21	0COMP_C	0FISCVAR	Fiscal Year	0000	X	2
21	0COMP_C	0LOGSYS	Source Sys	0000	X	1
21	0COMP_C	0OFPER	Open FY P	0000	X	1
21	0COMP_C	0OFPER3	Open Posti	0000	X	2
21	0COMP_C	0OFYEAR	Open Fisca	0000	X	2
21	0COMP_C	0RETROP	Post to Pre	0000	X	2
21	0COMP_C	0SOURSY	Source sys	0000	X	2
21	0FISCPER	0DATEFR(	Valid From	0000	X	2
21	0FISCPER	0DATETO	Valid To	0000	X	2
21	0FISCPER	0FISCPER	Posting pe	0000	X	2
21	0FISCPER	0FISCYEA	Fiscal year	0000	X	1
21	0FISCPER	0NUMDAY	Number of	0000	X	2
21	0FISCPER	0NUMWD/	Number of	0000	X	2
20	0COSTELI	0CSTELMI	CElem cat	0000	X	2
20	0COSTELI	0LOGSYS	Source Sys	0000	X	1
20	0COSTELI	0SEM_PO:	Planning It	0000	X	1
20	0COSTELI	0UNIT	Unit of Mea	0000	X	0
20	0COSTCEI	0BUS_ARE	Business a	0000	X	0
20	0COSTCEI	0COMP_C	Company c	0000	X	0
20	0COSTCEI	0LOGSYS	Source Sys	0000	X	1
20	0COSTCEI	0OBJ_CUF	Object curr	0000	X	0
20	0COSTCEI	0PROFIT_	Profit Cent	0000	X	0
20	0COSTCEI	0RESP_PE	Person res	0000	X	2
20	0COSTCEI	ZCOSTCT	Cost Cente	0000	X	1
20	0PROFIT_	0COMP_C	Company c	0000	X	0
20	0PROFIT_	0LOGSYS	Source Sys	0000	X	1
20	0PROFIT_	0OBJ_CUF	Object curr	0000	X	0
20	0PROFIT_	0RESP_PE	Person res	0000	X	2
20	0PROFIT_	0SOURSY	Source sys	0000	X	2
20	0COORDE	0BUS_ARE	Business a	0000	X	0
20	0COORDE	0COMP_C	Company c	0000	X	0
20	0COORDE	0COORD_	Order type	0000	X	2
20	0COORDE	0CO_ARE/	Controlling	0000	X	0
20	0COORDE	0IM_SIZE	Scale (IM)	0000	X	1
20	0COORDE	0LOGSYS	Source Sys	0000	X	1
20	0COORDE	0OBJ_CUF	Object curr	0000	X	0
20	0COORDE	0ORDCAT	Order Cate	0000	X	2
20	0COORDE	0PLANT	Plant	0000	X	0
20	0COORDE	0PROFIT_	Profit Cent	0000	X	0
20	0COORDE	0REQU_C	Req.cost c	0000	X	0
20	0COORDE	0RESP_C(	Resp. cost	0000	X	0
20	0COORDE	0STATUS!	BW Status	0000	X	2
20	0COORDE	0WBS_ELI	WBS elem	0000	X	0
19	0COSTELI	0CSTELMI	CElem cat	0000	X	2
19	0COSTELI	0LOGSYS	Source Sys	0000	X	1
19	0COSTELI	0SEM_PO:	Planning It	0000	X	1
19	0COSTELI	0UNIT	Unit of Mea	0000	X	0

19	0COSTCEI	0BUS_ARE	Business a	0000	X	0
19	0COSTCEI	0COMP_C	Company c	0000	X	0
19	0COSTCEI	0LOGSYS	Source Sys	0000	X	1
19	0COSTCEI	0OBJ_CUF	Object curr	0000	X	0
19	0COSTCEI	0PROFIT_	Profit Cent	0000	X	0
19	0COSTCEI	0RESP_PE	Person res	0000	X	2
19	0COSTCEI	ZCOSTCT	Cost Cente	0000	X	1
19	0PROFIT_	0COMP_C	Company c	0000	X	0
19	0PROFIT_	0LOGSYS	Source Sys	0000	X	1
19	0PROFIT_	0OBJ_CUF	Object curr	0000	X	0
19	0PROFIT_	0RESP_PE	Person res	0000	X	2
19	0PROFIT_	0SOURSY	Source sys	0000	X	2
19	0COORDE	0BUS_ARE	Business a	0000	X	0
19	0COORDE	0COMP_C	Company c	0000	X	0
19	0COORDE	0COORD_	Order type	0000	X	2
19	0COORDE	0CO_ARE/	Controlling	0000	X	0
19	0COORDE	0IM_SIZE	Scale (IM)	0000	X	1
19	0COORDE	0LOGSYS	Source Sys	0000	X	1
19	0COORDE	0OBJ_CUF	Object curr	0000	X	0
19	0COORDE	0ORDCAT	Order Cate	0000	X	2
19	0COORDE	0PLANT	Plant	0000	X	0
19	0COORDE	0PROFIT_	Profit Cent	0000	X	0
19	0COORDE	0REQU_C	Req.cost c	0000	X	0
19	0COORDE	0RESP_C(	Resp. cost	0000	X	0
19	0COORDE	0STATUSS	BW Status	0000	X	2
19	0COORDE	0WBS_ELI	WBS elem	0000	X	0
18	0COSTELI	0CSTELMI	CElem cat	0000	X	2
18	0COSTELI	0LOGSYS	Source Sys	0000	X	1
18	0COSTELI	0SEM_POS	Planning It	0000	X	1
18	0COSTELI	0UNIT	Unit of Mea	0000	X	0
18	0COSTCEI	0BUS_ARE	Business a	0000	X	0
18	0COSTCEI	0COMP_C	Company c	0000	X	0
18	0COSTCEI	0LOGSYS	Source Sys	0000	X	1
18	0COSTCEI	0OBJ_CUF	Object curr	0000	X	0
18	0COSTCEI	0PROFIT_	Profit Cent	0000	X	0
18	0COSTCEI	0RESP_PE	Person res	0000	X	2
18	0COSTCEI	ZCOSTCT	Cost Cente	0000	X	1
18	0PROFIT_	0COMP_C	Company c	0000	X	0
18	0PROFIT_	0LOGSYS	Source Sys	0000	X	1
18	0PROFIT_	0OBJ_CUF	Object curr	0000	X	0
18	0PROFIT_	0RESP_PE	Person res	0000	X	2
18	0PROFIT_	0SOURSY	Source sys	0000	X	2
18	0COORDE	0BUS_ARE	Business a	0000	X	0
18	0COORDE	0COMP_C	Company c	0000	X	0
18	0COORDE	0COORD_	Order type	0000	X	2
18	0COORDE	0CO_ARE/	Controlling	0000	X	0
18	0COORDE	0IM_SIZE	Scale (IM)	0000	X	1
18	0COORDE	0LOGSYS	Source Sys	0000	X	1
18	0COORDE	0OBJ_CUF	Object curr	0000	X	0
18	0COORDE	0ORDCAT	Order Cate	0000	X	2
18	0COORDE	0PLANT	Plant	0000	X	0
18	0COORDE	0PROFIT_	Profit Cent	0000	X	0

18	0COORDE	0REQU_C	Req.cost c	0000	X	0
18	0COORDE	0RESP_C(	Resp. cost	0000	X	0
18	0COORDE	0STATUSS	BW Status	0000	X	2
18	0COORDE	0WBS_ELI	WBS elem	0000	X	0
17	0COSTELI	0CSTELMI	CElem cat	0000	X	2
17	0COSTELI	0LOGSYS	Source Sy	0000	X	1
17	0COSTELI	0SEM_PO	Planning It	0000	X	1
17	0COSTELI	0UNIT	Unit of Me	0000	X	0
17	0COSTCE	0BUS_ARE	Business a	0000	X	0
17	0COSTCE	0COMP_C	Company c	0000	X	0
17	0COSTCE	0LOGSYS	Source Sy	0000	X	1
17	0COSTCE	0OBJ_CUF	Object curr	0000	X	0
17	0COSTCE	0PROFIT_	Profit Cent	0000	X	0
17	0COSTCE	0RESP_PE	Person res	0000	X	2
17	0COSTCE	ZCOSTCT	Cost Cente	0000	X	1
17	0PROFIT_	0COMP_C	Company c	0000	X	0
17	0PROFIT_	0LOGSYS	Source Sy	0000	X	1
17	0PROFIT_	0OBJ_CUF	Object curr	0000	X	0
17	0PROFIT_	0RESP_PE	Person res	0000	X	2
17	0PROFIT_	0SOURSY	Source sys	0000	X	2
17	0COORDE	0BUS_ARE	Business a	0000	X	0
17	0COORDE	0COMP_C	Company c	0000	X	0
17	0COORDE	0COORD_	Order type	0000	X	2
17	0COORDE	0CO_ARE/	Controlling	0000	X	0
17	0COORDE	0IM_SIZE	Scale (IM)	0000	X	1
17	0COORDE	0LOGSYS	Source Sy	0000	X	1
17	0COORDE	0OBJ_CUF	Object curr	0000	X	0
17	0COORDE	0ORDCAT	Order Cate	0000	X	2
17	0COORDE	0PLANT	Plant	0000	X	0
17	0COORDE	0PROFIT_	Profit Cent	0000	X	0
17	0COORDE	0REQU_C	Req.cost c	0000	X	0
17	0COORDE	0RESP_C(	Resp. cost	0000	X	0
17	0COORDE	0STATUSS	BW Status	0000	X	2
17	0COORDE	0WBS_ELI	WBS elem	0000	X	0
16	0COSTELI	0CSTELMI	CElem cat	0000	X	2
16	0COSTELI	0LOGSYS	Source Sy	0000	X	1
16	0COSTELI	0SEM_PO	Planning It	0000	X	1
16	0COSTELI	0UNIT	Unit of Me	0000	X	0
16	0COSTCE	0BUS_ARE	Business a	0000	X	0
16	0COSTCE	0COMP_C	Company c	0000	X	0
16	0COSTCE	0LOGSYS	Source Sy	0000	X	1
16	0COSTCE	0OBJ_CUF	Object curr	0000	X	0
16	0COSTCE	0PROFIT_	Profit Cent	0000	X	0
16	0COSTCE	0RESP_PE	Person res	0000	X	2
16	0COSTCE	ZCOSTCT	Cost Cente	0000	X	1
16	0PROFIT_	0COMP_C	Company c	0000	X	0
16	0PROFIT_	0LOGSYS	Source Sy	0000	X	1
16	0PROFIT_	0OBJ_CUF	Object curr	0000	X	0
16	0PROFIT_	0RESP_PE	Person res	0000	X	2
16	0PROFIT_	0SOURSY	Source sys	0000	X	2
16	0COORDE	0BUS_ARE	Business a	0000	X	0
16	0COORDE	0COMP_C	Company c	0000	X	0

16	0COORDE	0COORD_	Order type	0000	X	2
16	0COORDE	0CO_ARE/	Controlling	0000	X	0
16	0COORDE	0IM_SIZE	Scale (IM)	0000	X	1
16	0COORDE	0LOGSYS	Source Sys	0000	X	1
16	0COORDE	0OBJ_CUF	Object curr	0000	X	0
16	0COORDE	0ORDCAT	Order Cate	0000	X	2
16	0COORDE	0PLANT	Plant	0000	X	0
16	0COORDE	0PROFIT_	Profit Cent	0000	X	0
16	0COORDE	0REQU_C	Req.cost c	0000	X	0
16	0COORDE	0RESP_C(	Resp. cost	0000	X	0
16	0COORDE	0STATUSS	BW Status	0000	X	2
16	0COORDE	0WBS_ELI	WBS elem	0000	X	0
15	0COSTCEI	0BUS_ARE	Business a	0000	X	0
15	0COSTCEI	0COMP_C	Company (	0000	X	0
15	0COSTCEI	0LOGSYS	Source Sys	0000	X	1
15	0COSTCEI	0OBJ_CUF	Object curr	0000	X	0
15	0COSTCEI	0PROFIT_	Profit Cent	0000	X	0
15	0COSTCEI	0RESP_PE	Person res	0000	X	2
15	0COSTCEI	ZCOSTCT	Cost Cente	0000	X	1
15	0PROFIT_	0COMP_C	Company (	0000	X	0
15	0PROFIT_	0LOGSYS	Source Sys	0000	X	1
15	0PROFIT_	0OBJ_CUF	Object curr	0000	X	0
15	0PROFIT_	0RESP_PE	Person res	0000	X	2
15	0PROFIT_	0SOURSY	Source sys	0000	X	2
15	0COORDE	0BUS_ARE	Business a	0000	X	0
15	0COORDE	0COMP_C	Company (	0000	X	0
15	0COORDE	0COORD_	Order type	0000	X	2
15	0COORDE	0CO_ARE/	Controlling	0000	X	0
15	0COORDE	0IM_SIZE	Scale (IM)	0000	X	1
15	0COORDE	0LOGSYS	Source Sys	0000	X	1
15	0COORDE	0OBJ_CUF	Object curr	0000	X	0
15	0COORDE	0ORDCAT	Order Cate	0000	X	2
15	0COORDE	0PLANT	Plant	0000	X	0
15	0COORDE	0PROFIT_	Profit Cent	0000	X	0
15	0COORDE	0REQU_C	Req.cost c	0000	X	0
15	0COORDE	0RESP_C(	Resp. cost	0000	X	0
15	0COORDE	0STATUSS	BW Status	0000	X	2
15	0COORDE	0WBS_ELI	WBS elem	0000	X	0
15	0COMP_C	0CHRT_A(	Chart of ac	0000	X	0
15	0COMP_C	0COMPAN	Company	0000	X	0
15	0COMP_C	0COUNTR	Country	0000	X	0
15	0COMP_C	0CURREN	Currency	0000	X	0
15	0COMP_C	0C_CTR_/	Credit Con	0000	X	0
15	0COMP_C	0FISCVAR	Fiscal Year	0000	X	2
15	0COMP_C	0LOGSYS	Source Sys	0000	X	1
15	0COMP_C	0OFPER	Open FY P	0000	X	1
15	0COMP_C	0OFPER3	Open Posti	0000	X	2
15	0COMP_C	0OFYEAR	Open Fisca	0000	X	2
15	0COMP_C	0RETROP	Post to Pre	0000	X	2
15	0COMP_C	0SOURSY	Source sys	0000	X	2
15	0COSTELI	0CSTELMI	CElem cate	0000	X	2
15	0COSTELI	0LOGSYS	Source Sys	0000	X	1

15	0COSTELI	0SEM_PO:	Planning It	0000	X	1
15	0COSTELI	0UNIT	Unit of Mea	0000	X	0
14	0COSTCEI	0BUS_ARE	Business a	0000	X	0
14	0COSTCEI	0COMP_C	Company c	0000	X	0
14	0COSTCEI	0LOGSYS	Source Sys	0000	X	1
14	0COSTCEI	0OBJ_CUI	Object curr	0000	X	0
14	0COSTCEI	0PROFIT_	Profit Cent	0000	X	0
14	0COSTCEI	0RESP_PE	Person res	0000	X	2
14	0COSTCEI	ZCOSTCT	Cost Cente	0000	X	1
14	0PROFIT_	0COMP_C	Company c	0000	X	0
14	0PROFIT_	0LOGSYS	Source Sys	0000	X	1
14	0PROFIT_	0OBJ_CUI	Object curr	0000	X	0
14	0PROFIT_	0RESP_PE	Person res	0000	X	2
14	0PROFIT_	0SOURSY	Source sys	0000	X	2
14	0COORDE	0BUS_ARE	Business a	0000	X	0
14	0COORDE	0COMP_C	Company c	0000	X	0
14	0COORDE	0COORD_	Order type	0000	X	2
14	0COORDE	0CO_ARE/	Controlling	0000	X	0
14	0COORDE	0IM_SIZE	Scale (IM)	0000	X	1
14	0COORDE	0LOGSYS	Source Sys	0000	X	1
14	0COORDE	0OBJ_CUI	Object curr	0000	X	0
14	0COORDE	0ORDCAT	Order Cate	0000	X	2
14	0COORDE	0PLANT	Plant	0000	X	0
14	0COORDE	0PROFIT_	Profit Cent	0000	X	0
14	0COORDE	0REQU_C	Req.cost c	0000	X	0
14	0COORDE	0RESP_C(	Resp. cost	0000	X	0
14	0COORDE	0STATUSS	BW Status	0000	X	2
14	0COORDE	0WBS_ELI	WBS elem	0000	X	0
14	0COMP_C	0CHRT_A(	Chart of ac	0000	X	0
14	0COMP_C	0COMPAN	Company	0000	X	0
14	0COMP_C	0COUNTR	Country	0000	X	0
14	0COMP_C	0CURREN	Currency	0000	X	0
14	0COMP_C	0C_CTR_/	Credit Con	0000	X	0
14	0COMP_C	0FISCVAR	Fiscal Year	0000	X	2
14	0COMP_C	0LOGSYS	Source Sys	0000	X	1
14	0COMP_C	0OFPER	Open FY P	0000	X	1
14	0COMP_C	0OFPER3	Open Posti	0000	X	2
14	0COMP_C	0OFYEAR	Open Fisca	0000	X	2
14	0COMP_C	0RETROP	Post to Pre	0000	X	2
14	0COMP_C	0SOURSY	Source sys	0000	X	2
14	0COSTELI	0CSTELMI	CElem cat	0000	X	2
14	0COSTELI	0LOGSYS	Source Sys	0000	X	1
14	0COSTELI	0SEM_PO:	Planning It	0000	X	1
14	0COSTELI	0UNIT	Unit of Mea	0000	X	0
13	0COSTCEI	0BUS_ARE	Business a	0000	X	0
13	0COSTCEI	0COMP_C	Company c	0000	X	0
13	0COSTCEI	0LOGSYS	Source Sys	0000	X	1
13	0COSTCEI	0OBJ_CUI	Object curr	0000	X	0
13	0COSTCEI	0PROFIT_	Profit Cent	0000	X	0
13	0COSTCEI	0RESP_PE	Person res	0000	X	2
13	0COSTCEI	ZCOSTCT	Cost Cente	0000	X	1
13	0PROFIT_	0COMP_C	Company c	0000	X	0

13	0PROFIT_	0LOGSYS	Source Sys	0000	X	1
13	0PROFIT_	0OBJ_CUF	Object curr	0000	X	0
13	0PROFIT_	0RESP_PE	Person res	0000	X	2
13	0PROFIT_	0SOURSY	Source sys	0000	X	2
13	0COORDE	0BUS_ARE	Business a	0000	X	0
13	0COORDE	0COMP_C	Company c	0000	X	0
13	0COORDE	0COORD_	Order type	0000	X	2
13	0COORDE	0CO_ARE/	Controlling	0000	X	0
13	0COORDE	0IM_SIZE	Scale (IM)	0000	X	1
13	0COORDE	0LOGSYS	Source Sys	0000	X	1
13	0COORDE	0OBJ_CUF	Object curr	0000	X	0
13	0COORDE	0ORDCAT	Order Cate	0000	X	2
13	0COORDE	0PLANT	Plant	0000	X	0
13	0COORDE	0PROFIT_	Profit Cent	0000	X	0
13	0COORDE	0REQU_C	Req.cost c	0000	X	0
13	0COORDE	0RESP_C(	Resp. cost	0000	X	0
13	0COORDE	0STATUSS	BW Status	0000	X	2
13	0COORDE	0WBS_ELI	WBS elem	0000	X	0
13	0COMP_C	0CHRT_A(	Chart of ac	0000	X	0
13	0COMP_C	0COMPAN	Company	0000	X	0
13	0COMP_C	0COUNTR	Country	0000	X	0
13	0COMP_C	0CURREN	Currency	0000	X	0
13	0COMP_C	0C_CTR_/	Credit Con	0000	X	0
13	0COMP_C	0FISCVAR	Fiscal Year	0000	X	2
13	0COMP_C	0LOGSYS	Source Sys	0000	X	1
13	0COMP_C	0OFPER	Open FY P	0000	X	1
13	0COMP_C	0OFPER3	Open Posti	0000	X	2
13	0COMP_C	0OFYEAR	Open Fisca	0000	X	2
13	0COMP_C	0RETROP	Post to Pre	0000	X	2
13	0COMP_C	0SOURSY	Source sys	0000	X	2
13	0COSTELI	0CSTELMI	CElem cate	0000	X	2
13	0COSTELI	0LOGSYS	Source Sys	0000	X	1
13	0COSTELI	0SEM_PO:	Planning It	0000	X	1
13	0COSTELI	0UNIT	Unit of Mea	0000	X	0
12	0COSTCEI	0BUS_ARE	Business a	0000	X	0
12	0COSTCEI	0COMP_C	Company c	0000	X	0
12	0COSTCEI	0LOGSYS	Source Sys	0000	X	1
12	0COSTCEI	0OBJ_CUF	Object curr	0000	X	0
12	0COSTCEI	0PROFIT_	Profit Cent	0000	X	0
12	0COSTCEI	0RESP_PE	Person res	0000	X	2
12	0COSTCEI	ZCOSTCT	Cost Cente	0000	X	1
12	0PROFIT_	0COMP_C	Company c	0000	X	0
12	0PROFIT_	0LOGSYS	Source Sys	0000	X	1
12	0PROFIT_	0OBJ_CUF	Object curr	0000	X	0
12	0PROFIT_	0RESP_PE	Person res	0000	X	2
12	0PROFIT_	0SOURSY	Source sys	0000	X	2
12	0COORDE	0BUS_ARE	Business a	0000	X	0
12	0COORDE	0COMP_C	Company c	0000	X	0
12	0COORDE	0COORD_	Order type	0000	X	2
12	0COORDE	0CO_ARE/	Controlling	0000	X	0
12	0COORDE	0IM_SIZE	Scale (IM)	0000	X	1
12	0COORDE	0LOGSYS	Source Sys	0000	X	1

12	0COORDE	0OBJ_CUI	Object curr	0000	X	0
12	0COORDE	0ORDCAT	Order Cate	0000	X	2
12	0COORDE	0PLANT	Plant	0000	X	0
12	0COORDE	0PROFIT_	Profit Cent	0000	X	0
12	0COORDE	0REQU_C	Req.cost c	0000	X	0
12	0COORDE	0RESP_C(	Resp. cost	0000	X	0
12	0COORDE	0STATUS	BW Status	0000	X	2
12	0COORDE	0WBS_EL	WBS elem	0000	X	0
12	0COMP_C	0CHRT_A(	Chart of ac	0000	X	0
12	0COMP_C	0COMPAN	Company	0000	X	0
12	0COMP_C	0COUNTR	Country	0000	X	0
12	0COMP_C	0CURREN	Currency	0000	X	0
12	0COMP_C	0C_CTR_/	Credit Con	0000	X	0
12	0COMP_C	0FISCVAR	Fiscal Yeai	0000	X	2
12	0COMP_C	0LOGSYS	Source Sys	0000	X	1
12	0COMP_C	0OFPER	Open FY P	0000	X	1
12	0COMP_C	0OFPER3	Open Posti	0000	X	2
12	0COMP_C	0OFYEAR	Open Fisca	0000	X	2
12	0COMP_C	0RETROP	Post to Pre	0000	X	2
12	0COMP_C	0SOURSY	Source sys	0000	X	2
12	0COSTELI	0CSTELMI	CElem cat	0000	X	2
12	0COSTELI	0LOGSYS	Source Sys	0000	X	1
12	0COSTELI	0SEM_PO:	Planning It	0000	X	1
12	0COSTELI	0UNIT	Unit of Mea	0000	X	0
11	0COSTCE	0BUS_ARE	Business a	0000	X	0
11	0COSTCE	0COMP_C	Company c	0000	X	0
11	0COSTCE	0LOGSYS	Source Sys	0000	X	1
11	0COSTCE	0OBJ_CUI	Object curr	0000	X	0
11	0COSTCE	0PROFIT_	Profit Cent	0000	X	0
11	0COSTCE	0RESP_PE	Person res	0000	X	2
11	0COSTCE	ZCOSTCT	Cost Cente	0000	X	1
11	0PROFIT_	0COMP_C	Company c	0000	X	0
11	0PROFIT_	0LOGSYS	Source Sys	0000	X	1
11	0PROFIT_	0OBJ_CUI	Object curr	0000	X	0
11	0PROFIT_	0RESP_PE	Person res	0000	X	2
11	0PROFIT_	0SOURSY	Source sys	0000	X	2
11	0COORDE	0BUS_ARE	Business a	0000	X	0
11	0COORDE	0COMP_C	Company c	0000	X	0
11	0COORDE	0COORD_	Order type	0000	X	2
11	0COORDE	0CO_ARE/	Controlling	0000	X	0
11	0COORDE	0IM_SIZE	Scale (IM)	0000	X	1
11	0COORDE	0LOGSYS	Source Sys	0000	X	1
11	0COORDE	0OBJ_CUI	Object curr	0000	X	0
11	0COORDE	0ORDCAT	Order Cate	0000	X	2
11	0COORDE	0PLANT	Plant	0000	X	0
11	0COORDE	0PROFIT_	Profit Cent	0000	X	0
11	0COORDE	0REQU_C	Req.cost c	0000	X	0
11	0COORDE	0RESP_C(	Resp. cost	0000	X	0
11	0COORDE	0STATUS	BW Status	0000	X	2
11	0COORDE	0WBS_EL	WBS elem	0000	X	0
11	0COMP_C	0CHRT_A(	Chart of ac	0000	X	0
11	0COMP_C	0COMPAN	Company	0000	X	0

11	0COMP_C	0COUNTR	Country	0000	X	0
11	0COMP_C	0CURREN	Currency	0000	X	0
11	0COMP_C	0C_CTR_A	Credit Con	0000	X	0
11	0COMP_C	0FISCVAR	Fiscal Year	0000	X	2
11	0COMP_C	0LOGSYS	Source Sys	0000	X	1
11	0COMP_C	0OFPER	Open FY P	0000	X	1
11	0COMP_C	0OFPER3	Open Posti	0000	X	2
11	0COMP_C	0OFYEAR	Open Fisca	0000	X	2
11	0COMP_C	0RETROP	Post to Pre	0000	X	2
11	0COMP_C	0SOURSY	Source sys	0000	X	2
11	0COSTELM	0CSTELMI	CElem cate	0000	X	2
11	0COSTELM	0LOGSYS	Source Sys	0000	X	1
11	0COSTELM	0SEM_POS	Planning It	0000	X	1
11	0COSTELM	0UNIT	Unit of Mea	0000	X	0
10	0COSTCEI	0BUS_ARE	Business a	0000	X	0
10	0COSTCEI	0COMP_C	Company c	0000	X	0
10	0COSTCEI	0LOGSYS	Source Sys	0000	X	1
10	0COSTCEI	0OBJ_CUR	Object curr	0000	X	0
10	0COSTCEI	0PROFIT_	Profit Cent	0000	X	0
10	0COSTCEI	0RESP_PE	Person res	0000	X	2
10	0COSTCEI	ZCOSTCT	Cost Cente	0000	X	1
10	0PROFIT_	0COMP_C	Company c	0000	X	0
10	0PROFIT_	0LOGSYS	Source Sys	0000	X	1
10	0PROFIT_	0OBJ_CUR	Object curr	0000	X	0
10	0PROFIT_	0RESP_PE	Person res	0000	X	2
10	0PROFIT_	0SOURSY	Source sys	0000	X	2
10	0COORDE	0BUS_ARE	Business a	0000	X	0
10	0COORDE	0COMP_C	Company c	0000	X	0
10	0COORDE	0COORD_	Order type	0000	X	2
10	0COORDE	0CO_ARE/	Controlling	0000	X	0
10	0COORDE	0IM_SIZE	Scale (IM)	0000	X	1
10	0COORDE	0LOGSYS	Source Sys	0000	X	1
10	0COORDE	0OBJ_CUR	Object curr	0000	X	0
10	0COORDE	0ORDCAT	Order Cate	0000	X	2
10	0COORDE	0PLANT	Plant	0000	X	0
10	0COORDE	0PROFIT_	Profit Cent	0000	X	0
10	0COORDE	0REQU_C	Req.cost c	0000	X	0
10	0COORDE	0RESP_CO	Resp. cost	0000	X	0
10	0COORDE	0STATUSS	BW Status	0000	X	2
10	0COORDE	0WBS_ELI	WBS elem	0000	X	0
10	0COMP_C	0CHRT_AC	Chart of ac	0000	X	0
10	0COMP_C	0COMPAN	Company	0000	X	0
10	0COMP_C	0COUNTR	Country	0000	X	0
10	0COMP_C	0CURREN	Currency	0000	X	0
10	0COMP_C	0C_CTR_A	Credit Con	0000	X	0
10	0COMP_C	0FISCVAR	Fiscal Year	0000	X	2
10	0COMP_C	0LOGSYS	Source Sys	0000	X	1
10	0COMP_C	0OFPER	Open FY P	0000	X	1
10	0COMP_C	0OFPER3	Open Posti	0000	X	2
10	0COMP_C	0OFYEAR	Open Fisca	0000	X	2
10	0COMP_C	0RETROP	Post to Pre	0000	X	2
10	0COMP_C	0SOURSY	Source sys	0000	X	2

10	0COSTELI	0CSTELMI	CElem cat	0000	X	2
10	0COSTELI	0LOGSYS	Source Sys	0000	X	1
10	0COSTELI	0SEM_PO	Planning It	0000	X	1
10	0COSTELI	0UNIT	Unit of Mea	0000	X	0
9	0COSTCEI	0BUS_ARE	Business a	0000	X	0
9	0COSTCEI	0COMP_C	Company c	0000	X	0
9	0COSTCEI	0LOGSYS	Source Sys	0000	X	1
9	0COSTCEI	0OBJ_CUF	Object curr	0000	X	0
9	0COSTCEI	0PROFIT_	Profit Cent	0000	X	0
9	0COSTCEI	0RESP_PE	Person res	0000	X	2
9	0COSTCEI	ZCOSTCT	Cost Cente	0000	X	1
9	0PROFIT_	0COMP_C	Company c	0000	X	0
9	0PROFIT_	0LOGSYS	Source Sys	0000	X	1
9	0PROFIT_	0OBJ_CUF	Object curr	0000	X	0
9	0PROFIT_	0RESP_PE	Person res	0000	X	2
9	0PROFIT_	0SOURSY	Source sys	0000	X	2
9	0COORDE	0BUS_ARE	Business a	0000	X	0
9	0COORDE	0COMP_C	Company c	0000	X	0
9	0COORDE	0COORD_	Order type	0000	X	2
9	0COORDE	0CO_ARE	Controlling	0000	X	0
9	0COORDE	0IM_SIZE	Scale (IM)	0000	X	1
9	0COORDE	0LOGSYS	Source Sys	0000	X	1
9	0COORDE	0OBJ_CUF	Object curr	0000	X	0
9	0COORDE	0ORDCAT	Order Cate	0000	X	2
9	0COORDE	0PLANT	Plant	0000	X	0
9	0COORDE	0PROFIT_	Profit Cent	0000	X	0
9	0COORDE	0REQU_C	Req.cost c	0000	X	0
9	0COORDE	0RESP_C(	Resp. cost	0000	X	0
9	0COORDE	0STATUS	BW Status	0000	X	2
9	0COORDE	0WBS_ELI	WBS elem	0000	X	0
9	0COMP_C	0CHRT_A(	Chart of ac	0000	X	0
9	0COMP_C	0COMPAN	Company	0000	X	0
9	0COMP_C	0COUNTR	Country	0000	X	0
9	0COMP_C	0CURREN	Currency	0000	X	0
9	0COMP_C	0C_CTR_A	Credit Con	0000	X	0
9	0COMP_C	0FISCVAR	Fiscal Yea	0000	X	2
9	0COMP_C	0LOGSYS	Source Sys	0000	X	1
9	0COMP_C	0OFPER	Open FY P	0000	X	1
9	0COMP_C	0OFPER3	Open Posti	0000	X	2
9	0COMP_C	0OFYEAR	Open Fisca	0000	X	2
9	0COMP_C	0RETROP	Post to Pre	0000	X	2
9	0COMP_C	0SOURSY	Source sys	0000	X	2
9	0COSTELI	0CSTELMI	CElem cat	0000	X	2
9	0COSTELI	0LOGSYS	Source Sys	0000	X	1
9	0COSTELI	0SEM_PO	Planning It	0000	X	1
9	0COSTELI	0UNIT	Unit of Mea	0000	X	0
8	0COSTCEI	0BUS_ARE	Business a	0000	X	0
8	0COSTCEI	0COMP_C	Company c	0000	X	0
8	0COSTCEI	0LOGSYS	Source Sys	0000	X	1
8	0COSTCEI	0OBJ_CUF	Object curr	0000	X	0
8	0COSTCEI	0PROFIT_	Profit Cent	0000	X	0
8	0COSTCEI	0RESP_PE	Person res	0000	X	2

8	0COSTCEI	ZCOSTCT	Cost Cente	0000	X	1
8	0PROFIT_	0COMP_C	Company c	0000	X	0
8	0PROFIT_	0LOGSYS	Source Sys	0000	X	1
8	0PROFIT_	0OBJ_CUF	Object curr	0000	X	0
8	0PROFIT_	0RESP_PE	Person res	0000	X	2
8	0PROFIT_	0SOURSY	Source sys	0000	X	2
8	0COORDE	0BUS_ARE	Business a	0000	X	0
8	0COORDE	0COMP_C	Company c	0000	X	0
8	0COORDE	0COORD_	Order type	0000	X	2
8	0COORDE	0CO_ARE/	Controlling	0000	X	0
8	0COORDE	0IM_SIZE	Scale (IM)	0000	X	1
8	0COORDE	0LOGSYS	Source Sys	0000	X	1
8	0COORDE	0OBJ_CUF	Object curr	0000	X	0
8	0COORDE	0ORDCAT	Order Cate	0000	X	2
8	0COORDE	0PLANT	Plant	0000	X	0
8	0COORDE	0PROFIT_	Profit Cent	0000	X	0
8	0COORDE	0REQU_C	Req.cost c	0000	X	0
8	0COORDE	0RESP_C(	Resp. cost	0000	X	0
8	0COORDE	0STATUS:	BW Status	0000	X	2
8	0COORDE	0WBS_ELI	WBS elem	0000	X	0
8	0COMP_C	0CHRT_A(	Chart of ac	0000	X	0
8	0COMP_C	0COMPAN	Company	0000	X	0
8	0COMP_C	0COUNTR	Country	0000	X	0
8	0COMP_C	0CURREN	Currency	0000	X	0
8	0COMP_C	0C_CTR_/	Credit Con	0000	X	0
8	0COMP_C	0FISCVAR	Fiscal Year	0000	X	2
8	0COMP_C	0LOGSYS	Source Sys	0000	X	1
8	0COMP_C	0OFPER	Open FY P	0000	X	1
8	0COMP_C	0OFPER3	Open Posti	0000	X	2
8	0COMP_C	0OFYEAR	Open Fisca	0000	X	2
8	0COMP_C	0RETROP	Post to Pre	0000	X	2
8	0COMP_C	0SOURSY	Source sys	0000	X	2
8	0COSTELI	0CSTELMI	CElem cat	0000	X	2
8	0COSTELI	0LOGSYS	Source Sys	0000	X	1
8	0COSTELI	0SEM_PO:	Planning It	0000	X	1
8	0COSTELI	0UNIT	Unit of Mea	0000	X	0
7	0COSTELI	0CSTELMI	CElem cat	0000	X	2
7	0COSTELI	0LOGSYS	Source Sys	0000	X	1
7	0COSTELI	0SEM_PO:	Planning It	0000	X	1
7	0COSTELI	0UNIT	Unit of Mea	0000	X	0
7	0COSTCEI	0BUS_ARE	Business a	0000	X	0
7	0COSTCEI	0COMP_C	Company c	0000	X	0
7	0COSTCEI	0LOGSYS	Source Sys	0000	X	1
7	0COSTCEI	0OBJ_CUF	Object curr	0000	X	0
7	0COSTCEI	0PROFIT_	Profit Cent	0000	X	0
7	0COSTCEI	0RESP_PE	Person res	0000	X	2
7	0COSTCEI	ZCOSTCT	Cost Cente	0000	X	1
7	0PROFIT_	0COMP_C	Company c	0000	X	0
7	0PROFIT_	0LOGSYS	Source Sys	0000	X	1
7	0PROFIT_	0OBJ_CUF	Object curr	0000	X	0
7	0PROFIT_	0RESP_PE	Person res	0000	X	2
7	0PROFIT_	0SOURSY	Source sys	0000	X	2

7	0COORDE	0BUS_ARE	Business a	0000	X	0
7	0COORDE	0COMP_C	Company c	0000	X	0
7	0COORDE	0COORD_	Order type	0000	X	2
7	0COORDE	0CO_ARE/	Controlling	0000	X	0
7	0COORDE	0IM_SIZE	Scale (IM)	0000	X	1
7	0COORDE	0LOGSYS	Source Sys	0000	X	1
7	0COORDE	0OBJ_CUF	Object curr	0000	X	0
7	0COORDE	0ORDCAT	Order Cate	0000	X	2
7	0COORDE	0PLANT	Plant	0000	X	0
7	0COORDE	0PROFIT_	Profit Cent	0000	X	0
7	0COORDE	0REQU_C	Req.cost c	0000	X	0
7	0COORDE	0RESP_C(	Resp. cost	0000	X	0
7	0COORDE	0STATUSS	BW Status	0000	X	2
7	0COORDE	0WBS_ELI	WBS elem	0000	X	0
6	0COSTELN	0CSTELMI	CElem cate	0000	X	2
6	0COSTELN	0LOGSYS	Source Sys	0000	X	1
6	0COSTELN	0SEM_POS	Planning It	0000	X	1
6	0COSTELN	0UNIT	Unit of Mea	0000	X	0
6	0COSTCEI	0BUS_ARE	Business a	0000	X	0
6	0COSTCEI	0COMP_C	Company c	0000	X	0
6	0COSTCEI	0LOGSYS	Source Sys	0000	X	1
6	0COSTCEI	0OBJ_CUF	Object curr	0000	X	0
6	0COSTCEI	0PROFIT_	Profit Cent	0000	X	0
6	0COSTCEI	0RESP_PE	Person res	0000	X	2
6	0COSTCEI	ZCOSTCT	Cost Cente	0000	X	1
6	0PROFIT_	0COMP_C	Company c	0000	X	0
6	0PROFIT_	0LOGSYS	Source Sys	0000	X	1
6	0PROFIT_	0OBJ_CUF	Object curr	0000	X	0
6	0PROFIT_	0RESP_PE	Person res	0000	X	2
6	0PROFIT_	0SOURSY	Source sys	0000	X	2
6	0COORDE	0BUS_ARE	Business a	0000	X	0
6	0COORDE	0COMP_C	Company c	0000	X	0
6	0COORDE	0COORD_	Order type	0000	X	2
6	0COORDE	0CO_ARE/	Controlling	0000	X	0
6	0COORDE	0IM_SIZE	Scale (IM)	0000	X	1
6	0COORDE	0LOGSYS	Source Sys	0000	X	1
6	0COORDE	0OBJ_CUF	Object curr	0000	X	0
6	0COORDE	0ORDCAT	Order Cate	0000	X	2
6	0COORDE	0PLANT	Plant	0000	X	0
6	0COORDE	0PROFIT_	Profit Cent	0000	X	0
6	0COORDE	0REQU_C	Req.cost c	0000	X	0
6	0COORDE	0RESP_C(	Resp. cost	0000	X	0
6	0COORDE	0STATUSS	BW Status	0000	X	2
6	0COORDE	0WBS_ELI	WBS elem	0000	X	0
5	0COMP_C	0CHRT_A(	Chart of ac	0000	X	0
5	0COMP_C	0COMPAN	Company	0000	X	0
5	0COMP_C	0COUNTR	Country	0000	X	0
5	0COMP_C	0CURREN	Currency	0000	X	0
5	0COMP_C	0C_CTR_/	Credit Con	0000	X	0
5	0COMP_C	0FISCVAR	Fiscal Year	0000	X	2
5	0COMP_C	0LOGSYS	Source Sys	0000	X	1
5	0COMP_C	0SOURSY	Source sys	0000	X	2

5	0COSTCE	0BUS_ARE	Business a	0000	X	0
5	0COSTCE	0COMP_C	Company c	0000	X	0
5	0COSTCE	0LOGSYS	Source Sys	0000	X	1
5	0COSTCE	0OBJ_CUF	Object curr	0000	X	0
5	0COSTCE	0PROFIT_	Profit Cent	0000	X	0
5	0COSTCE	0RESP_PE	Person res	0000	X	2
5	0COSTCE	ZCOSTCT	Cost Cente	0000	X	1
5	0COMP_C	0OFPER	Open FY P	0001	X	1
5	0COMP_C	0OFPER3	Open Posti	0002	X	2
5	0COMP_C	0OFYEAR	Open Fisca	0003	X	2
5	0COMP_C	0RETROP	Post to Pre	0004	X	2
4	0COSTELI	0CSTELMI	CElem cate	0000	X	2
4	0COSTELI	0LOGSYS	Source Sys	0000	X	1
4	0COSTELI	0SEM_PO:	Planning It	0000	X	1
4	0COSTELI	0UNIT	Unit of Mea	0000	X	0
4	0COSTCE	0BUS_ARE	Business a	0000	X	0
4	0COSTCE	0COMP_C	Company c	0000	X	0
4	0COSTCE	0LOGSYS	Source Sys	0000	X	1
4	0COSTCE	0OBJ_CUF	Object curr	0000	X	0
4	0COSTCE	0PROFIT_	Profit Cent	0000	X	0
4	0COSTCE	0RESP_PE	Person res	0000	X	2
4	0COSTCE	ZCOSTCT	Cost Cente	0000	X	1
4	0PROFIT_	0COMP_C	Company c	0000	X	0
4	0PROFIT_	0LOGSYS	Source Sys	0000	X	1
4	0PROFIT_	0OBJ_CUF	Object curr	0000	X	0
4	0PROFIT_	0RESP_PE	Person res	0000	X	2
4	0PROFIT_	0SOURSY	Source sys	0000	X	2
4	0COORDE	0BUS_ARE	Business a	0000	X	0
4	0COORDE	0COMP_C	Company c	0000	X	0
4	0COORDE	0COORD_	Order type	0000	X	2
4	0COORDE	0CO_ARE/	Controlling	0000	X	0
4	0COORDE	0IM_SIZE	Scale (IM)	0000	X	1
4	0COORDE	0LOGSYS	Source Sys	0000	X	1
4	0COORDE	0OBJ_CUF	Object curr	0000	X	0
4	0COORDE	0ORDCAT	Order Cate	0000	X	2
4	0COORDE	0PLANT	Plant	0000	X	0
4	0COORDE	0PROFIT_	Profit Cent	0000	X	0
4	0COORDE	0REQU_C	Req.cost c	0000	X	0
4	0COORDE	0RESP_C(	Resp. cost	0000	X	0
4	0COORDE	0STATUS$	BW Status	0000	X	2
4	0COORDE	0WBS_ELI	WBS elem	0000	X	0
24	0COSTELI	0CSTELMI	CElem cate	0000	X	2
24	0COSTELI	0LOGSYS	Source Sys	0000	X	1
24	0COSTELI	0SEM_PO:	Planning It	0000	X	1
24	0COSTELI	0UNIT	Unit of Mea	0000	X	0
24	0COSTCE	0BUS_ARE	Business a	0000	X	0
24	0COSTCE	0COMP_C	Company c	0000	X	0
24	0COSTCE	0LOGSYS	Source Sys	0000	X	1
24	0COSTCE	0OBJ_CUF	Object curr	0000	X	0
24	0COSTCE	0PROFIT_	Profit Cent	0000	X	0
24	0COSTCE	0RESP_PE	Person res	0000	X	2
24	0COSTCE	ZCOSTCT	Cost Cente	0000	X	1

24	0PROFIT_	0COMP_C	Company c	0000	X	0
24	0PROFIT_	0LOGSYS	Source Sys	0000	X	1
24	0PROFIT_	0OBJ_CUF	Object curr	0000	X	0
24	0PROFIT_	0RESP_PE	Person res	0000	X	2
24	0PROFIT_	0SOURSY	Source sys	0000	X	2
24	0COORDE	0BUS_ARE	Business a	0000	X	0
24	0COORDE	0COMP_C	Company c	0000	X	0
24	0COORDE	0COORD_	Order type	0000	X	2
24	0COORDE	0CO_ARE/	Controlling	0000	X	0
24	0COORDE	0IM_SIZE	Scale (IM)	0000	X	1
24	0COORDE	0LOGSYS	Source Sys	0000	X	1
24	0COORDE	0OBJ_CUF	Object curr	0000	X	0
24	0COORDE	0ORDCAT	Order Cate	0000	X	2
24	0COORDE	0PLANT	Plant	0000	X	0
24	0COORDE	0PROFIT_	Profit Cent	0000	X	0
24	0COORDE	0REQU_C	Req.cost c	0000	X	0
24	0COORDE	0RESP_C(	Resp. cost	0000	X	0
24	0COORDE	0STATUS	BW Status	0000	X	2
24	0COORDE	0WBS_EL	WBS elem	0000	X	0
26	0COSTEL	0CSTELM	CElem cat	0000	X	2
26	0COSTEL	0LOGSYS	Source Sys	0000	X	1
26	0COSTEL	0SEM_PO	Planning It	0000	X	1
26	0COSTEL	0UNIT	Unit of Mea	0000	X	0
26	0COSTCE	0BUS_ARE	Business a	0000	X	0
26	0COSTCE	0COMP_C	Company c	0000	X	0
26	0COSTCE	0LOGSYS	Source Sys	0000	X	1
26	0COSTCE	0OBJ_CUF	Object curr	0000	X	0
26	0COSTCE	0PROFIT_	Profit Cent	0000	X	0
26	0COSTCE	0RESP_PE	Person res	0000	X	2
26	0COSTCE	ZCOSTCT	Cost Cente	0000	X	1
26	0PROFIT_	0COMP_C	Company c	0000	X	0
26	0PROFIT_	0LOGSYS	Source Sys	0000	X	1
26	0PROFIT_	0OBJ_CUF	Object curr	0000	X	0
26	0PROFIT_	0RESP_PE	Person res	0000	X	2
26	0PROFIT_	0SOURSY	Source sys	0000	X	2
26	0COORDE	0BUS_ARE	Business a	0000	X	0
26	0COORDE	0COMP_C	Company c	0000	X	0
26	0COORDE	0COORD_	Order type	0000	X	2
26	0COORDE	0CO_ARE/	Controlling	0000	X	0
26	0COORDE	0IM_SIZE	Scale (IM)	0000	X	1
26	0COORDE	0LOGSYS	Source Sys	0000	X	1
26	0COORDE	0OBJ_CUF	Object curr	0000	X	0
26	0COORDE	0ORDCAT	Order Cate	0000	X	2
26	0COORDE	0PLANT	Plant	0000	X	0
26	0COORDE	0PROFIT_	Profit Cent	0000	X	0
26	0COORDE	0REQU_C	Req.cost c	0000	X	0
26	0COORDE	0RESP_C(	Resp. cost	0000	X	0
26	0COORDE	0STATUS	BW Status	0000	X	2
26	0COORDE	0WBS_EL	WBS elem	0000	X	0
25	0COSTEL	0CSTELM	CElem cat	0000	X	2
25	0COSTEL	0LOGSYS	Source Sys	0000	X	1
25	0COSTEL	0SEM_PO	Planning It	0000	X	1

25	0COSTELM	0UNIT	Unit of Mea	0000	X	0
25	0COSTCE	0BUS_ARE	Business a	0000	X	0
25	0COSTCE	0COMP_C	Company c	0000	X	0
25	0COSTCE	0LOGSYS	Source Sys	0000	X	1
25	0COSTCE	0OBJ_CUF	Object curr	0000	X	0
25	0COSTCE	0PROFIT_	Profit Cent	0000	X	0
25	0COSTCE	0RESP_PE	Person res	0000	X	2
25	0COSTCE	ZCOSTCT	Cost Cente	0000	X	1
25	0PROFIT_	0COMP_C	Company c	0000	X	0
25	0PROFIT_	0LOGSYS	Source Sys	0000	X	1
25	0PROFIT_	0OBJ_CUF	Object curr	0000	X	0
25	0PROFIT_	0RESP_PE	Person res	0000	X	2
25	0PROFIT_	0SOURSY	Source sys	0000	X	2
25	0COORDE	0BUS_ARE	Business a	0000	X	0
25	0COORDE	0COMP_C	Company c	0000	X	0
25	0COORDE	0COORD_	Order type	0000	X	2
25	0COORDE	0CO_ARE/	Controlling	0000	X	0
25	0COORDE	0IM_SIZE	Scale (IM)	0000	X	1
25	0COORDE	0LOGSYS	Source Sys	0000	X	1
25	0COORDE	0OBJ_CUF	Object curr	0000	X	0
25	0COORDE	0ORDCAT	Order Cate	0000	X	2
25	0COORDE	0PLANT	Plant	0000	X	0
25	0COORDE	0PROFIT_	Profit Cent	0000	X	0
25	0COORDE	0REQU_C	Req.cost c	0000	X	0
25	0COORDE	0RESP_C(	Resp. cost	0000	X	0
25	0COORDE	0STATUSS	BW Status	0000	X	2
25	0COORDE	0WBS_ELI	WBS elem	0000	X	0
27	0COSTCE	0BUS_ARE	Business a	0000	X	0
27	0COSTCE	0COMP_C	Company c	0000	X	0
27	0COSTCE	0LOGSYS	Source Sys	0000	X	1
27	0COSTCE	0OBJ_CUF	Object curr	0000	X	0
27	0COSTCE	0PROFIT_	Profit Cent	0000	X	0
27	0COSTCE	0RESP_PE	Person res	0000	X	2
27	0COSTCE	ZCOSTCT	Cost Cente	0000	X	1
27	0PROFIT_	0COMP_C	Company c	0000	X	0
27	0PROFIT_	0LOGSYS	Source Sys	0000	X	1
27	0PROFIT_	0OBJ_CUF	Object curr	0000	X	0
27	0PROFIT_	0RESP_PE	Person res	0000	X	2
27	0PROFIT_	0SOURSY	Source sys	0000	X	2
27	0COORDE	0BUS_ARE	Business a	0000	X	0
27	0COORDE	0COMP_C	Company c	0000	X	0
27	0COORDE	0COORD_	Order type	0000	X	2
27	0COORDE	0CO_ARE/	Controlling	0000	X	0
27	0COORDE	0IM_SIZE	Scale (IM)	0000	X	1
27	0COORDE	0LOGSYS	Source Sys	0000	X	1
27	0COORDE	0OBJ_CUF	Object curr	0000	X	0
27	0COORDE	0ORDCAT	Order Cate	0000	X	2
27	0COORDE	0PLANT	Plant	0000	X	0
27	0COORDE	0PROFIT_	Profit Cent	0000	X	0
27	0COORDE	0REQU_C	Req.cost c	0000	X	0
27	0COORDE	0RESP_C(	Resp. cost	0000	X	0
27	0COORDE	0STATUSS	BW Status	0000	X	2

27	0COORDE	0WBS_ELI	WBS elem	0000	X	0
27	0COMP_C	0CHRT_A(	Chart of ac	0000	X	0
27	0COMP_C	0COMPAN	Company	0000	X	0
27	0COMP_C	0COUNTR	Country	0000	X	0
27	0COMP_C	0CURREN	Currency	0000	X	0
27	0COMP_C	0C_CTR_A	Credit Con	0000	X	0
27	0COMP_C	0FISCVAR	Fiscal Year	0000	X	2
27	0COMP_C	0LOGSYS	Source Sys	0000	X	1
27	0COMP_C	0OFPER	Open FY P	0000	X	1
27	0COMP_C	0OFPER3	Open Posti	0000	X	2
27	0COMP_C	0OFYEAR	Open Fisca	0000	X	2
27	0COMP_C	0RETROP	Post to Pre	0000	X	2
27	0COMP_C	0SOURSY	Source sys	0000	X	2
27	0COSTELI	0CSTELMI	CElem cate	0000	X	2
27	0COSTELI	0LOGSYS	Source Sys	0000	X	1
27	0COSTELI	0SEM_POS	Planning It	0000	X	1
27	0COSTELI	0UNIT	Unit of Mea	0000	X	0
28	0COSTCEI	0BUS_ARE	Business a	0000	X	0
28	0COSTCEI	0COMP_C	Company c	0000	X	0
28	0COSTCEI	0LOGSYS	Source Sys	0000	X	1
28	0COSTCEI	0OBJ_CUF	Object curr	0000	X	0
28	0COSTCEI	0PROFIT_	Profit Cent	0000	X	0
28	0COSTCEI	0RESP_PE	Person res	0000	X	2
28	0COSTCEI	ZCOSTCT	Cost Cente	0000	X	1
28	0PROFIT_	0COMP_C	Company c	0000	X	0
28	0PROFIT_	0LOGSYS	Source Sys	0000	X	1
28	0PROFIT_	0OBJ_CUF	Object curr	0000	X	0
28	0PROFIT_	0RESP_PE	Person res	0000	X	2
28	0PROFIT_	0SOURSY	Source sys	0000	X	2
28	0COORDE	0BUS_ARE	Business a	0000	X	0
28	0COORDE	0COMP_C	Company c	0000	X	0
28	0COORDE	0COORD_	Order type	0000	X	2
28	0COORDE	0CO_AREA	Controlling	0000	X	0
28	0COORDE	0IM_SIZE	Scale (IM)	0000	X	1
28	0COORDE	0LOGSYS	Source Sys	0000	X	1
28	0COORDE	0OBJ_CUF	Object curr	0000	X	0
28	0COORDE	0ORDCAT	Order Cate	0000	X	2
28	0COORDE	0PLANT	Plant	0000	X	0
28	0COORDE	0PROFIT_	Profit Cent	0000	X	0
28	0COORDE	0REQU_C	Req.cost c	0000	X	0
28	0COORDE	0RESP_C(	Resp. cost	0000	X	0
28	0COORDE	0STATUSS	BW Status	0000	X	2
28	0COORDE	0WBS_ELI	WBS elem	0000	X	0
28	0COMP_C	0CHRT_A(	Chart of ac	0000	X	0
28	0COMP_C	0COMPAN	Company	0000	X	0
28	0COMP_C	0COUNTR	Country	0000	X	0
28	0COMP_C	0CURREN	Currency	0000	X	0
28	0COMP_C	0C_CTR_A	Credit Con	0000	X	0
28	0COMP_C	0FISCVAR	Fiscal Year	0000	X	2
28	0COMP_C	0LOGSYS	Source Sys	0000	X	1
28	0COMP_C	0OFPER	Open FY P	0000	X	1
28	0COMP_C	0OFPER3	Open Posti	0000	X	2

28	0COMP_C	0OFYEAR	Open Fisca	0000	X	2
28	0COMP_C	0RETROP	Post to Pre	0000	X	2
28	0COMP_C	0SOURSY	Source sys	0000	X	2
28	0COSTELI	0CSTELMI	CElem cate	0000	X	2
28	0COSTELI	0LOGSYS	Source Sys	0000	X	1
28	0COSTELI	0SEM_PO:	Planning It	0000	X	1
28	0COSTELI	0UNIT	Unit of Mea	0000	X	0

0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000

0	0		0000
0	0		0000
0	0		0000
0	0		0000
0	0		0000
0	0		0000
0	0		0000
0	0		0000
0	0		0000
0	0		0000
0	0		0000
0	0		0000
0	0		0000
0	0		0000
0	0		0000
0	0		0000
0	0		0000
0	0		0000
0	0		0000
0	0		0000
0	0		0000
0	0		0000
0	0		0000
0	0		0000
0	0		0000
0	0		0000
0	0		0000
0	0		0000
0	0		0000
0	0		0000
0	0		0000
0	0		0000
0	0		0000
0	0		0000
0	0		0000
0	0		0000
0	0		0000
0	0		0000
0	0		0000
0	0		0000
8	0	3QQOMD0	0000
0	0		0000
0	0		0000
0	0		0000
0	0		0000
0	0		0000
0	0		0000
0	0		0000
0	0		0000
0	0		0000
0	0		0000
0	0		0000

0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000

0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000

0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000

0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000

0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000

0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000

0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000

0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000

0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000

0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000

0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000

0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000

0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000

0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000

0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000

0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000
0	0	0000

266
13

23	415IDIY7U	000000000		0
23	415IDJ5WI	000000000		0
23	415IDJDK\	000000000		0
23	415IDJL9E	000000000		2
23	415IDJSX)	000000000		0
23	415IDK0M(	000000000		0
23	415IDK8A2	000000000		0
23	415IDKFZI	000000000		2
23	415IDKNO	000000000		0
23	415IDKVCI	000000000		2
23	415IDL313	000000000		0
23	415IDLAPI	000000000		0
23	4EMZXR3'	000000000		0
22	3TS7AJEJI	000000000		0
21	3YXK63RE	000000000	0	0
21	3YXK63Z2	000000000		0
21	3YXK646R	000000000		0
21	3YXK64EF	000000000		1
21	3YXK64M4	000000000		0
21	3YXK64TS	000000000	0	0
21	3YXK651H	000000000		0
21	3YXK6595	000000000		1
21	3YXK66BK	000000000		0
21	4EJW1TO(	000000000		0
21	4MS97EZA	000000000		0
20	3OW227V4	000000000		0
20	3OW2282T	000000000		0
20	3OW228AI	000000000		0
20	3OW22957	000000000		0
20	3OW23W(	000000000		0
20	3OW7W9\	000000000		0
20	3WRKQL8	000000000		0
20	3WRKQLG	000000000		2
20	3WRKQLC	000000000		0
20	3WRKQLV	000000000		2
19	3OW227V4	000000000		0
19	3OW2282T	000000000		0
19	3OW228AI	000000000		0
19	3OW22957	000000000		0

19	3OW23W(	000000000	0
19	3OW7W9\	000000000	0
19	3WRKQL8	000000000	0
19	3WRKQLG	000000000	2
19	3WRKQLC	000000000	0
19	3WRKQLV	000000000	2
18	3OW227V	000000000	0
18	3OW2282	000000000	0
18	3OW228AI	000000000	0
18	3OW2295	000000000	0
18	3OW23W(	000000000	0
18	3OW7W9\	000000000	0
18	3WRKQL8	000000000	0
18	3WRKQLG	000000000	2
18	3WRKQLC	000000000	0
18	3WRKQLV	000000000	2
17	3OW227V	000000000	0
17	3OW2282	000000000	0
17	3OW228AI	000000000	0
17	3OW2295	000000000	0
17	3OW23W(	000000000	0
17	3OW7W9\	000000000	0
17	3WRKQL8	000000000	0
17	3WRKQLG	000000000	2
17	3WRKQLC	000000000	0
17	3WRKQLV	000000000	2
16	3OW227V	000000000	0
16	3OW2282	000000000	0
16	3OW228AI	000000000	0
16	3OW2295	000000000	0
16	3OW23W(	000000000	0
16	3OW7W9\	000000000	0
16	3WRKQL8	000000000	0
16	3WRKQLG	000000000	2
16	3WRKQLC	000000000	0
16	3WRKQLV	000000000	2
15	415IDIY7U	000000000	0
15	415IDJ5WI	000000000	0
15	415IDJDK\	000000000	0
15	415IDJL9E	000000000	2
15	415IDJSX	000000000	0
15	415IDK0M	000000000	0
15	415IDK8A	000000000	0
15	415IDKFZI	000000000	2
15	415IDKNO	000000000	0
15	415IDKVCI	000000000	2
15	415IDL313	000000000	0
15	415IDLAPI	000000000	0
15	4EMZXR3	000000000	0
14	415IDIY7U	000000000	0
14	415IDJ5WI	000000000	0
14	415IDJDK\	000000000	0

14	415IDJL9E	000000000	2
14	415IDJSX	000000000	0
14	415IDK0M	000000000	0
14	415IDK8A	000000000	0
14	415IDKFZI	000000000	2
14	415IDKNO	000000000	0
14	415IDKVC	000000000	2
14	415IDL313	000000000	0
14	415IDLAP	000000000	0
14	4EMZXR3	000000000	0
13	415IDIY7U	000000000	0
13	415IDJ5W	000000000	0
13	415IDJDK	000000000	0
13	415IDJL9E	000000000	2
13	415IDJSX	000000000	0
13	415IDK0M	000000000	0
13	415IDK8A	000000000	0
13	415IDKFZI	000000000	2
13	415IDKNO	000000000	0
13	415IDKVC	000000000	2
13	415IDL313	000000000	0
13	415IDLAP	000000000	0
13	4EMZXR3	000000000	0
12	415IDIY7U	000000000	0
12	415IDJ5W	000000000	0
12	415IDJDK	000000000	0
12	415IDJL9E	000000000	2
12	415IDJSX	000000000	0
12	415IDK0M	000000000	0
12	415IDK8A	000000000	0
12	415IDKFZI	000000000	2
12	415IDKNO	000000000	0
12	415IDKVC	000000000	2
12	415IDL313	000000000	0
12	415IDLAP	000000000	0
12	4EMZXR3	000000000	0
11	415IDIY7U	000000000	0
11	415IDJ5W	000000000	0
11	415IDJDK	000000000	0
11	415IDJL9E	000000000	2
11	415IDJSX	000000000	0
11	415IDK0M	000000000	0
11	415IDK8A	000000000	0
11	415IDKFZI	000000000	2
11	415IDKNO	000000000	0
11	415IDKVC	000000000	2
11	415IDL313	000000000	0
11	415IDLAP	000000000	0
11	4EMZXR3	000000000	0
10	415IDIY7U	000000000	0
10	415IDJ5W	000000000	0
10	415IDJDK	000000000	0

10	415IDJL9E	000000000	2
10	415IDJSX	000000000	0
10	415IDK0M	000000000	0
10	415IDK8A	000000000	0
10	415IDKFZI	000000000	2
10	415IDKNO	000000000	0
10	415IDKVCI	000000000	2
10	415IDL313	000000000	0
10	415IDLAPI	000000000	0
10	4EMZXR3	000000000	0
9	415IDIY7U	000000000	0
9	415IDJ5WI	000000000	0
9	415IDJDK	000000000	0
9	415IDJL9E	000000000	2
9	415IDJSX	000000000	0
9	415IDK0M	000000000	0
9	415IDK8A	000000000	0
9	415IDKFZI	000000000	2
9	415IDKNO	000000000	0
9	415IDKVCI	000000000	2
9	415IDL313	000000000	0
9	415IDLAPI	000000000	0
9	4EMZXR3	000000000	0
8	415IDIY7U	000000000	0
8	415IDJ5WI	000000000	0
8	415IDJDK	000000000	0
8	415IDJL9E	000000000	2
8	415IDJSX	000000000	0
8	415IDK0M	000000000	0
8	415IDK8A	000000000	0
8	415IDKFZI	000000000	2
8	415IDKNO	000000000	0
8	415IDKVCI	000000000	2
8	415IDL313	000000000	0
8	415IDLAPI	000000000	0
8	4EMZXR3	000000000	0
7	3OW227V	000000000	0
7	3OW2282T	000000000	0
7	3OW228AI	000000000	0
7	3OW2295	000000000	0
7	3OW23W	000000000	0
7	3OW7W9	000000000	0
7	3WRKQL8	000000000	0
7	3WRKQLG	000000000	2
7	3WRKQLC	000000000	0
7	3WRKQLV	000000000	2
6	3OW227V	000000000	0
6	3OW2282T	000000000	0
6	3OW228AI	000000000	0
6	3OW2295	000000000	0
6	3OW23W	000000000	0
6	3OW7W9	000000000	0

6	3WRKQL8	000000000	0
6	3WRKQLG	000000000	2
6	3WRKQLC	000000000	0
6	3WRKQLV	000000000	2
5	3TS7AJEJI	000000000	0
4	3OW227V4	000000000	0
4	3OW2282T	000000000	0
4	3OW228AI	000000000	0
4	3OW22957	000000000	0
4	3OW23WC	000000000	0
4	3OW7W9V	000000000	0
4	3WRKQL8	000000000	0
4	3WRKQLG	000000000	2
4	3WRKQLC	000000000	0
4	3WRKQLV	000000000	2
24	3OW227V4	000000000	0
24	3OW2282T	000000000	0
24	3OW228AI	000000000	0
24	3OW22957	000000000	0
24	3OW23WC	000000000	0
24	3OW7W9V	000000000	0
24	3WRKQL8	000000000	0
24	3WRKQLG	000000000	2
24	3WRKQLC	000000000	0
24	3WRKQLV	000000000	2
26	3OW227V4	000000000	0
26	3OW2282T	000000000	0
26	3OW228AI	000000000	0
26	3OW22957	000000000	0
26	3OW23WC	000000000	0
26	3OW7W9V	000000000	0
26	3WRKQL8	000000000	0
26	3WRKQLG	000000000	2
26	3WRKQLC	000000000	0
26	3WRKQLV	000000000	2
25	3OW227V4	000000000	0
25	3OW2282T	000000000	0
25	3OW228AI	000000000	0
25	3OW22957	000000000	0
25	3OW23WC	000000000	0
25	3OW7W9V	000000000	0
25	3WRKQL8	000000000	0
25	3WRKQLG	000000000	2
25	3WRKQLC	000000000	0
25	3WRKQLV	000000000	2
27	415IDIY7U	000000000	0
27	415IDJ5WI	000000000	0
27	415IDJDK\	000000000	0
27	415IDJL9E	000000000	2
27	415IDJSX)	000000000	0
27	415IDK0M	000000000	0
27	415IDK8AZ	000000000	0

27	415IDKFZI	000000000	2
27	415IDKNO	000000000	0
27	415IDKVCI	000000000	2
27	415IDL313	000000000	0
27	415IDLAPI	000000000	0
27	4EMZXR3	000000000	0
28	415IDIY7U	000000000	0
28	415IDJ5WI	000000000	0
28	415IDJDK\	000000000	0
28	415IDJL9E	000000000	2
28	415IDJSX	000000000	0
28	415IDK0M	000000000	0
28	415IDK8A	000000000	0
28	415IDKFZI	000000000	2
28	415IDKNO	000000000	0
28	415IDKVCI	000000000	2
28	415IDL313	000000000	0
28	415IDLAPI	000000000	0
28	4EMZXR3	000000000	0

00		1	0
00		2	0
00		3	0
00		4	0
00		5	0
00		6	0
00		7	0
00		8	0
00		9	0
00		10	0
00		11	0
00		12	0
00	X	13	0
00		1	0
00		4	0
00		6	0
00		7	0
00	X	10	0
00		11	0
00		12	0
00	X	13	0
00	X	14	0
00		2	0
00	X	3	0
00		1	0
00	X	2	0
00	X	4	0
00	X	5	0
00	X	7	0
00	X	6	0
00	X	3	0
00	X	8	0
00	X	9	0
00	X	10	0
00	X	11	0
00	X	2	0
00	X	4	0
00	X	5	0
00	X	7	0

00	X	6	0
00	X	3	0
00	X	8	0
00	X	9	0
00	X	10	0
00	X	11	0
00	X	2	0
00	X	4	0
00	X	5	0
00	X	7	0
00	X	6	0
00	X	3	0
00	X	8	0
00	X	9	0
00	X	10	0
00	X	11	0
00	X	2	0
00	X	4	0
00	X	5	0
00	X	7	0
00	X	6	0
00	X	3	0
00	X	8	0
00	X	9	0
00	X	10	0
00	X	11	0
00	X	2	0
00	X	4	0
00	X	5	0
00	X	7	0
00	X	6	0
00	X	3	0
00	X	8	0
00	X	9	0
00	X	10	0
00	X	11	0
00		1	0
00		2	0
00		3	0
00		4	0
00		5	0
00		6	0
00		7	0
00		8	0
00		9	0
00		10	0
00		11	0
00		12	0
00	X	13	0
00		1	0
00		2	0
00		3	0

00		4	0
00		5	0
00		6	0
00		7	0
00		8	0
00		9	0
00		10	0
00		11	0
00		12	0
00	X	13	0
00		1	0
00		2	0
00		3	0
00		4	0
00		5	0
00		6	0
00		7	0
00		8	0
00		9	0
00		10	0
00		11	0
00		12	0
00	X	13	0
00		1	0
00		2	0
00		3	0
00		4	0
00		5	0
00		6	0
00		7	0
00		8	0
00		9	0
00		10	0
00		11	0
00		12	0
00	X	13	0
00		1	0
00		2	0
00		3	0
00		4	0
00		5	0
00		6	0
00		7	0
00		8	0
00		9	0
00		10	0
00		11	0
00		12	0
00	X	13	0
00		1	0
00		2	0
00		3	0

00		4	0
00		5	0
00		6	0
00		7	0
00		8	0
00		9	0
00		10	0
00		11	0
00		12	0
00	X	13	0
00		1	0
00		2	0
00		3	0
00		4	0
00		5	0
00		6	0
00		7	0
00		8	0
00		9	0
00		10	0
00		11	0
00		12	0
00	X	13	0
00		1	0
00		2	0
00		3	0
00		4	0
00		5	0
00		6	0
00		7	0
00		8	0
00		9	0
00		10	0
00		11	0
00		12	0
00	X	13	0
00	X	2	0
00	X	4	0
00	X	5	0
00	X	7	0
00	X	6	0
00	X	3	0
00	X	8	0
00	X	9	0
00	X	10	0
00	X	11	0
00	X	2	0
00	X	4	0
00	X	5	0
00	X	7	0
00	X	6	0
00	X	3	0

00	X	8	0
00	X	9	0
00	X	10	0
00	X	11	0
00		1	0
00	X	2	0
00	X	4	0
00	X	5	0
00	X	7	0
00	X	6	0
00	X	3	0
00	X	8	0
00	X	9	0
00	X	10	0
00	X	11	0
00	X	2	0
00	X	4	0
00	X	5	0
00	X	7	0
00	X	6	0
00	X	3	0
00	X	8	0
00	X	9	0
00	X	10	0
00	X	11	0
00	X	2	0
00	X	4	0
00	X	5	0
00	X	7	0
00	X	6	0
00	X	3	0
00	X	8	0
00	X	9	0
00	X	10	0
00	X	11	0
00	X	2	0
00	X	4	0
00	X	5	0
00	X	7	0
00	X	6	0
00	X	3	0
00	X	8	0
00	X	9	0
00	X	10	0
00	X	11	0
00		1	0
00		2	0
00		3	0
00		4	0
00		5	0
00		6	0
00		7	0

00		8	0
00		9	0
00		10	0
00		11	0
00		12	0
00	X	13	0
00		1	0
00		2	0
00		3	0
00		4	0
00		5	0
00		6	0
00		7	0
00		8	0
00		9	0
00		10	0
00		11	0
00		12	0
00	X	13	0

68		
11		
23	0COSTEL	19
23	0COSTEL	19
23	0COSTCE	4
23	0COSTCE	4
22	0COSTCE	4
22	0COSTCE	4
22	0COSTEL	19
22	0COSTEL	19
21	0COSTCE	4
21	0COSTCE	4
20	0COSTCE	4
20	0COSTCE	4
19	0COSTCE	4
19	0COSTCE	4
18	0COSTCE	4
18	0COSTCE	4
17	0COSTCE	4
17	0COSTCE	4
16	0COSTCE	4
16	0COSTCE	4
15	0COSTCE	4
15	0COSTCE	4
15	0COSTEL	19
15	0COSTEL	19
14	0COSTCE	4
14	0COSTCE	4
14	0COSTEL	19
14	0COSTEL	19
13	0COSTCE	4
13	0COSTCE	4
13	0COSTEL	19
13	0COSTEL	19
12	0COSTCE	4
12	0COSTCE	4
12	0COSTEL	19
12	0COSTEL	19
11	0COSTCE	4
11	0COSTCE	4
11	0COSTEL	19

11	0COSTELM	19
10	0COSTELM	19
10	0COSTELM	19
10	0COSTCEI	4
10	0COSTCEI	4
9	0PROFIT_	3
9	0PROFIT_	3
9	0COSTELM	19
9	0COSTELM	19
8	0PROFIT_	3
8	0PROFIT_	3
8	0COSTELM	19
8	0COSTELM	19
7	0COSTCEI	4
7	0COSTCEI	4
6	0COSTCEI	4
6	0COSTCEI	4
5	0COSTCEI	4
5	0COSTCEI	4
4	0COSTCEI	4
4	0COSTCEI	4
4	0COSTELM	19
4	0COSTELM	19
24	0COSTCEI	4
24	0COSTCEI	4
26	0COSTCEI	4
26	0COSTCEI	4
25	0COSTCEI	4
25	0COSTCEI	4

Cost Eleme	T	0	19	0COSTELI	0
Hierarchy I	T	0	18	0HIER_NC	0
Cost cente	T	0	4	0COSTCE	0
Hierarchy I	T	0	18	0HIER_NC	0
Cost cente	T	0	4	0COSTCE	0
Hierarchy I	T	0	18	0HIER_NC	0
Cost Eleme	T	0	19	0COSTELI	0
Hierarchy I	T	0	18	0HIER_NC	0
Cost cente	T	0	4	0COSTCE	0
Hierarchy I	T	0	18	0HIER_NC	0
Cost cente	T	0	4	0COSTCE	0
Hierarchy I	T	0	18	0HIER_NC	0
Cost cente	T	0	4	0COSTCE	0
Hierarchy I	T	0	18	0HIER_NC	0
Cost cente	T	0	4	0COSTCE	0
Hierarchy I	T	0	18	0HIER_NC	0
Cost cente	T	0	4	0COSTCE	0
Hierarchy I	T	0	18	0HIER_NC	0
Cost cente	T	0	4	0COSTCE	0
Hierarchy I	T	0	18	0HIER_NC	0
Cost cente	T	0	4	0COSTCE	0
Hierarchy I	T	0	18	0HIER_NC	0
Cost Eleme	T	0	19	0COSTELI	1
Hierarchy I	T	0	18	0HIER_NC	1
Cost cente	T	0	4	0COSTCE	0
Hierarchy I	T	0	18	0HIER_NC	0
Cost Eleme	T	0	19	0COSTELI	1
Hierarchy I	T	0	18	0HIER_NC	1
Cost cente	T	0	4	0COSTCE	0
Hierarchy I	T	0	18	0HIER_NC	0
Cost Eleme	T	0	19	0COSTELI	1
Hierarchy I	T	0	18	0HIER_NC	1
Cost cente	T	0	4	0COSTCE	0
Hierarchy I	T	0	18	0HIER_NC	0
Cost Eleme	T	0	19	0COSTELI	1
Hierarchy I	T	0	18	0HIER_NC	1
Cost cente	T	0	4	0COSTCE	0
Hierarchy I	T	0	18	0HIER_NC	0
Cost Eleme	T	0	19	0COSTELI	1

Hierarchy N	T	0	18	0HIER_NC	1
Cost Eleme	T	0	19	0COSTELM	1
Hierarchy N	T	0	18	0HIER_NC	1
Cost cente	T	0	4	0COSTCEI	1
Hierarchy N	T	0	18	0HIER_NC	1
Profit Cent	T	0	3	0PROFIT_	0
Hierarchy N	T	0	18	0HIER_NC	0
Cost Eleme	T	0	19	0COSTELM	0
Hierarchy N	T	0	18	0HIER_NC	0
Profit Cent	T	0	3	0PROFIT_	0
Hierarchy N	T	0	18	0HIER_NC	0
Cost Eleme	T	0	19	0COSTELM	0
Hierarchy N	T	0	18	0HIER_NC	0
Cost cente	T	0	4	0COSTCEI	0
Hierarchy N	T	0	18	0HIER_NC	0
Cost cente	T	0	4	0COSTCEI	0
Hierarchy N	T	0	18	0HIER_NC	0
Cost cente	T	0	4	0COSTCEI	1
Hierarchy N	T	0	18	0HIER_NC	0
Cost cente	T	0	4	0COSTCEI	0
Hierarchy N	T	0	18	0HIER_NC	0
Cost Eleme	T	0	19	0COSTELM	1
Hierarchy N	T	0	18	0HIER_NC	1
Cost cente	T	0	4	0COSTCEI	0
Hierarchy N	T	0	18	0HIER_NC	0
Cost cente	T	0	4	0COSTCEI	0
Hierarchy N	T	0	18	0HIER_NC	0
Cost cente	T	0	4	0COSTCEI	0
Hierarchy N	T	0	18	0HIER_NC	0

157
21

23	0P_FPER	1	P	I	EQ	2013006	006/2013	
23	ZCE_NO8(	1	I	I	BT	00006000C	600000	00008010E
23	ZYTDVAR	1	I	I	BT	2013001	001/2013	2013006
23	ZCSTELH(	5	P	I	EQ	PURDFA_/	PURDFA_/	
23	ZVERSION	1	P	I	EQ	000	0	
23	YTD_2001	1	I	I	BT	2013001	001/2013	2013012
22	EFF_DATE	1	P	I	EQ	20130630	6/30/2013	
21	ZFULLTES	1	I	I	BT	2012001	001/2012	2012012
21	ZCE_NO8(	1	I	I	BT	00006000C	600000	00008010E
21	ZYTDVAR	1	I	I	BT	2013001	001/2013	2013006
21	ZCSTELH(	5	P	I	EQ	PURDOPE	PURDOPE	
21	ZCSTELH(	5	P	I	EQ	PURDFA_/	PURDFA_/	
21	Z_YTD02	1	I	I	BT	2011001	001/2011	2011012
21	PER000	1	P	I	EQ	2013000	000/2013	
21	ZRANGE	1	I	I	BT	2013001	001/2013	2013012
21	0N_CCTR	2	P					
21	0I_CUFYE	1	I	I	BT	2013001	001/2013	2013012
20	0P_FPER	1	P	I	EQ	2013006	006/2013	
20	ZYTDVAR	1	I	I	BT	2013001	001/2013	2013006
20	ZCSTELH(	5	P	I	EQ	PURDOPE	PURDOPE	
20	ZCSTELH(	5	P	I	EQ	PURDFA_/	PURDFA_/	
20	ZVERSION	1	P	I	EQ	000	0	
20	YTD_2001	1	I	I	BT	2013001	001/2013	2013012
20	0N_CCTR	2	P					
19	0P_FPER	1	P	I	EQ	2013006	006/2013	
19	ZYTDVAR	1	I	I	BT	2013001	001/2013	2013006
19	ZCSTELH(	5	P	I	EQ	PURDOPE	PURDOPE	
19	ZCSTELH(	5	P	I	EQ	PURDFA_/	PURDFA_/	
19	ZVERSION	1	P	I	EQ	000	0	
19	YTD_2001	1	I	I	BT	2013001	001/2013	2013012
19	0N_CCTR	2	P					
18	0P_FPER	1	P	I	EQ	2013006	006/2013	
18	ZYTDVAR	1	I	I	BT	2013001	001/2013	2013006
18	ZCSTELH(	5	P	I	EQ	PURDOPE	PURDOPE	
18	ZCSTELH(	5	P	I	EQ	PURDFA_/	PURDFA_/	
18	ZVERSION	1	P	I	EQ	000	0	
18	YTD_2001	1	I	I	BT	2013001	001/2013	2013012
18	0N_CCTR	2	P					
17	0P_FPER	1	P	I	EQ	2013006	006/2013	

17	ZYTDVAR	1	I	I	BT	2013001	001/2013	2013006
17	ZCSTELHS	5	P	I	EQ	PURDOPE	PURDOPE	
17	ZCSTELHS	5	P	I	EQ	PURDFA_/	PURDFA_/	
17	ZVERSION	1	P	I	EQ	000	0	
17	YTD_2001	1	I	I	BT	2013001	001/2013	2013012
17	0N_CCTR	2	P					
16	0P_FPER	1	P	I	EQ	2013006	006/2013	
16	ZYTDVAR	1	I	I	BT	2013001	001/2013	2013006
16	ZCSTELHS	5	P	I	EQ	PURDOPE	PURDOPE	
16	ZCSTELHS	5	P	I	EQ	PURDFA_/	PURDFA_/	
16	ZVERSION	1	P	I	EQ	000	0	
16	YTD_2001	1	I	I	BT	2013001	001/2013	2013012
16	0N_CCTR	2	P					
15	0P_FPER	1	P	I	EQ	2013006	006/2013	
15	ZCE_NO89	1	I	I	BT	000060000	600000	000080108
15	ZYTDVAR	1	I	I	BT	2013001	001/2013	2013006
15	ZCSTELHS	5	P	I	EQ	PURDFA_/	PURDFA_/	
15	ZVERSION	1	P	I	EQ	000	0	
15	YTD_2001	1	I	I	BT	2013001	001/2013	2013012
14	0P_FPER	1	P	I	EQ	2013006	006/2013	
14	ZCE_NO89	1	I	I	BT	000060000	600000	000080108
14	ZYTDVAR	1	I	I	BT	2013001	001/2013	2013006
14	ZCSTELHS	5	P	I	EQ	PURDFA_/	PURDFA_/	
14	ZCSTELHS	5	P	I	EQ	PURDOPE	PURDOPE	
14	ZVERSION	1	P	I	EQ	000	0	
14	YTD_2001	1	I	I	BT	2013001	001/2013	2013012
13	0P_FPER	1	P	I	EQ	2013006	006/2013	
13	ZCE_NO89	1	I	I	BT	000060000	600000	000080108
13	ZYTDVAR	1	I	I	BT	2013001	001/2013	2013006
13	ZCSTELHS	5	P	I	EQ	PURDFA_/	PURDFA_/	
13	ZCSTELHS	5	P	I	EQ	PURDOPE	PURDOPE	
13	ZVERSION	1	P	I	EQ	000	0	
13	YTD_2001	1	I	I	BT	2013001	001/2013	2013012
12	0P_FPER	1	P	I	EQ	2013006	006/2013	
12	ZCE_NO89	1	I	I	BT	000060000	600000	000080108
12	ZYTDVAR	1	I	I	BT	2013001	001/2013	2013006
12	ZCSTELHS	5	P	I	EQ	PURDFA_/	PURDFA_/	
12	ZCSTELHS	5	P	I	EQ	PURDOPE	PURDOPE	
12	ZVERSION	1	P	I	EQ	000	0	
12	YTD_2001	1	I	I	BT	2013001	001/2013	2013012
11	0P_FPER	1	P	I	EQ	2013006	006/2013	
11	ZCE_NO89	1	I	I	BT	000060000	600000	000080108
11	ZYTDVAR	1	I	I	BT	2013001	001/2013	2013006
11	ZCSTELHS	5	P	I	EQ	PURDFA_/	PURDFA_/	
11	ZCSTELHS	5	P	I	EQ	PURDOPE	PURDOPE	
11	ZVERSION	1	P	I	EQ	000	0	
11	YTD_2001	1	I	I	BT	2013001	001/2013	2013012
10	0P_FPER	1	P	I	EQ	2013006	006/2013	
10	ZCE_NO89	1	I	I	BT	000060000	600000	000080108
10	ZYTDVAR	1	I	I	BT	2013001	001/2013	2013006
10	ZCSTELHS	5	P	I	EQ	PURDFA_/	PURDFA_/	
10	ZCSTELHS	5	P	I	EQ	PURDOPE	PURDOPE	

10	ZVERSION	1	P	I	EQ	000	0	
10	YTD_2001	1	I	I	BT	2013001	001/2013	2013012
9	0P_FPER	1	P	I	EQ	2013006	006/2013	
9	ZCE_NO89	1	I	I	BT	000060000	600000	00008010
9	ZYTDVAR	1	I	I	BT	2013001	001/2013	2013006
9	ZCSTELHS	5	P	I	EQ	PURDFA_	PURDFA_	
9	ZCSTELHS	5	P	I	EQ	PURDOPE	PURDOPE	
9	ZVERSION	1	P	I	EQ	000	0	
9	YTD_2001	1	I	I	BT	2013001	001/2013	2013012
8	0P_FPER	1	P	I	EQ	2013006	006/2013	
8	ZCE_NO89	1	I	I	BT	000060000	600000	00008010
8	ZYTDVAR	1	I	I	BT	2013001	001/2013	2013006
8	ZCSTELHS	5	P	I	EQ	PURDFA_	PURDFA_	
8	ZCSTELHS	5	P	I	EQ	PURDOPE	PURDOPE	
8	ZVERSION	1	P	I	EQ	000	0	
8	YTD_2001	1	I	I	BT	2013001	001/2013	2013012
7	0P_FPER	1	P	I	EQ	2013006	006/2013	
7	ZYTDVAR	1	I	I	BT	2013001	001/2013	2013006
7	ZCSTELHS	5	P	I	EQ	PURDOPE	PURDOPE	
7	ZVERSION	1	P	I	EQ	000	0	
7	YTD_2001	1	I	I	BT	2013001	001/2013	2013012
7	0N_CCTR	2	P					
6	0P_FPER	1	P	I	EQ	2013006	006/2013	
6	ZYTDVAR	1	I	I	BT	2013001	001/2013	2013006
6	ZCSTELHS	5	P	I	EQ	PURDOPE	PURDOPE	
6	ZCSTELHS	5	P	I	EQ	PURDFA_	PURDFA_	
6	ZVERSION	1	P	I	EQ	000	0	
6	YTD_2001	1	I	I	BT	2013001	001/2013	2013012
6	0N_CCTR	2	P					
5	EFF_DATE	1	P	I	EQ	20130630	6/30/2013	
4	0P_FPER	1	P	I	EQ	2013006	006/2013	
4	ZYTDVAR	1	I	I	BT	2013001	001/2013	2013006
4	ZCSTELHS	5	P	I	EQ	PURDOPE	PURDOPE	
4	ZVERSION	1	P	I	EQ	000	0	
4	YTD_2001	1	I	I	BT	2013001	001/2013	2013012
4	0N_CCTR	2	P					
24	0P_FPER	1	P	I	EQ	2013006	006/2013	
24	ZYTDVAR	1	I	I	BT	2013001	001/2013	2013006
24	ZCSTELHS	5	P	I	EQ	PURDOPE	PURDOPE	
24	ZVERSION	1	P	I	EQ	W16	W16	
24	YTD_2001	1	I	I	BT	2013001	001/2013	2013012
24	0N_CCTR	2	P					
26	0P_FPER	1	P	I	EQ	2013006	006/2013	
26	ZYTDVAR	1	I	I	BT	2013001	001/2013	2013006
26	ZCSTELHS	5	P	I	EQ	PURDOPE	PURDOPE	
26	ZVERSION	1	P	I	EQ	W16	W16	
26	YTD_2001	1	I	I	BT	2013001	001/2013	2013012
26	0N_CCTR	2	P					
25	0P_FPER	1	P	I	EQ	2013006	006/2013	
25	ZYTDVAR	1	I	I	BT	2013001	001/2013	2013006
25	ZCSTELHS	5	P	I	EQ	PURDOPE	PURDOPE	
25	ZVERSION	1	P	I	EQ	W16	W16	

25	YTD_2001	1	I	I	BT	2013001	001/2013	2013012
25	0N_CCTR	2	P					
27	0P_FPER	1	P	I	EQ	2013006	006/2013	
27	ZCE_NO8!	1	I	I	BT	00006000C	600000	00008010E
27	ZYTDVAR	1	I	I	BT	2013001	001/2013	2013006
27	ZCSTELHS	5	P	I	EQ	PURDFA_/	PURDFA_/	
27	ZVERSIO	1	P	I	EQ	W16	W16	
27	YTD_2001	1	I	I	BT	2013001	001/2013	2013012
28	0P_FPER	1	P	I	EQ	2013006	006/2013	
28	ZCE_NO8!	1	I	I	BT	00006000C	600000	00008010E
28	ZYTDVAR	1	I	I	BT	2013001	001/2013	2013006
28	ZCSTELHS	5	P	I	EQ	PURDFA_/	PURDFA_/	
28	ZVERSIO	1	P	I	EQ	W16	W16	
28	YTD_2001	1	I	I	BT	2013001	001/2013	2013012

	June 2013	20		0	0	Period/Fisc	60
801080	Land	20	Shipping E	20	0	Expenses I	60
006/2013	January 20	20	June 2013	20	0	YTD	60
	TOTAL R&	0		0	0	Cost Elem	60
	Purdue An	40		0	0	Version	60
012/2013	January 20	20	December	20	0	Full Year P	60
		0		0	0	Effective D	60
012/2012	January 20	20	December	20	0	PY Actual I	60
801080	Land	20	Shipping E	20	0	Expenses I	60
006/2013	January 20	20	June 2013	20	0	YTD	60
	Operating I	0		0	0	Cost Elem	60
	Operating I	0		0	0	Cost Elem	60
012/2011	January 20	20	December	20	0	PY-1 Actua	60
	Period 00 2	20		0	0	Annual Val	60
012/2013	January 20	20	December	20	0	LE Period	60
		0		0	0	Cost cente	60
012/2013	January 20	20	December	20	0	All Periods	60
	June 2013	20		0	0	Period/Fisc	60
006/2013	January 20	20	June 2013	20	0	YTD	60
	Operating I	0		0	0	Cost Elem	60
	Operating I	0		0	0	Cost Elem	60
	Purdue An	40		0	0	Version	60
012/2013	January 20	20	December	20	0	Full Year P	60
		0		0	0	Cost cente	60
	June 2013	20		0	0	Period/Fisc	60
006/2013	January 20	20	June 2013	20	0	YTD	60
	Operating I	0		0	0	Cost Elem	60
	Operating I	0		0	0	Cost Elem	60
	Purdue An	40		0	0	Version	60
012/2013	January 20	20	December	20	0	Full Year P	60
		0		0	0	Cost cente	60
	June 2013	20		0	0	Period/Fisc	60
006/2013	January 20	20	June 2013	20	0	YTD	60
	Operating I	0		0	0	Cost Elem	60
	Operating I	0		0	0	Cost Elem	60
	Purdue An	40		0	0	Version	60
012/2013	January 20	20	December	20	0	Full Year P	60
		0		0	0	Cost cente	60
	June 2013	20		0	0	Period/Fisc	60

006/2013	January 20	20	June 2013	20	0	YTD	60
	Operating I	0		0	0	Cost Eleme	60
	Operating I	0		0	0	Cost Eleme	60
	Purdue Ani	40		0	0	Version	60
012/2013	January 20	20	December	20	0	Full Year P	60
		0		0	0	Cost cente	60
	June 2013	20		0	0	Period/Fisc	60
006/2013	January 20	20	June 2013	20	0	YTD	60
	Operating I	0		0	0	Cost Eleme	60
	Operating I	0		0	0	Cost Eleme	60
	Purdue Ani	40		0	0	Version	60
012/2013	January 20	20	December	20	0	Full Year P	60
		0		0	0	Cost cente	60
	June 2013	20		0	0	Period/Fisc	60
801080	Land	20	Shipping E	20	0	Expenses I	60
006/2013	January 20	20	June 2013	20	0	YTD	60
	TOTAL R&	0		0	0	Cost Eleme	60
	Purdue Ani	40		0	0	Version	60
012/2013	January 20	20	December	20	0	Full Year P	60
	June 2013	20		0	0	Period/Fisc	60
801080	Land	20	Shipping E	20	0	Expenses I	60
006/2013	January 20	20	June 2013	20	0	YTD	60
	TOTAL R&	0		0	0	Cost Eleme	60
	TOTAL R&	0		0	0	Cost Eleme	60
	Purdue Ani	40		0	0	Version	60
012/2013	January 20	20	December	20	0	Full Year P	60
	June 2013	20		0	0	Period/Fisc	60
801080	Land	20	Shipping E	20	0	Expenses I	60
006/2013	January 20	20	June 2013	20	0	YTD	60
	TOTAL R&	0		0	0	Cost Eleme	60
	TOTAL R&	0		0	0	Cost Eleme	60
	Purdue Ani	40		0	0	Version	60
012/2013	January 20	20	December	20	0	Full Year P	60
	June 2013	20		0	0	Period/Fisc	60
801080	Land	20	Shipping E	20	0	Expenses I	60
006/2013	January 20	20	June 2013	20	0	YTD	60
	TOTAL R&	0		0	0	Cost Eleme	60
	TOTAL R&	0		0	0	Cost Eleme	60
	Purdue Ani	40		0	0	Version	60
012/2013	January 20	20	December	20	0	Full Year P	60
	June 2013	20		0	0	Period/Fisc	60
801080	Land	20	Shipping E	20	0	Expenses I	60
006/2013	January 20	20	June 2013	20	0	YTD	60
	TOTAL R&	0		0	0	Cost Eleme	60
	TOTAL R&	0		0	0	Cost Eleme	60
	Purdue Ani	40		0	0	Version	60
012/2013	January 20	20	December	20	0	Full Year P	60
	June 2013	20		0	0	Period/Fisc	60
801080	Land	20	Shipping E	20	0	Expenses I	60
006/2013	January 20	20	June 2013	20	0	YTD	60
	TOTAL R&	0		0	0	Cost Eleme	60
	TOTAL R&	0		0	0	Cost Eleme	60

	Purdue Ani	40		0	0	Version	60
012/2013	January 20	20	December	20	0	Full Year P	60
	June 2013	20		0	0	Period/Fisc	60
801080	Land	20	Shipping E	20	0	Expenses I	60
006/2013	January 20	20	June 2013	20	0	YTD	60
	TOTAL R&	0		0	0	Cost Eleme	60
	TOTAL R&	0		0	0	Cost Eleme	60
	Purdue Ani	40		0	0	Version	60
012/2013	January 20	20	December	20	0	Full Year P	60
	June 2013	20		0	0	Period/Fisc	60
801080	Land	20	Shipping E	20	0	Expenses I	60
006/2013	January 20	20	June 2013	20	0	YTD	60
	TOTAL R&	0		0	0	Cost Eleme	60
	TOTAL R&	0		0	0	Cost Eleme	60
	Purdue Ani	40		0	0	Version	60
012/2013	January 20	20	December	20	0	Full Year P	60
	June 2013	20		0	0	Period/Fisc	60
006/2013	January 20	20	June 2013	20	0	YTD	60
	Operating I	0		0	0	Cost Eleme	60
	Purdue Ani	40		0	0	Version	60
012/2013	January 20	20	December	20	0	Full Year P	60
		0		0	0	Cost cente	60
	June 2013	20		0	0	Period/Fisc	60
006/2013	January 20	20	June 2013	20	0	YTD	60
	Operating I	0		0	0	Cost Eleme	60
	Operating I	0		0	0	Cost Eleme	60
	Purdue Ani	40		0	0	Version	60
012/2013	January 20	20	December	20	0	Full Year P	60
		0		0	0	Cost cente	60
		0		0	0	Effective D	60
	June 2013	20		0	0	Period/Fisc	60
006/2013	January 20	20	June 2013	20	0	YTD	60
	Operating I	0		0	0	Cost Eleme	60
	Purdue Ani	40		0	0	Version	60
012/2013	January 20	20	December	20	0	Full Year P	60
		0		0	0	Cost cente	60
	June 2013	20		0	0	Period/Fisc	60
006/2013	January 20	20	June 2013	20	0	YTD	60
	Operating I	0		0	0	Cost Eleme	60
	W16	40		0	0	Version	60
012/2013	January 20	20	December	20	0	Full Year P	60
		0		0	0	Cost cente	60
	June 2013	20		0	0	Period/Fisc	60
006/2013	January 20	20	June 2013	20	0	YTD	60
	Operating I	0		0	0	Cost Eleme	60
	W16	40		0	0	Version	60
012/2013	January 20	20	December	20	0	Full Year P	60
		0		0	0	Cost cente	60
	June 2013	20		0	0	Period/Fisc	60
006/2013	January 20	20	June 2013	20	0	YTD	60
	Operating I	0		0	0	Cost Eleme	60
	W16	40		0	0	Version	60

012/2013	January 20	20	December	20	0	Full Year P	60
		0		0	0	Cost cente	60
	June 2013	20		0	0	Period/Fisc	60
801080	Land	20	Shipping E	20	0	Expenses I	60
006/2013	January 20	20	June 2013	20	0	YTD	60
	TOTAL R&	0		0	0	Cost Eleme	60
	W16	40		0	0	Version	60
012/2013	January 20	20	December	20	0	Full Year P	60
	June 2013	20		0	0	Period/Fisc	60
801080	Land	20	Shipping E	20	0	Expenses I	60
006/2013	January 20	20	June 2013	20	0	YTD	60
	TOTAL R&	0		0	0	Cost Eleme	60
	W16	40		0	0	Version	60
012/2013	January 20	20	December	20	0	Full Year P	60

0FISCPER	K12013006
0COSTELI	PURD0000600000
0FISCPER	K12013001
0COSTELI	
0VERSION	000
0FISCPER	K12013001
ZEFFCDA	20130630
0FISCPER	K12012001
0COSTELI	PURD0000600000
0FISCPER	K12013001
0COSTELI	
0COSTELI	
0FISCPER	K12011001
0FISCPER	K12013000
0FISCPER	K12013001
0COSTCE	
0FISCPER	K12013001
0FISCPER	K12013006
0FISCPER	K12013001
0COSTELI	
0COSTELI	
0VERSION	000
0FISCPER	K12013001
0COSTCE	
0FISCPER	K12013006
0FISCPER	K12013001
0COSTELI	
0COSTELI	
0VERSION	000
0FISCPER	K12013001
0COSTCE	
0FISCPER	K12013006
0FISCPER	K12013001
0COSTELI	
0COSTELI	
0VERSION	000
0FISCPER	K12013001
0COSTCE	
0FISCPER	K12013006

0FISCPER	K12013001
0COSTELI	
0COSTELI	
0VERSION	000
0FISCPER	K12013001
0COSTCE	
0FISCPER	K12013006
0FISCPER	K12013001
0COSTELI	
0COSTELI	
0VERSION	000
0FISCPER	K12013001
0COSTCE	
0FISCPER	K12013006
0COSTELI	PURD0000600000
0FISCPER	K12013001
0COSTELI	
0VERSION	000
0FISCPER	K12013001
0FISCPER	K12013006
0COSTELI	PURD0000600000
0FISCPER	K12013001
0COSTELI	
0COSTELI	
0VERSION	000
0FISCPER	K12013001
0FISCPER	K12013006
0COSTELI	PURD0000600000
0FISCPER	K12013001
0COSTELI	
0COSTELI	
0VERSION	000
0FISCPER	K12013001
0FISCPER	K12013006
0COSTELI	PURD0000600000
0FISCPER	K12013001
0COSTELI	
0COSTELI	
0VERSION	000
0FISCPER	K12013001
0FISCPER	K12013006
0COSTELI	PURD0000600000
0FISCPER	K12013001
0COSTELI	
0COSTELI	
0VERSION	000
0FISCPER	K12013001
0FISCPER	K12013006
0COSTELI	PURD0000600000
0FISCPER	K12013001
0COSTELI	
0COSTELI	

0VERSION	000
0FISCPER	K12013001
0FISCPER	K12013006
0COSTELM	PURD0000600000
0FISCPER	K12013001
0COSTELM	
0COSTELM	
0VERSION	000
0FISCPER	K12013001
0FISCPER	K12013006
0COSTELM	PURD0000600000
0FISCPER	K12013001
0COSTELM	
0COSTELM	
0VERSION	000
0FISCPER	K12013001
0FISCPER	K12013006
0FISCPER	K12013001
0COSTELM	
0VERSION	000
0FISCPER	K12013001
0COSTCE	
0FISCPER	K12013006
0FISCPER	K12013001
0COSTELM	
0COSTELM	
0VERSION	000
0FISCPER	K12013001
0COSTCE	
ZEFFCDAT	20130630
0FISCPER	K12013006
0FISCPER	K12013001
0COSTELM	
0VERSION	000
0FISCPER	K12013001
0COSTCE	
0FISCPER	K12013006
0FISCPER	K12013001
0COSTELM	
0VERSION	W16
0FISCPER	K12013001
0COSTCE	
0FISCPER	K12013006
0FISCPER	K12013001
0COSTELM	
0VERSION	W16
0FISCPER	K12013001
0COSTCE	
0FISCPER	K12013006
0FISCPER	K12013001
0COSTELM	
0VERSION	W16

0FISCPER	K12013001
0COSTCE	
0FISCPER	K12013006
0COSTELI	PURD0000600000
0FISCPER	K12013001
0COSTELI	
0VERSION	W16
0FISCPER	K12013001
0FISCPER	K12013006
0COSTELI	PURD0000600000
0FISCPER	K12013001
0COSTELI	
0VERSION	W16
0FISCPER	K12013001

750		
2		
23	00000001C	X
23	00000001C	
23	00000001C	
23	00000001C	1
23	00000001C	
23	00000001C	1
23	00000090C	
23	00000001C	415IDGTEKH0OCQ8U
23	00000100C	415IDLQ2OKVZ94O5\
23	00000100C	ZPL_ACT
23	000000001	
23	00000001C	0
23	000000011	
23	000000002	
23	000000003	
23	000000004	
23	000000004	
23	000000004	00
23	000000004	00
23	000000002	
23	000000002	
23	000000002	
23	00000100C	415IDGTEKH0OCQ8U
23	00000001C	
23	00000001C	
23	000000011	0
23	00000002C	X
23	00000040C	X
23	00000090C	Monthly Cost Center R
23	000000011	1
22	00000001C	
22	00000001C	
22	00000001C	
22	00000001C	1
22	00000001C	
22	00000001C	1
22	00000090C	
22	00000001C	3TS79ZK6LEII7WABL
22	00000100C	3TS7A3EG2PD9J60EI

22	00000100C	ZHEADCT
22	000000001	
22	00000001C	0
22	000000011	
22	000000002	
22	000000003	
22	000000004	
22	000000004	
22	000000004	00
22	000000004	00
22	000000002	
22	000000002	
22	000000002	
22	00000100C	3TS79ZK6LEII7WABL
22	00000001C	
22	00000001C	
22	000000011	0
22	00000002C	X
22	00000040C	X
22	00000090C	Purdue Query for Heac
22	000000011	1
21	00000001C	X
21	00000001C	X
21	00000001C	
21	00000001C	1
21	00000001C	
21	00000001C	1
21	00000090C	
21	00000001C	3N4R71RYA7MMG0Y
21	00000100C	3N4R74C4LQV4NJFS
21	00000100C	ZPL_PLN
21	000000001	
21	00000001C	0
21	000000011	
21	000000002	
21	000000003	
21	000000004	
21	000000004	
21	000000004	00
21	000000004	00
21	000000002	
21	000000002	
21	000000002	
21	00000100C	3N4R71RYA7MMG0Y
21	00000001C	
21	00000001C	
21	000000011	0
21	00000002C	X
21	00000040C	X
21	00000090C	BUD CC by Cost Elem
21	000000011	1
20	00000001C	X

20	00000001C	
20	00000001C	
20	00000001C	1
20	00000001C	X
20	00000001C	3
20	00000090C	
20	00000001C	3NWHL0XBWMXKV9)
20	00000100C	3NWHL27F2EJTZ16A
20	00000100C	ZPL_ACT
20	000000001	
20	00000001C	0
20	000000011	
20	000000002	
20	000000003	
20	000000004	
20	000000004	
20	000000004	00
20	000000004	00
20	000000002	
20	000000002	
20	000000002	
20	00000100C	3NWHL0XBWMXKV9)
20	00000001C	
20	00000001C	
20	000000011	0
20	00000002C	X
20	00000040C	X
20	00000090C	SP_Cost Center Repor
20	000000011	1
19	00000001C	X
19	00000001C	
19	00000001C	
19	00000001C	1
19	00000001C	X
19	00000001C	3
19	00000090C	
19	00000001C	3NWHL0XBWMXKV9)
19	00000100C	3NWHL27F2EJTZ16A
19	00000100C	ZPL_ACT
19	000000001	
19	00000001C	0
19	000000011	
19	000000002	
19	000000003	
19	000000004	
19	000000004	
19	000000004	00
19	000000004	00
19	000000002	
19	000000002	
19	000000002	
19	00000100C	3NWHL0XBWMXKV9)

19	000000010	
19	000000010	
19	0000000110	0
19	000000020	X
19	000000400	X
19	000000900	SP_Cost Center Repor
19	0000000111	1
18	000000010	X
18	000000010	
18	000000010	
18	000000010	1
18	000000010	X
18	000000010	3
18	000000900	
18	000000010	3NWHL0XBWMXKV9X
18	000001000	3NWHL27F2EJTZ16A
18	000001000	ZPL_ACT
18	000000001	
18	000000010	0
18	000000011	
18	000000002	
18	000000003	
18	000000004	
18	000000004	
18	000000004	00
18	000000004	00
18	000000002	
18	000000002	
18	000000002	
18	000001000	3NWHL0XBWMXKV9X
18	000000010	
18	000000010	
18	0000000110	0
18	000000020	X
18	000000400	X
18	000000900	SP_Cost Center Repor
18	0000000111	1
17	000000010	X
17	000000010	
17	000000010	
17	000000010	1
17	000000010	X
17	000000010	3
17	000000900	
17	000000010	3NWHL0XBWMXKV9X
17	000001000	3NWHL27F2EJTZ16A
17	000001000	ZPL_ACT
17	000000001	
17	000000010	0
17	000000011	
17	000000002	
17	000000003	

17	000000004	
17	000000004	
17	000000004	00
17	000000004	00
17	000000002	
17	000000002	
17	000000002	
17	00000100C	3NWHL0XBWMXKV9)
17	00000001C	
17	00000001C	
17	0000000011	0
17	00000002C	X
17	00000040C	X
17	00000090C	SP_Cost Center Repoı
17	0000000011	1
16	00000001C	X
16	00000001C	
16	00000001C	
16	00000001C	1
16	00000001C	X
16	00000001C	3
16	00000090C	
16	00000001C	3NWHL0XBWMXKV9)
16	00000100C	3NWHL27F2EJTZ16A
16	00000100C	ZPL_ACT
16	000000001	
16	00000001C	0
16	000000011	
16	000000002	
16	000000003	
16	000000004	
16	000000004	
16	000000004	00
16	000000004	00
16	000000002	
16	000000002	
16	000000002	
16	00000100C	3NWHL0XBWMXKV9)
16	00000001C	
16	00000001C	
16	0000000011	0
16	00000002C	X
16	00000040C	X
16	00000090C	SP_Cost Center Repoı
16	0000000011	1
15	00000001C	X
15	00000001C	
15	00000001C	
15	00000001C	1
15	00000001C	
15	00000001C	1
15	00000090C	

15	00000001C	415IDGTEKH0OCQ8U
15	00000100C	415IDLQ2OKVZ94O5\
15	00000100C	ZPL_ACT
15	000000001	
15	00000001C	0
15	000000011	
15	000000002	
15	000000003	
15	000000004	
15	000000004	
15	000000004	00
15	000000004	00
15	000000002	
15	000000002	
15	000000002	
15	00000100C	415IDGTEKH0OCQ8U
15	00000001C	
15	00000001C	
15	000000011	0
15	00000002C	X
15	00000040C	X
15	00000090C	Monthly Cost Center R
15	000000011	1
14	00000001C	X
14	00000001C	
14	00000001C	
14	00000001C	1
14	00000001C	
14	00000001C	1
14	00000090C	
14	00000001C	415IDGTEKH0OCQ8U
14	00000100C	415IDLQ2OKVZ94O5\
14	00000100C	ZPL_ACT
14	000000001	
14	00000001C	0
14	000000011	
14	000000002	
14	000000003	
14	000000004	
14	000000004	
14	000000004	00
14	000000004	00
14	000000002	
14	000000002	
14	000000002	
14	00000100C	415IDGTEKH0OCQ8U
14	00000001C	
14	00000001C	
14	000000011	0
14	00000002C	X
14	00000040C	X
14	00000090C	Monthly Cost Center R

14	0000000011	1
13	000000010	X
13	000000010	
13	000000010	
13	000000010	1
13	000000010	
13	000000010	1
13	000000900	
13	000000010	415IDGTEKH0OCQ8U
13	000001000	415IDLQ2OKVZ94O5\
13	000001000	ZPL_ACT
13	000000001	
13	000000010	0
13	000000011	
13	000000002	
13	000000003	
13	000000004	
13	000000004	
13	000000004	00
13	000000004	00
13	000000002	
13	000000002	
13	000000002	
13	000001000	415IDGTEKH0OCQ8U
13	000000010	
13	000000010	
13	0000000011	0
13	000000020	X
13	000000400	X
13	000000900	Monthly Cost Center R
13	0000000011	1
12	000000010	X
12	000000010	
12	000000010	
12	000000010	1
12	000000010	
12	000000010	1
12	000000900	
12	000000010	415IDGTEKH0OCQ8U
12	000001000	415IDLQ2OKVZ94O5\
12	000001000	ZPL_ACT
12	000000001	
12	000000010	0
12	000000011	
12	000000002	
12	000000003	
12	000000004	
12	000000004	
12	000000004	00
12	000000004	00
12	000000002	
12	000000002	

12	000000002	
12	00000100C	415IDGTEKH0OCQ8L
12	00000001C	
12	00000001C	
12	000000011	0
12	00000002C	X
12	00000040C	X
12	00000090C	Monthly Cost Center R
12	000000011	1
11	00000001C	X
11	00000001C	
11	00000001C	
11	00000001C	1
11	00000001C	
11	00000001C	1
11	00000090C	
11	00000001C	415IDGTEKH0OCQ8L
11	00000100C	415IDLQ2OKVZ94O5\
11	00000100C	ZPL_ACT
11	000000001	
11	00000001C	0
11	000000011	
11	000000002	
11	000000003	
11	000000004	
11	000000004	
11	000000004	00
11	000000004	00
11	000000002	
11	000000002	
11	000000002	
11	00000100C	415IDGTEKH0OCQ8L
11	00000001C	
11	00000001C	
11	000000011	0
11	00000002C	X
11	00000040C	X
11	00000090C	Monthly Cost Center R
11	000000011	1
10	00000001C	X
10	00000001C	
10	00000001C	
10	00000001C	1
10	00000001C	
10	00000001C	1
10	00000090C	
10	00000001C	415IDGTEKH0OCQ8L
10	00000100C	415IDLQ2OKVZ94O5\
10	00000100C	ZPL_ACT
10	000000001	
10	00000001C	0
10	000000011	

10	000000002	
10	000000003	
10	000000004	
10	000000004	
10	000000004	00
10	000000004	00
10	000000002	
10	000000002	
10	000000002	
10	00000100C	415IDGTEKH0OCQ8U
10	00000001C	
10	00000001C	
10	0000000011	0
10	00000002C	X
10	00000040C	X
10	00000090C	Monthly Cost Center R
10	0000000011	1
9	00000001C	X
9	00000001C	
9	00000001C	
9	00000001C	1
9	00000001C	
9	00000001C	1
9	00000090C	
9	00000001C	415IDGTEKH0OCQ8U
9	00000100C	415IDLQ2OKVZ94O5\
9	00000100C	ZPL_ACT
9	000000001	
9	00000001C	0
9	000000011	
9	000000002	
9	000000003	
9	000000004	
9	000000004	
9	000000004	00
9	000000004	00
9	000000002	
9	000000002	
9	000000002	
9	00000100C	415IDGTEKH0OCQ8U
9	00000001C	
9	00000001C	
9	0000000011	0
9	00000002C	X
9	00000040C	X
9	00000090C	Monthly Cost Center R
9	0000000011	1
8	00000001C	X
8	00000001C	
8	00000001C	
8	00000001C	1
8	00000001C	X

8	00000001C	1
8	00000090C	
8	00000001C	415IDGTEKH0OCQ8L
8	00000100C	415IDLQ2OKVZ94O5\
8	00000100C	ZPL_ACT
8	000000001	
8	00000001C	0
8	000000011	
8	000000002	
8	000000003	
8	000000004	
8	000000004	
8	000000004	00
8	000000004	00
8	000000002	
8	000000002	
8	000000002	
8	00000100C	415IDGTEKH0OCQ8L
8	00000001C	
8	00000001C	
8	000000011	0
8	00000002C	X
8	00000040C	X
8	00000090C	Monthly Cost Center R
8	000000011	1
7	00000001C	X
7	00000001C	
7	00000001C	
7	00000001C	1
7	00000001C	
7	00000001C	3
7	00000090C	
7	00000001C	3NWHL0XBWMXKV9)
7	00000100C	3NWHL27F2EJTZ16A
7	00000100C	ZPL_ACT
7	000000001	
7	00000001C	0
7	000000011	
7	000000002	
7	000000003	
7	000000004	
7	000000004	
7	000000004	00
7	000000004	00
7	000000002	
7	000000002	
7	000000002	
7	00000100C	3NWHL0XBWMXKV9)
7	00000001C	
7	00000001C	
7	000000011	0
7	00000002C	X

7	00000040(	X
7	00000090(	SP_Cost Center Repoı
7	0000000111	1
6	00000001(	X
6	00000001(	
6	00000001(	
6	00000001(	1
6	00000001(	
6	00000001(	3
6	00000090(	
6	00000001(	3NWHL0XBWMXKV9)
6	00000100(	3NWHL27F2EJTZ16A
6	00000100(	ZPL_ACT
6	000000001	
6	00000001(	0
6	000000011	
6	000000002	
6	000000003	
6	000000004	
6	000000004	
6	000000004	00
6	000000004	00
6	000000002	
6	000000002	
6	000000002	
6	00000100(	3NWHL0XBWMXKV9)
6	00000001(	
6	00000001(	
6	0000000110	0
6	00000002(	X
6	00000040(	X
6	00000090(	SP_Cost Center Repoı
6	0000000111	1
5	00000001(	
5	00000001(	
5	00000001(	
5	00000001(	1
5	00000001(	
5	00000001(	1
5	00000090(	
5	00000001(	3TS79ZK6LEII7WABL
5	00000100(	3TS7A3EG2PD9J60EI
5	00000100(	ZHEADCT
5	000000001	
5	00000001(	0
5	000000011	
5	000000002	
5	000000003	
5	000000004	
5	000000004	
5	000000004	00
5	000000004	00

5	000000002	
5	000000002	
5	000000002	
5	00000100C	3TS79ZK6LEII7WABL
5	00000001C	
5	00000001C	
5	0000000011	0
5	00000002C	X
5	00000040C	X
5	00000090C	Purdue Query for Heac
5	0000000011	1
4	00000001C	X
4	00000001C	
4	00000001C	
4	00000001C	1
4	00000001C	X
4	00000001C	3
4	00000090C	
4	00000001C	3NWHL0XBWMXKV9X
4	00000100C	3NWHL27F2EJTZ16A
4	00000100C	ZPL_ACT
4	000000001	
4	00000001C	0
4	000000011	
4	000000002	
4	000000003	
4	000000004	
4	000000004	
4	000000004	00
4	000000004	00
4	000000002	
4	000000002	
4	000000002	
4	00000100C	3NWHL0XBWMXKV9X
4	00000001C	
4	00000001C	
4	0000000011	0
4	00000002C	X
4	00000040C	X
4	00000090C	SP_Cost Center Repor
4	0000000011	1
24	00000001C	X
24	00000001C	
24	00000001C	
24	00000001C	1
24	00000001C	X
24	00000001C	3
24	00000090C	
24	00000001C	3NWHL0XBWMXKV9X
24	00000100C	3NWHL27F2EJTZ16A
24	00000100C	ZPL_ACT
24	000000001	

24	00000001C	0
24	000000011	
24	000000002	
24	000000003	
24	000000004	
24	000000004	
24	000000004	00
24	000000004	00
24	000000002	
24	000000002	
24	000000002	
24	00000100C	3NWHL0XBWMXKV9)
24	00000001C	
24	00000001C	
24	000000011	0
24	00000002C	X
24	00000040C	X
24	00000090C	SP_Cost Center Repor
24	000000011	1
26	00000001C	X
26	00000001C	
26	00000001C	
26	00000001C	1
26	00000001C	
26	00000001C	3
26	00000090C	
26	00000001C	3NWHL0XBWMXKV9)
26	00000100C	3NWHL27F2EJTZ16A
26	00000100C	ZPL_ACT
26	000000001	
26	00000001C	0
26	000000011	
26	000000002	
26	000000003	
26	000000004	
26	000000004	
26	000000004	00
26	000000004	00
26	000000002	
26	000000002	
26	000000002	
26	00000100C	3NWHL0XBWMXKV9)
26	00000001C	
26	00000001C	
26	000000011	0
26	00000002C	X
26	00000040C	X
26	00000090C	SP_Cost Center Repor
26	000000011	1
25	00000001C	X
25	00000001C	
25	00000001C	

25	00000001C	1
25	00000001C	
25	00000001C	3
25	00000090C	
25	00000001C	3NWHL0XBWMXKV9
25	00000100C	3NWHL27F2EJTZ16A
25	00000100C	ZPL_ACT
25	000000001	
25	00000001C	0
25	000000011	
25	000000002	
25	000000003	
25	000000004	
25	000000004	
25	000000004	00
25	000000004	00
25	000000002	
25	000000002	
25	000000002	
25	00000100C	3NWHL0XBWMXKV9
25	00000001C	
25	00000001C	
25	000000011	0
25	00000002C	X
25	00000040C	X
25	00000090C	SP_Cost Center Repo
25	000000011	1
27	00000001C	X
27	00000001C	
27	00000001C	
27	00000001C	1
27	00000001C	
27	00000001C	1
27	00000090C	
27	00000001C	415IDGTEKH0OCQ8U
27	00000100C	415IDLQ2OKVZ94O5
27	00000100C	ZPL_ACT
27	000000001	
27	00000001C	0
27	000000011	
27	000000002	
27	000000003	
27	000000004	
27	000000004	
27	000000004	00
27	000000004	00
27	000000002	
27	000000002	
27	000000002	
27	00000100C	415IDGTEKH0OCQ8U
27	00000001C	
27	00000001C	

27	0000000110	0
27	000000020	X
27	000000400	X
27	000000900	Monthly Cost Center R
27	0000000111	1
28	000000010	X
28	000000010	
28	000000010	
28	000000010	1
28	000000010	
28	000000010	1
28	000000900	
28	000000010	415IDGTEKH0OCQ8U
28	000001000	415IDLQ2OKVZ94O5\
28	000001000	ZPL_ACT
28	000000001	
28	000000010	0
28	000000011	
28	000000002	
28	000000003	
28	000000004	
28	000000004	
28	000000004	00
28	000000004	00
28	000000002	
28	000000002	
28	000000002	
28	000001000	415IDGTEKH0OCQ8U
28	000000010	
28	000000010	
28	0000000110	0
28	000000020	X
28	000000400	X
28	000000900	Monthly Cost Center R
28	0000000111	1


X
X